University of New Mexico

UNM Digital Repository
Biomedical Engineering ETDs

Engineering ETDs

Summer 8-18-2019

ASSESSMENT OF THE BIOCOMPATIBILTY, STABILITY, AND
SUITABILITY OF NATURAL AND SYNTHETIC POLYMERS AND
DRUGS IN THE FDA APPROVAL PROCESS
Phuong Anh Hoang Nguyen
University of New Mexico

Follow this and additional works at: https://digitalrepository.unm.edu/bme_etds
Part of the Biomaterials Commons, Other Biomedical Engineering and Bioengineering Commons,
Other Chemicals and Drugs Commons, and the Pharmaceutical Preparations Commons

Recommended Citation
Nguyen, Phuong Anh Hoang. "ASSESSMENT OF THE BIOCOMPATIBILTY, STABILITY, AND SUITABILITY OF
NATURAL AND SYNTHETIC POLYMERS AND DRUGS IN THE FDA APPROVAL PROCESS." (2019).
https://digitalrepository.unm.edu/bme_etds/29

This Dissertation is brought to you for free and open access by the Engineering ETDs at UNM Digital Repository. It
has been accepted for inclusion in Biomedical Engineering ETDs by an authorized administrator of UNM Digital
Repository. For more information, please contact amywinter@unm.edu, lsloane@salud.unm.edu,
sarahrk@unm.edu.

Phuong Anh Hoang Nguyen
Candidate

Center for Biomedical Engineering
Department

This dissertation is approved, and it is acceptable in quality and form for publication:
Approved by the Dissertation Committee:

Heather Canavan, Chairwoman

Eva Chi

David Whitten

Christina Salas

Steven Walsh

i

ASSESSMENT OF THE BIOCOMPATIBILTY, STABILITY, AND SUITABILITY OF
NATURAL AND SYNTHETIC POLYMERS AND DRUGS IN THE FDA APPROVAL
PROCESS

BY
Phuong Anh Hoang Nguyen
MBA, University of New Mexico, 2017
M.S. Biomedical Engineering, University of New Mexico, 2016
B.S Biology, University of New Mexico, 2014
B.S. Psychology, University of New Mexico, 2014
DISSERTATION
Submitted in Partial Fulfillment of the Requirements for the Degree of:
Doctor of Philosophy, Engineering
The University of New Mexico
Albuquerque, New Mexico

December 2019

ii

Acknowledgements
The path towards this work has been difficult, but I would not have overcome these demanding
5 years without the assistance from many individuals. I would like to start by thanking my
faculty advisor, mentor, and one of my primary levels of support, Prof. Heather Canavan. She
has helped me navigate through many difficult situations and circumstances while teaching me
what being a mentor and Professor truly means. She’s dedicated to her students, her class, and
is always striving to have all her students succeed. She changes the lives of everyone she
interacts with, and I’m truly grateful that she is my advisor. Like a previous student has said,
Prof. Canavan is the “Michael Phelps of teachers” and without her, I would not be able to
accomplish this work.
I would also like to thank my committee members, Profs. Eva Chi, David Whitten, Steve
Walsh, and Christina Salas for taking time out of their tremendous workload to be a part of my
dissertation committee.
Within the Center for Biomedical Engineering, many individuals – undergraduate students,
graduate students and professors alike have helped train me, troubleshoot my experiments, and
listened to me talk about my experiments. I would like to thank all of them, including Darnell
Cuylear, Sarah Mounho, Lyndsay Stapleton, Adrian Ledesma-Mendoza, Prof. Linnea Ista, Dr.
Jamie Reed, Dr. Marta Cooperstein, Dr. Kent Coombs, Dr. Matthew Rush, Ben Matheson, and
other members of the HEC lab Group. Special thanks to Dr. Tye Martin and Angelina Malagodi
for letting me into your office and being available to listen and act as a sounding board for
ideas.

iii

Individuals and staff at CBME have helped made my life so much easier, and much of my
work couldn’t have been done without their help. Thank you to Linda Stewart who helped me
organize all my paperwork, and ensured that I’m on task and schedule to graduate. I would
also like to thank Joanna Rex, and Mary Rhodes for helping me order supplies and ensuring
that all of the things I order gets delivered. Finally, thank you to Isela Roeder and Elsa Castillo
for helping me navigate scholarships, grant submission protocols, etc.
I would also like to thank the I-Corps Site Program and the mentors within who have taught
me much about the translational process between the start of an idea to getting it into the
market. Thank you Dr. Rob Del Campo and Dr. Elizabeth (Lisa) Kuuttila for starting the
program and allowing students to pursue our interests. Thank you, Cara Michalyszin, for her
great organization and assistance. Finally, a thank you mentors Susan Cornelius and John
Chavez for helping me find interviewees, introducing me to your friends, and for spending
countless hours going through my presentations as I go through the I-Corps process.
The work within this dissertation could not have been completed without the assistance of
other individuals outside of UNM with additional instrumentation that was valuable to the
project. In particular, I would like to thank NESAC/BIO, specifically Drs. Gerry Hammer, Dan
Graham, and Lara Gamble for their assistance in obtaining XPS data and analyzing my
pNIPAM substrates (used in Chapter 3). I would also like to thank Drs. Karyn Jarvis, and
Sally McArthur for their assistance in helping me analyze my data as well as obtain XPS data
for my hydrogels (used in Chapter 7). From UNM’s Health Science Center, I would also like
to thank Drs. Michael Paffett, Michael Burnett, and Russell Morton for training me on the use
of the confocal microscope, flow cytometer, and the cryotome.

iv

Finally, I must thank family and friends who have helped mentor me, train me, reminded me
to work hard, and stood up for me during times where I was about to give up. I wish to thank
my mother, Joyce Nguyen, who threatened me with homelessness and picking up cans off the
street, so that I would continue my education. I also wish to thank my older sister, Dr. Ngoc
Nguyen who listened to me voice all of my issues. Thank you also to my eldest sister, Dr. Anh
Nguyen, for her inspirational bubble tea. I would also like to thank my grandparents, Dieu
Nguyen and Van Nguyen and my in-laws, Hao Tat and Muoi Truong. I would also like to
extend an extra special thank you to those individuals who have become surrogate parents to
me as well as deep close personal friends during this time. So, once again, thank you Elena
Benton, Mark Sarnowski, Emily Rhoades Clark, and Arniel Ortega who are personal friends
that have become my family. None of this would have been possible without the love and
support of my husband, Sam Truong.
The following work was supported by these funding sources: the UNM Center of Biomedical
Engineering, the UNM Clinical and Translation Science Center (CTSC), the Women in
Science Award (NSF ADVANCE @ UNM), the NSF I-Corps Site award to the Lobo
Rainforest, the UNM School of Engineering Excellence Award, the AVS Graduate Student
Award, the UNM Doctoral Travel Award, and the Gates Millennium Scholars Program.
Additional funding to from NIH MARC funded my co-author DLC for experiments in
Chapters 6 and 7.

v

ASSESSMENT OF THE BIOCOMPATIBILTY, STABILITY, AND SUITABILITY OF
NATURAL AND SYNTHETIC POLYMERS AND DRUGS IN THE FDA APPROVAL
PROCESS
BY
Phuong Anh Hoang Nguyen
MBA, University of New Mexico, 2017
M.S. Biomedical Engineering, University of New Mexico, 2016
B.S Biology, University of New Mexico, 2014
B.S. Psychology, University of New Mexico, 2014
DISSERTATION
Submitted in Partial Fulfillment of the Requirements for the Degree of:
Doctor of Philosophy, Engineering

Abstract
Regulation of the development, production, marketing, and sales of medical pharmaceuticals
and devices in the United States fall under the regulatory functions of the Food and Drug
Administration (FDA). The current FDA approval process takes an average of 10 years from
start to completion, and costs over $100 million. As a result, companies use many different
methods to find additional use of their drugs through marketing directly to the physician, or
recycling of previously approved drug moieties. In this work, an evaluation of the in vitro and
ex vivo biocompatibility of polymers and drugs in different phases of FDA approval are
evaluated. These include polymers and drugs that are 1) being studied for FDA approval
(Chapter 3), 2) used for purposes other than their initial clinical setting purposes (Chapter 4
and 5), and 3) deemed safe from studies in the 1960s-1970s and have been used due to their
low “toxicity” (Chapter 6). An alternative method of drug delivery is explored to improve the
palatability and allow for more precise control of the concentration of drugs delivered for
colonoscopy preparations to help alleviate side effects and improve compliance rates is
vi

explored in Chapter 7. The cytotoxicity of reagents (NIPAM) used in current experimental
protocols prior to FDA approval were investigated as described in Chapter 3. Although other
forms of polymerized NIPAM are non-toxic to cells, cpNIPAM purchased from retailers
should be purified prior to use to prevent unintended cytotoxic effects. Current surgical
procedures often encourage the use of antifibrinolytics to prevent excessive bleeding (Chapter
4), antibiotics, and antiseptics to prevent infection (Chapter 5). This work demonstrated that
each of the antibiotics, antiseptics, and antifibrinolytic tested are detrimental to knee joint cells.
Chapter 6 showed that PEG 3350 at current therapeutic concentrations changes the behavior
of gut cells. Taken together, these chapters emphasize the need for careful evaluation of the
possible cytotoxic effects of antibiotics in surgical applications prior to their use. Chapter 7
characterizes the ideal concentrations and their effectiveness as a potential delivery vehicle for
PEG 3350 and identifies the optimal fabrication of hydrogels using natural polymers to deliver
the maximum amount of drug. Studies were completed evaluating the hydrogels’ pH
responsiveness utilizing simple pH solutions as well as simulated gastrointestinal and small
intestinal simulation fluids.
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Chapter 1: Introduction
1.1 A brief history of the FDA
Regulation of the development, production, marketing, and sales of medical pharmaceuticals
and devices in the United States fall under the regulatory functions of the U.S. Food and Drug
Administration (FDA). The FDA is the oldest consumer agency in the United States,
originating in the U.S. Patent office in 1848, and later inherited by the Department of
Agriculture’s Division of Chemistry (later Bureau of Chemistry) in 1862 under the leadership
of Harvey Washington Wiley (see Figure 1.1 for timeline summary).1

1848

1862

• Drug Importation Act passed by Congress requiring U.S. Customs Service
inspetion to stop entry of tainted drugs.
• Formation of the first form of the FDA
• Formation of Division of Chemistry under the Department of Agriculture

1906

• Pure Food and Drug Act
• Prevents the transport of food and drugs that have been "adulterated"

1927

• Formation of Food, Drug, and Insecticide Administration
• Shortened to Food and Drug Administration 3 years later

1938

• Food, Drug, and Cosmetic Act
• Allows the FDA to regulate, and pre-approve drugs
• Beginning of "prescription-only" drug

1976

• FDA given power to regulate medical devices

Figure 1.1 Timeline of FDA history from 1848-1976.
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The FDA had minimal powers of oversight and was unable to oversee drug and medical device
marketing until 1906 when President Theodore Roosevelt signed into the law the Pure Food
and Drug Act.2,3 The act prohibited under penalty of seizure of goods, the interstate transport
of food and drugs that had been “adulterated”.

2,3

The responsibility of examining food and

drugs for such “adulteration” or “misbranding” was given to the Bureau of Chemistry.1
However, the Bureau of Chemistry’s powers were limited by judicial decisions, as they stated
that the basis of the law rested on the regulation of product labeling rather than pre-market
approval and charges could not be made without proof of “fraudulent intent”.1 In 1927, the
Bureau of Chemistry’s regulatory functions were reorganized under a new USDA body: the
Food, Drug, and Insecticide organization. 3 years later, the name was shortened to the Food
and Drug Administration.1
By the 1930s, campaigns for stronger regulatory authority prior to the release of drugs was
pushed by regulators, journalists, and the public as a result of several drugs and foods such as
false diabetes and cancer cures that was still in the market due to the limitation of the Pure
Food and Drug Act.1 However, it was not a until the release of “Elixir Sulfanilamide”, a
pediatric drug meant to cure Streptococcal infections that causes cough, that new law was
passed through congress. Sulfanilamide have been safely used in powder and tablet form until
this time, when a chemist and pharmacist named Harold Watkins experimented and found that
he could dissolve it in diethylene glycol (now used as a antifreeze agent).1 As there were no
requirements at that time to test drugs safety on humans or other mammals, the drug was
released.4 Within one month, several patients had died taking the medication, and by the time
the FDA stopped the use of the medication – over 100 children had passed away.1

2

This led to the push of Food, Drug, and Cosmetic Act that was signed into law by President
Franklin Roosevelt in 1938.2 This required FDA regulators to review both pre-clinical and
clinical test for new drugs. Although the law did not specify the tests required for approval, the
new authority allowed the FDA to block the marketing of new drugs by requiring additional
data. 2 The Act also requires that safe limits be set for unavoidable poisonous matter and allows
for factory inspections.4 The FDA was now allowed to set certain drugs as “prescription-only”
and allowed the FDA to designate certain as safe for use only under the supervision of a
medical professional.4
The FDA’s regulatory powers strengthened in 1962 by the Kefauver-Harris amendment
following Thalidomide’s problems in Europe.5 Thalidomide, known by its brand name as
Kevadon, applied to market in America in 1960. It was already sold to pregnant women in
Europe for morning sickness, but Dr. Frances Kelsey, the new medical officer at the FDA
denied the company’s requests, asking for more evidence.5 By late 1961, thalidomide was
found cause thousands of babies to be born with birth defects in Europe, Britain, Canada, and
the Middle East.5 The U.S. attributed its success in preventing thalidomide from coming to the
U.S. to the FDA, and the Kefauver-Harris amendment now required that drugs be proven
“effective” as well as safe, placing stringent controls on the use of investigational drugs that
had previously not been regulated.3 Since then, the FDA has lost some powers such as the
regulation of consumer products including hazardous toys, but gained many more involving
the regulation of drugs and food – including regulation of medical devices in 1976.6 Since
then, the powers of the FDA have remained relatively constant with primary changes focused
on updating the process of obtaining FDA approval for drugs, medical devices, etc. These

3

changes led to the establishment of laboratory practices and guidelines for clinical trials and
pre-clinical trials to ensure the quality and integrity of the safety data filed with the FDA.7
The FDA now ensures the safety and effectiveness of over $2.5 trillion of products used by
consumers, representing about $0.20 of every $1 spent by U.S. consumers.8 Figure 1.2 shows
the highlights of all the products that was regulated by the FDA in 2017, which includes over
19,000 prescription drugs, and 6,000 medical devices.8

Figure 1.2. All of the human products regulated by the FDA in 2017.8 Obtained from the Food
and Drug Administration website.8

1.2 Current FDA approval process
1.2.1 Preclinical phase in drug development
Not every substance taken by patients for their health is considered a drug by the FDA. The
FDA defines a drug as: 1) a substance recognized by an official pharmacopoeia or formulary,
2) a substance intended for use in the diagnosis, cure, mitigation, treatment or prevention of
disease, 3) a substance (other than food) intended to affect the structure or any function of the
body, 4) a substance intended for use as a component of a medicine but not a device or a
component, part, or accessory of a device.9
Drug development can be divided into 4 phases. The first is the preclinical phase, which usually
takes ≤2 years to complete. During this time, the drug is tested in the laboratory – assessing its
4

safety, effectiveness, toxicity and biological activity. Here, drugs are required to undergo
chemical and in vitro/in vivo testing.7 The results of these tests are then used to complete an
investigational new drug (IND) application, which is submitted by a physician and the investor
and includes potential targets for pharmaceutical action, chemicals that modify the targets, in
vitro and in vivo (animal testing) results to test for the efficacy and cytotoxicity of the drug,
initial work to determine pharmaceutical formulations and outline potential manufacturing
process, evaluate the drug’s purity and stability through the manufacturing process, explain the
rationale behind testing a compound in humans, show strategies for protecting human
volunteers, and create a plan for clinical testing. If the FDA believes the paperwork to be
completed, phase I studies are set to begin (see Figure 1.3 for the overview of the drug
development and review process).7,9,10
1.2.2 Clinical phase in drug development
The clinical trials phase can be split into 4 phases. Phase 1 is often completed with a small
group of healthy volunteers to determine acute toxicity and dosage (see Figure 1.3). Safe doses
can be tested at this time including a single dose, a single ascending dose, or even multiple
ascending doses. The escalation of dose ends when “unacceptable” side effects occur –
determined by the FDA and the investigator, and the previous dose is considered the maximum
tolerated dose. Of all IND applications, ~70% will pass this phase and be found safe enough
to progress to phase 2. On average, this process will cost $4-$15.2 million and take ~1-2 years
to complete.7,9–12

5

Figure 1.3. Overview of time and money invested during the drug development and review process,
as well as the resulting success rates of those drugs. IND – investigational new drug. NDA – New
Drug Application. Obtained from Norman: Drugs, Devices, and the FDA: Part 1: An Overview of
Approval Processes for Drugs.10

Phase 2 studies the effectiveness of a compound. To avoid unnecessarily exposing a human
volunteer to a potentially harmful substance, studies are based on an analysis of the fewest
volunteers needed to provide statistical power to determine efficacy. In phase 2, researchers
seek to determine the effective dose, the best method of delivery (oral vs intravenous), the
dosing interval, and reconfirm product safety. A substantial number of drug trials are
discontinued during phase 2 due to ineffectiveness, safety problems, or intolerable side
6

effects.7,9–11 Only ~20%-33% of all INDs will pass phase 2, which costs ~$13 million on
average and take 1-2 years to complete.7,9–12
Following phase 2 testing, the investigator or sponsor must submit updated information to the
FDA regarding continuing safety for subjects, incorporating toxicity information found in
Phase 2. Phase 3 testing is then allowed to begin. Phase 3 confirms the safety and efficacy of
the drug, but in large cohorts. The trials evaluate effectiveness, monitor side effects, and
compare the drug with commonly used alternative treatments. These studies can take anywhere
from 2-10 years, involving thousands of patients from multiple sites, with an average of 3-5
years, and costing $20-$100 million to complete. If a drug survives the clinical trials, an NDA
– New Drug Application, is submitted to the FDA containing all the preclinical and clinical
information obtained during the testing phase. The FDA will then complete an independent
review and make its recommendations, this process is required to take a maximum of 12
months.
If the drug is approved by the FDA, a request for a phase 4 trial may be requested where the
users are often the test subjects. This is often to evaluate the longer-term effects of drug
exposure, optimize dose, evaluate the effects on pediatric patients, or to examine the
effectiveness of the drug for additional indications. At this stage, data of potential drug side
effects rely on physicians’ reports.7,13
1.3 Controversies with the FDA
1.3.1 Race to Approve: Industry Pressure
Following the Kefauver-Harris amendment to the 1938 Food, Cosmetic and Drug Act, which
required the evaluation of old drugs, proof of effectiveness, and safety for all new drugs prior
to their approval, disclose of contraindications of their labels, overview of advertising, and
7

reporting of all adverse effects made known to companies, the FDA gained new powers to
withdraw approved drugs if they were found to be unsafe or lacking evidence of
effectiveness.14 The review of old drugs found that half were not effective, evidence that
companies devoted most of their efforts to developing clinically ineffective new drugs and then
marketing them as effective. Hundreds of prescription were removed from use, hundreds more
stayed on and continued to be prescribed.14
Starting in the mid-1970s, the pharmaceutical industry began a backlash against the FDA: they
sponsored economists and conferences emphasizing how the heightened standards of safety
and efficacy since 1962 were cutting into profits, reducing companies’ ability to fund research,
leading to the higher costs of drugs, and keeping American patients’ from obtaining benefits

Figure 1.4. The rise of corporate fees proportional to FDA total funding from 1992-2004. Obtained
from Donald Light’s The Food and Drug Administration: Inadequate Protection from Serious
Risks.14

8

of new drugs that were approved quickly. The pressure led the FDA from becoming
overburdened with more backlash and cases than they could process quickly. To further push
the FDA, the pharmaceutical industry created FDA advocacy council to find ways to improve
regulatory operations. They found that a “user fee” system would be the best option: companies
would pay for each new drug application, which provide money to the FDA to hire new
reviewers. This became law in 1992 in the form of the Prescription Drug User Fee Act.14
The pharmaceutical industry in now paying large fees to fund its regulators: the FDA (see
Figure 1.4). The pharmaceutical industry’s funding also comes at a price: the FDA is now
required to complete 90% of reviews for all priority drugs and supplements be completed in
less than 6 months, and those for standard drugs and supplements in less than 12 months. The
accelerated reviews combined with mass marketing of these new medications for uses
approved and unapproved, created a dangerous situation where over 20 million Americans
were exposed to drugs approved under PDUFA I that were withdrawn soon after for their
severe adverse effects.14 The industry required speed-up has resulted in substantially more risk
for patients as the deadline-crunch approvals have resulted in drugs being put on the market
that are three times more likely to result in toxic effects leading to severe or serious harm.14
1.3.2 Race to approve: Public displeasure
The push for rapid FDA approval was not only made by industry. The public, politicians,
doctors and even insurance companies were also involved in many instances. Such as a case
involving breast cancer in the 1980 when a promising new therapy was developed for women
with metastatic breast cancer: high dose chemotherapy followed by bone marrow transplant
(HDCT+/BMT). Small, early phase 2 clinical trials of this technique showed a substantial
increase in the number of patients with metastatic breast cancer responding to this new therapy
9

as compared to those treated with standard chemotherapy.15 While these studies appeared
promising, David Eddy published a review in 1992 outlining a number of criticisms that he
had found in the studies associated with this therapy. He noted that there were publication bias
in favor of positive results, lead-time bias, short follow-up time, small sample sizes, and that
there was a markedly increased risk of serious morbidities compared with the risk of standard
dose chemotherapy that was not evaluated in these phase 2 studies.16 Starting in the early
1990s, researchers began doing large, randomized, phase 3 studies to evaluate HDCT+/BMT.
Many studies including large multi-centered studies completed by Stadtmauer, Rodenhuis,
Peters, Tallman, etc. found no demonstrated no advantage of HDCT+/BMT in comparison to
standard chemotherapy.17
Only two other studies completed by Dr. Werner Bezwoda reached a different conclusion and
found a significant increase in survival rates of breast cancer patients who received
HDCT+/BMT in comparison to standard chemotherapy (See Table 1.1 for summary of
findings of randomized studies of HDCT+/BMT).18,19 Further investigations into the studies
conducted by Dr. Bezwoda showed missing data and paperwork for half of the women he
claimed were part of his study. Furthermore, after being confronted by investigators, Dr.
Bezwoda admitted to “improving” his results by lying about the drugs given to women in his
control group (the chemotherapy dose in his control group was lower than those found in
standard controls).20,21
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Study
Bezwoda et. al.

# Randomized
patients
154

Metastatic

% Survival

Disease-free
survival

83% 5-year survival 100 months with
with HDCT+/BMT HDCT+/BMT
65% 5-year survival 46.5 months with
with standard
standard
chemotherapy
chemotherapy

Stadtmauer et. al.

184

Metastatic

32% 3-year survival 9.6 months with
with HDCT+/BMT HDCT+/BMT
38% 3-year survival 9.0 months with
control
standard
chemotherapy

Rodenhuis et. al.

885

73% 5-year survival 65% disease free at
with HDCT+/BMT 5-years with
HDCT+/BMT
73% 5-year survival
control
59% disease free at
5-years control

783

79% 3-year survival 71% disease free at
with HDCT+/BMT 3-years with
HDCT+/BMT
79% 3-year survival
control
64% disease free at
3-years control

511

58% 6-year survival 49% disease free at
with HDCT+/BMT 6-years with
HDCT+/BMT
62% 6-year survival
control
47% disease free at
6-years control

High risk

Peters et. al.
High risk

Tallman et. al.
High risk

Table 1.1. Results of the study by Betzwoda et. al. and four other randomized clinical trials
of HDCT+/BMT for breast cancer.15-19
As skepticism grew in the research community about HDCT+/BMT’s efficacy to treat late
stage breast cancer, the perception of the public and oncologists were quite strong and positive.
As there were few effective treatments for advanced breast cancer patients, public’s demand
for this treatment was high even prior to its approval by the FDA. Public outcry greatly
increased in 1991 when the television show 60 minutes aired a piece decrying Aetna’s decision
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to deny insurance coverage for HDCT+/BMT to treat breast cancer.15,16 At the same time,
Nelene Fox, a 38-year old patient with advanced breast cancer sued her insurance company,
HealthNet, for refusing to pay HDCT+/BMT for Fox even though it had recently paid a relative
of its CEO to receive the same treatment. Mrs. Fox died of breast cancer before a verdict was
reached, but her family was awarded $89 million dollars. The case received widespread
publicity and in 1993, before HDCT+/BMT was ever approved by the FDA or indicated clear
positive results, Massachusetts passed a law mandating insurance to pay for HDCT+/BMT.15,16
Even in states without mandated benefits laws, the politicization and threat of litigation caused
a domino effect in the insurance industry leading to more insurance companies offering
HDCT+/BMT although it was an experimental treatment. Furthermore, because coverage was
mandated outside the context of randomized clinical trials, only one in ten breast cancer
patients who received HDCT+/BMT in the 1990s did so within a clinical trial. 15,16
The HDCT+/BMT controversy bears two important lessons about experimental treatments and
the FDA. In this case, the FDA was almost entirely bypassed in which more patients were
receiving the treatment than those typically found in other standard phase 3 trials and, not only
that, many of the patients receiving treatments were not even within a clinical trial context.
The political and public pressure caused a domino effect in which the FDA’s capabilities and
clinical research on safety and effectiveness was hindered. Even so, more cases such as these
are being found throughout the United States where the FDA is bypassed due to controversy
surrounding access to treatment and care, regardless of effectiveness.
1.3.3 Barriers of entry
Research completed by DiMasi et. al. in 2013, showed that the average cost of new drug and
biologicals development, including FDA approval is at ~$2.6 billion.22 As a result,
12

pharmaceutical companies often take advantage of the FDA’s quick approval process for
similar compounds, allowing companies to skip much of phase 1, and even phase 2 trials
allowing them to flood the market with hundreds of minor variations.23,24 As a result, a review
of new drugs released in 2002-2011 showed that only 2 of 994 new drugs released were
breakthroughs, with 13 considered real advances, 61 some advantage, and 918 new drugs that
offered little to no improvement to their predecessors (see Figure 1.5).25
Furthermore, due to the high costs associated with approvals, new smaller companies have
difficulties entering the market and undergoing FDA approval even though their product may
be novel. Large pharmaceutical companies use this to their advantage. These larger companies,
such as Merck reports show that they spend only 1.3% of their sales revenue for basic research

Figure 1.5. Overview of New Drugs released from 2002-2011
assessing them for clinical advances vs drugs that were
already on the market. Obtained from Donald Light’s Serious
Risks and few new Benefits from FDA-Approved Drugs.25
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to discover new drugs. Big companies are less interested in discovering new drugs and instead,
let thousands of research labs and biotechnology firms try to find promising new products,
absorbing the initial costs of FDA approvals, prior to one of these large companies buying in
and marketing the products.23
1.4 Exceptions to the FDA approval process
1.4.1 Unapproved Uses of Approved Drugs
Public regulation to protect patients from unsafe or ineffective drugs rests on the company
selecting the indication for which a new drug is to be tested before designing and conducting
trials to prove it is more effective than a placebo for that indication.26 After approval, it is
illegal for companies to market a drug for any condition or population inconsistent with the
evidence of its specific effectiveness against specific conditions summarized in its labels.23
However, this does not prevent company-sponsored studies and trials in which clinicians are
funded to try out a drug for other uses in small trials that do not meet full FDA scientific
standards. These clinicians then publish the results in journals that the company supports.
Furthermore, the clinicians are also paid to give sponsored grand rounds, talks, educational
courses, conference presentation at which these publications are shown as scientific evidence
for unapproved (off-label) uses or extensions of approved uses.23
This push in unapproved use research have led to unapproved prescriptions becoming more
common over time. In fact, estimates show that about one in every five prescriptions being
written is for unapproved use (see Figure 1.6 for estimated number of prescriptions for off and
on-label uses in 2011).23,27 The highest rates of unapproved use were for anticonvulsants
(74%), antipsychotics (60%), and antibiotics (41%).27
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Companies are very interested in subtly pushing unapproved (or what Stafford calls “off-label
use”). A study shows that unapproved prescriptions of 160 common drugs accounted for 21%
of all prescriptions and most unapproved uses (73%) had little to no scientific support.27 Even
when unapproved uses become the norm, companies are under no obligation to conduct
scientifically rigorous studies to assess benefits and risks.23
According to the FDA, the FDA perspective is that once the FDA approves a drug, healthcare
providers may prescribe and utilize the drug for an unapproved use when they judge that it is
medically appropriate for their patient.28 Furthermore, there are no laws regulating or
preventing the use of approved drugs in unapproved cases. The only limitation is that the FDA
policy prohibits direct promotion of products for unapproved use.14,27 The drug industry,
however, may facilitate unapproved use by having their representatives bring physicians
research studies that show unapproved uses. Thus, patients are not being protected by

Figure 1.6. Stafford et. al’s estimation of prescription on-label (approved) and off-label
(unapproved) uses in a number of functional drug class in 2011.23
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regulators and this puts a growing risk back on patients for uses that have no proven benefit/risk
assessment.14,27
1.4.2 Classes of NDA and recycling of approved drug moieties
Within an IND application for an investigation new drug, pharmaceutical companies must
identify the type/class of new drug application (NDA) they are submitting (see Table 1.2).29 It
is possible for one NDA to contain >1 classification, although, as mentioned previously,
companies have avoided extensive costs associated with clinical trials by utilizing similar
drugs in different concentrations and combinations.
As such, there are few drugs that are classified as Class 1, or new molecular entities (NMEs).
NMEs are drugs that contain an active moiety that has not been approved previously or used
before and require clinical trials as well as in vivo work prior to approval. However, non-class
I drugs can skip these clinical trial requirements. This push makes companies more interested
in investing in formulations that have previously been used and established, requiring little
innovation as formulary changes require little additional clinical trials of these “new” and
“improved” drugs on their effectiveness in comparison to previously marketed concentrations.
To further their ease of submission, moieties that are deemed low risk, i.e.. When the benefits
outweigh the “risks” (side effects) and the “risks” are reversible or minimal, then they can
continue to be used over and over again with few trials to no trials or additional work needed
by the FDA for approval.
One example of this is seen with poly(ethylene glycol) (PEG) 3350 which are manufactured
by many different companies with different names and in different concentrations. In fact, PEG
3350 is the basis for a number of osmotic laxatives and is used to treat constipation and as a
bowel irrigation tool in bowel preparation therapy (such as before a colonoscopy). As the drug
16

Classification
Code #

Name

Summary

1

New Molecular
Entity (NME)

A type 1 NDA is for a drug that contains a NME which is an
active ingredient that contains no active compounds/moiety
that has previously been approved by the FDA.

2

New Active
Ingredient

A type 2 NDA is for a drug product that contains a new active
ingredient, but not an NME. A new active ingredient includes
those products whose active moiety has been previously
approved or marketed in the U.S.

3

New Dosage Form

A type 3 NDA is for a new dosage form of an active
ingredient that has been approved or marketed in the US by
the same or another applicant but in a different dosage form.

4

New Combination

A type 4 NDA is for a new drug-drug combination with >2
ingredients. This may be >2 active ingredients in a single
dosage or >2 ingredients combined together in a label

5

New formulation or
other differences

New Formulation or Other differences (e.g., new indication,
new applicant, new manufacturer

6

New indication or
claim

New indication or claim, same applicant
NOTE: this classification is no longer used as it has been
replaced by type/class 9 and 10

7

Previously marketed
but not approved
NDA

Previously marketed but without an approved NDA

8

Rx to OTC

Rx to OTC, this is specifically for a drug product intended to
for over the counter marketing that contains an active
ingredient that has been approved previously or marketed in
the United States only for dispensing by prescription

9

New indication or
claim

A type 9 NDA is for a new indication or claim for a drug
product that is currently being reviewed under a different
name and the applicant does not intend to market this drug
product under the Type 9 NDA after approval

10

New indication or
claim

This is for a new indication or claim for a drug product that is
reviewed or recently approved and the applicant intends to
market this drug product under the type 10 NDA following
approval

Table 1.2. New Drug Application Classification Codes.29

has previously been deemed “safe” by the FDA in the 1970s, it is deemed low risk. Companies
that place applications into the FDA are therefore not required to undergo additional studies
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on its safety, and are only required to prove that their dosage forms are similar and effective to
previous dosages used for constipation and/or bowel preparation.30 Subsequently, PEG 3350
is a part of 8 different patents and there are >220 approved products by the FDA for use under
different companies and different concentrations as a prescription product, generic prescription
product, over the counter product, mixture product, etc.
1.5 Another look: Drugs and polymers of interest
In this work, an evaluation of the in vitro and ex vivo biocompatibility of polymers and drugs
in different phases of FDA approval are evaluated. These include polymers and drugs that are
1) being studied for FDA approval (Chapter 3), 2) used for purposes other than their initial
clinical setting purposes (Chapter 4 and 5), and 3) deemed safe from studies in the 1960s1970s and have been used due to their low “toxicity” (Chapter 6). Furthermore, an alternative
method of drug delivery is explored to improve the palatability and allow for more precise
control of the concentration of drugs delivered for colonoscopy preparations to help alleviate
side effects and improve compliance rates. A summary of the chemical structures of the drugs
and polymers of interest can be found in Table 1.3.
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FDA
approval
status

Name

Chemical structure

Preapproval

Poly(N-isopropyl
acrylamide)
(pNIPAM)

3

Approved,
Nonapproved
use

Chlrohexidine
Gluconate

4

Approved,
Nonapproved
use

Vancomycin

4

Approved,
Nonapproved
use

Bacitracin

4

Approved,
Nonapproved
use

Povidone-Iodine

4

Approved,
Nonapproved
use

Tranexamic Acid

5

Approved

Poly(ethylene glycol)
3350 (PEG 3350)

6

Table 1.3. Chemical structures of drugs and polymers of interest.
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Discussed in
Chapter #

1.5.1 Pre-Clinical phase of development: Poly(N-isopropyl acrylamide)
Poly(N-isopropyl acrylamide) (pNIPAM) is a thermoresponsive polymer that is widely used
in bioengineering applications due to its ability to undergo phase changes at physiologically
relevant temperatures of around 32°C.31,32 As such, pNIPAM has been used in many different
works including tissue engineering,33–35 drug delivery systems,36–38 wound healing,39,40
thermo-responsive multifunctional membrane,41 and ocular adhesives.40,42 However, prior to
being used in patients and to obtain FDA approval, pNIPAM’s in vitro cytotoxicity needs to
be thoroughly evaluated. Previous work has shown that although many mechanisms of
polymerizing NIPAM is non-toxic, our group found that commercially polymerized NIPAM
exhibit signs of toxicity similar to those found in monomeric NIPAM. Chapter 3 further
evaluates the biocompatibility of commercially polymerized NIPAM on three cell lines and
attempts to answer the reasons behind its toxic effects.
1.5.2 Unapproved use of approved drugs: Tranexamic Acid, Vancomycin, Bacitracin,
Chlorhexidine, and Povidone-iodine
Antibiotics and antiseptics are often used in orthopedic surgeries to prevent infections.43–46
These include vancomycin, bacitracin, chlorhexidine gluconate (chlorhexidine), and povidoneiodine all of which were originally FDA approved for non-orthopedic surgery uses. Prior to
being commonly used in orthopedic surgeries such as total knee arthroplasties, studies were
conducted evaluating their effectiveness in preventing infections following surgery which
showed great promise.43–46 However, all of these studies only evaluate their effectiveness with
only one study focusing on biocompatibility. In fact, this study only tested chlorhexidine’s
biocompatibility on knee chondrocytes using a live/dead assay and found that it was cytotoxic
at concentrations currently used in orthopedic surgeries.47 To follow up on this study, Chapter
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4 evaluates the biocompatibility of tranexamic acid towards ex vivo chondrocytes using
live/dead assays.
Tranexamic acid is a synthetic derivative of the amino acid lysine that functions as a reversible
competitive inhibitor to the lysin receptor found on plasminogen, preventing plasmin
(activated form of plasminogen) from binding to and stabilizing the fibrin matrix, thereby
reducing blood loss. The only FDA-approved usage for TXA is for heavy menstrual bleeding
and short-term prevention of excessive blood loss in patients with hemophilia. Since its
approval, oral, topical, and intravenous TXA have been used in many different situations
including tooth extractions, surgical operations including total knee arthroplasties. However,
the cytotoxicity of TXA towards knee chondrocytes not been evaluated prior to its adaptation
into the surgical setting. As such, Chapter 5 evaluates the biocompatibility of tranexamic acid
towards ex vivo chondrocytes using live/dead assays.
1.5.3 “Low Risk” drugs and polymers and other potential Uses: Poly(ethylene glycol),
sodium alginate, and chitosan
As mentioned previously, PEG 3350 is considered a “low risk” drug/polymer used as an
osmotic laxative. There are many iterations and forms of PEG 3350 in the market, and it is the
go-to drug for colonoscopy preparations. However, few studies have evaluated its
biocompatibility in the human gastrointestinal tract as use in humans have shown “minimal”,
reversible side effects including: nausea, vomiting, dehydration, severe and worsening
stomach cramping and bloating, dizziness, rectal bleeding, etc. In Chapter 6, we test PEG
3350 at multiple concentrations for its biocompatibility in vitro on human gastrointestinal cells.
It appears that although current concentrations are technically biocompatible, assumptions are
made about the uniformity of drug concentration in the delivery method. However, this is not
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true as patients who undergo colonoscopies receive a drug packet along with a 1 gallon bottle
and told to shake the PEG 3350 into the solution. Patients often describe the solution as
“clumpy” which is indicative that the current delivery method is non-uniform which could be
a reason why patients of smaller stature can experience more side effects than those found in
the study in 1970. In Chapter 7, we encapsulate PEG 3350 using sodium alginate and chitosan
to create a pH responsive hydrogel system that allows for greater control of the delivery process
of PEG 3350 as a colonoscopy preparation solution.
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Chapter 2: Cytotoxicity Analysis of Mammalian Cells Exposed to Drugs and
Polymeric Surfaces and Extracts (Experimental Procedures and Equipment)
Invited tutorial article in preparation for a publication in Biointerphases by Nguyen, P.A.H.;
Lenz, K; and Canavan, H.E.
2.1 Introduction
Many tests can be used to describe a polymer/drug, some of those that have been used in this
work include X-ray photoelectron spectroscopy (XPS), goniometry, rheology, and nuclear
magnetic resonance (NMR). Additional techniques used to analyze polymer/drug interactions
with cells in vitro include cell morphology tests, live/dead assays, and XTT assays. A
description of these techniques are presented below.
2.2 X-Ray Photoelectron Spectroscopy (XPS)
X-ray photoelectron spectroscopy is a quantitative technique that can be used to determine the
elemental composition, bonding environments, and often times, the relative thickness of a
surface. Surfaces are irradiated with monoenergetic X-rays (photons) causing photoelectrons
to be emitted (See Figure 2.1). 48
The process corresponds to Equation 2.1 where KE is the kinetic energy of the emitted
photoelectrons, hv is the energy of the photon, BE is the binding energy of the emitted
photoelectron and φ is the work function of the device.48
𝐾𝐸 = ℎ𝑣 − 𝐵𝐸 − 𝜑 (Equation 2.1)
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The kinetic energy is measured using an electron energy analyzer, which allows for the
calculation of the binding energy:48,49

Figure 2.1. Schematic illustrating the function of an XPS instrument. X-rays are bomboarded onto
a surface, and electrons are ejected from the very top of the surface (~100 Å), then collected at the
detector. The kinetic energy of each electron is measured by the analyzer and can be related to the
binding energy, which is specific to each element – in this example, it is Si.49

Electrons can escape from the top ~100 Å of the surface. From the binding energy and the
intensity of the photoelectron peak (based on the number of photoelectrons detected), the
identity of the elements on the surface, the chemical state of each element, and the quantity of
each element may be determined.50–53 [Note: In regards to quantity, there is an error of ~5-10%
that could be determined]

50–53

The survey spectrum will allow for the determination of

elements that are present as well as the elemental composition (atomic %) while a high
resolution spectrum will allow for the determination of the elemental binding elements. [It
should also be noted the error of estimation is often higher when evaluating the elemental
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binding elements.] As a result, XPS is often used to measure the elemental composition of
surfaces, empirical formulas of pure materials, elements that may contaminate a surface, the
chemical or electronic state of each element in the surface, and the uniformity of the elemental
composition across the top surface.
Some disadvantages are associated with the use of XPS. XPS is ran under high vacuum (10=8
to 10-11 Torr) meaning that XPS is only ideal for solid samples and focuses on examining
surfaces of semi-conductors, thin films and coatings (metal/metal oxide/ DNA films),
biosensors, and dry powder pharmaceutical materials.54 Biological samples, as well as
nanoparticles often fracture under high vacuum and are not always ideal as this can change
regions exposed for characterization.55
2.3 Contact Angle (Goniometry)
A contact angle goniometer is an instrument used to measure the static contact angle of a
surface.56 It is a measuring device that uses the angle of interactions with water (or other
solutions) on a surface to characterize the relative wettability of surfaces.56 This is especially
important when depositing materials onto a surface that greatly changes its properties, or in
the use of polymers such as poly(N-isopropyl acrylamide). In Chapter 3, poly(N-isopropyl
acrylamide) is studied, and its relative wettability is highly dependent on temperature.57 Below
its lower critical solution temperature (LCST), pNIPAM is hydrophilic, and above its LCST,
pNIPAM is hydrophobic. Contact angles using goniometry can be taken to determine surface
wettability of pNIPAM on Si as well as on a Si control chip to test the surface properties
following deposition of pNIPAM onto the surface. If deposition was successful, exposure to
different temperatures will lead to relative wettability changes below and above the LCST. If
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not, pNIPAM deposited surfaces will behave similar to Si control chips where no changes are
seen.56,58

Figure 2.2. Schematic of inverted contact angle measurements on the left, showing a sample air
bubble on a substrate and the contact angle that is measured. A snapshot of an air bubble on a
pNIPAM substrate is shown on the right. 56,58

These experiments rely on the use of a technique known as captive (or inverted) bubble. The
surface is placed upside down in a quart cell filled with Millipore water. Using a syringe with
an inverted needle, an air bubble is placed on the surface and the angle between the drop and
the surface is measured (see Figure 2.2). This procedure is repeated at different temperatures
to evaluate the surfaces’ relative hydrophobicity and hydrophilicity in a quick and affordable
manner.56,58
2.4 Nuclear Magnetic Resonance (NMR)
Nuclear magnetic resonance (NMR) spectroscopy is an analytical chemistry technique used in
quality control and research for determining the content and purity of a sample as well as its
molecular structure.59 For NMR, the spin and electrical charge of nuclei are used to identify
them. In the absence of an eternal magnetic field, the direction of the spin of the nuclei will be
randomly oriented (see Figure 2.3).60 An external magnetic field is applied, the direction of
the field will cause the nuclei to align with it, leading to two possible orientations (parallel to
26

the magnetic field or antiparallel magnetic field). an energy transfer is possible between the
base energy to a higher energy level (usually within a single energy gap). If the ordered nuclei
are then subjected to electromagnetic radiation of the proper frequency the nuclei aligned with
the field will absorb energy and “spin-flip” to align themselves against the field, at a higher
energy state. When this spin-flip occurs, the nuclei are said to be in resonance. The amount of
energy, and the exact frequency of electromagnetic radiation required for resonance to occur
is dependent on both the strength of the magnetic field applied and the type of nuclei being
studied. As the strength of the magnetic field increases, the energy difference between the two
spin states increases and a higher frequency (more energy) need to be achieved for a spin-flip.
The amount of energy it takes, and the signal that matches this transfer is measured and
processed to yield an NMR spectrum which displays the plot of applied radio frequency vs the
absorption.59 In general, all nuclei with an odd number of protons or nuclei with an odd number
of neutrons are required for NMR.59

Figure 2.3. Random nuclear spin without an external magnetic field (left). Ordered nuclear
spin in an external magnetic field (right).60
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The most common use of NMR spectroscopy is in the study of liquids, including samples
dissolved in solvent to characterize for contaminants. This process is used in Chapter 3 and
7 to detect for possible contaminants in leachates from surfaces and hydrogels.
2.5 Rheology
Rheology is used to describe and assess the deformation and flow behavior of materials.61
Fluids are often subjected to rheology to study their viscosities, and dispersion behavior.
Another process that is often studied is the viscoelastic behavior of fluids, hydrogels, and even
solids. An ideally elastic solid, or fluid is a material that has the ability to resist a distorting
influence (force) and return to its original size and shape when that force is removed.61 To
determine viscoelastic behavior, a two-plate model is often used (see Figure 2.4). Here, the
sample is subjected to shear while sandwiched between two plates, with the upper plate moving
and the lower plate being stationary. By understanding the shear stress and shear strain applied,
and using the shear stress and shear modulus equations (Equations 2.2, and 2.3), the storage
modulus (G’) and the loss modulus (G’’) can be found. [Note: In equations 2.2 and 2.3, F
denotes force, A denotes area, s is the deflection path (in m) and h describes the shear gap.]
The storage modulus (G’, described in Pascal units) represents the elastic portion of the
viscoelastic behavior which describes the solid-state behavior of the sample. The loss modulus
(G’’, described in Pascal units) characterizes the viscous portion of the viscoelastic behavior,
or the liquid-state behavior of the sample.
𝐹

𝜏 = 𝐴 (Equation 2.2, shear stress)
𝑠

𝛾 = ℎ (Equation 2.3, shear strain)
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Figure 2.4. Schematic of the two plate model to determine the viscoelastic behavior of a
hydrogel, liquid, or other test material. 61

Due to its ability to describe the viscoelastic behavior of hydrogels, rheology is often used with
hydrogels to determine gelling point, and chemical stability. The loss tangent or tan δ = G’/G’’
is the measure of damping of a material and can give information about the change in chemical
properties of hydrogels. Gels are considered “stronger” or more solid-like when G’<G’’, in
contrast gels are considered “weaker” or softer and more liquid-like when G’>G’’. At G’ =
G’’, gels are considered stoichiometrically balanced. This is essential when characterizing gels
to understand their response to outside stimuli.
2.6 Cell Morphology
Cell cultures take one of two forms: suspension (as single cells, or small free floating clumps
in medium) or monolayers that are attached to the tissue culture flask (see Figure 2.5).62,63
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Monolayered cells can come
from many different cell
types including endothelial
(such
a)

b)

as

bovine

aortic

endothelial

Figure 2.5. Mammalian cells grown in (a) suspension
(lymphoblast-like cells are round) or (b) monolayers (epitheliallike cells).62,63

cells

(BAECs)),64,65
(such

as

epithelial

HeLa

cells),63

neuronal (such as SH-SY5Y),63 or fibroblasts (such as 3T3s)66 (see Figure 2.6).
Cells grown in culture can
be evaluated over time to
examine their health by
comparing
a)

b)

their

shape, structure and form
(morphology)
controls
published

c)

size,

d)

with
(previously

images

of

healthy cells).62 You can

Figure 2.6. Examples of types of monolayered cells: a) endothelial
cells (BAECs), b) epithelial cells (HeLa), neuronal cells (SHSYSY), and fibroblasts (3T3s).2-5

determine the cytotoxicity
of novel biomaterials by

examining the changes in morphology of cells after short-term and long-term exposure. In the
presence of cytotoxic materials, adherent cell lines can detach, shrink in size, have a decrease
in culture density (decrease in confluence), and experience condensation of nuclear chromatin
due to apoptosis or cell lysis.65–70 Considering the high prevalence of morphology testing to
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confirm cell health, almost every cell type, that can be purchased, has published images of
healthy cells, which can then be used as experimental controls. As a result, cell morphology is
often used in cytotoxicity experiments of novel biomaterials in vitro.70
Protocols for cell culture and observation of morphology are detailed in Chapters 3 and 6.
Briefly, cells are deposited into tissue culture flasks and grown to ~80% confluence. Cells are
then exposed to the biomaterial through direct contact, indirect contact, or elution tests.
Following exposure, cells are observed/imaged over time using a light microscope, phasecontrast microscope, scanning electron microscope (SEM), video microscope, or confocal
microscope. The duration of the experiment and type of microscope used will depend on the
focus of the experiment itself. For most applications with short-term cytotoxicity testing,
images should be taken every 12-24 hours over a 48-hour period; for mid-term cytotoxicity
testing, it can be every 24-48 hours over a 96 hour period.
While this is a relatively simple technique, the results must be observed over a relatively short
time frame. In previous studies where cell are observed over a 24 hour period using video
microscopy, morphological changes begin to take place in less than 2 hours.71,72 However, the
point of irreversible cell injury has been shown to take place several hours before the
appearance of morphologic changes.71,72 In vivo, apoptotic cell death has been estimated to be
6-24 hours.71 Due to the short time frame of apoptosis in vitro, only a few cells are undergoing
apoptosis at a single time point, and so that quantitative value of cytotoxicity may be
underestimated.71 Furthermore, cells undergoing apoptosis or cell lysis have already reached
irreversible cell injuries, so biomaterials that are mildly cytotoxic or cause reversible cell
injuries, may not be seen in cell morphology experiments.72
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This technique is dependent upon the experience of the user to be standardized and knowing
how their cells generally behave. In Chapters 3 and 6, cells are adherent cell lines that are
generally elongated and will attach to the surface. As they are detaching or experiencing
cytotoxicity, cells will begin to round over time, and detach from the flask they are adhered to.
(see Figure 2.7). Left of Figure 2.7shows the side view of this process, while right of Figure
2.7 shows the top view of this process.

Figure 2.7. Schematic of the detachment process that adherent cells undergo from a cell culture
plate or flask. Left column is a side view of the process, and right column is a top view (or
microscopy view).
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2.7 Live/Dead Stain (Ethidium homodimer I/III and Calcein AM)
The Live/Dead™ stain is a two-color fluorescence cell viability assay that simultaneously
determines live and dead cells with two different probes that measure two parameters of cell
viability: intracellular esterase activity and plasma membrane integrity.73 Live cells are
distinguished by the presence of intracellular esterase activity, which is determined by the
conversion of the non-fluorescent cell-permeant calcein AM to the green fluorescent calcein
(ex/em ~495 nm/~515nm).73 Ethidium homodimer I (EthD-1) and Ethidium homodimer III
(EthD-3O) enter cells with damaged membranes and undergo a conformational change upon
binding to nucleic acids, producing a bright red fluorescence in dead cells (ex/em ~495
nm/~635nm).73 EthD-1 and EthD-3 are both incapable of permeating intact cell membranes,
and are therefore, excluded from live cells. EthD-3 is an improved/alternative form EthD-1
developed by Biotium, as it is able to stain DNA 45% brighter than EthD-1.74 See Figure 2.8
for fluorescent images of BAECs on plasma polymerized NIPAM,32 3T3s grown on sol-gel
NIPAM,66 HELAs treated with 0.111 µm of Saurosporine,75 immortalized human corneal
epithelial cells,76 and Human recombinant muscarinic acetylcholine receptor (CHO-M1)
cells75
Calcein AM and EthD can be purchased individually to create a generic form of the
Live/Dead™ kit and are often used in place of trypan blue to determine cell viability77 and
cytotoxicity.66,73,78

[Note: it is the generic version used in this dissertation, hence the

trademarked name is not listed.] Previous studies have used calcein AM and EthD to measure
the cytotoxic effects of tumor necrosis factor (TNF),79 β-amyloid protein,80 adenovirus
protein,81 polymers such as poly(N-isopropyl acrylamide) (pNIPAM),66 etc. Furthermore, the
assay has also been used to quantify apoptotic cell death82 and cell-mediated cytotoxicity83. As
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seen from Figure 2.8, calcein AM and Eth-D are compatible with many mammalian cell types,
including adherent and non-adherent cell lines.
For all techniques, cells are cultured to confluence. Then, to perform viability assays, cells are
exposed to calcein AM and EthD and incubated for 30-45 minutes at room temperature (less
time is needed if at 37°C). After exposure, the labeled cells are viewed and the level of
cytotoxicity is evaluated qualitatively by using fluorescent microscopy, or quantitatively by
using fluorescent microplating or flow cytometry.84 All protocols have been described in detail
in Chapters 3-6.
Assays such as live/dead determine the viability of individual cells by counting point signals

a)

d)

b)

c)

e)

Figure 2.8. Fluorescent images of a) BAECs on plasma polymerized NIPAM,32 b) 3T3s grown
on sol-gel NIPAM,66 c) HELAs treated with 0.111 µm of Saurosporine,75 d) immortalized human
corneal epithelial cells,76 and e) Human recombinant muscarinic acetylcholine receptor (CHOM1) cells75 stained by calcein AM and EthD-1/EthD-3.

rather than a homogenous signal that represents a population of cells. As a result, this makes it
highly difficult for high throughput screening of cell viability in 96 well plates.78 Furthermore,
users should take into consideration the materials they are testing for cell cytotoxicity.
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Nanomaterials have been found to settle on top of cell monolayers, which are attached to the
bottom of wells causing point signal interference within the cells, and can obliterate cells and
make it difficult to quantify individual cells by a live/dead assay.78
Although highly used and successful in informing the user if cells are dead – the assay lacks
the capability to differentiate between mechanisms of death. Cell death typically occur by
necrosis, or apoptosis.85 In vivo, necrotic cell death typically induces inflammation while
apoptotic cell death does not.86 As a result, it is important to understand the mechanism of
cytotoxicity as well as whether the material is cytotoxic through biological implications. In
addition, use of this technique requires access to more advanced equipment such as a
fluorescence microscope, a microplate reader/spectrometer, and/or a flow cytometer and user
experience is required.
2.8 XTT
XTT is a colorimetric assay that assesses cell metabolic activity by reducing tetrazolium
compounds to an insoluble colored product called formazan.87 XTT is negatively charged and
do not readily penetrate cells.88 XTT is often used with an intermediate electron acceptor that
can transfer electrons from the cytoplasm or plasma membrane to assist the reduction of
tetrazolium into formazan (see Figure 2.9). 88
This set of assays is often used as a measurement of cell viability, proliferation, and testing
drug cytotoxicity.89–92 Viable cells with active metabolisms will convert these tetrazolium salts
into a colored formazan product. Whereas, when cells die, they lose the ability to convert
tetrazolium salts into formazan. As a result, the quantity of formazan is presumed to be directly
proportional to the number of viable cells.88
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a)

b)
Figure 2.9. a) XTT reduction into formazan. b) Sample XTT plate with increasing cell number,
greater amounts of cells = more detectable formazan (which is orange in color).

Several studies have compared the XTT viability assay against LDH leakage assays, trypan
blue assays, etc. and have found XTT to be a more useful and sensitive test for the
determination of acute toxicity.78,90,93 However, XTT and its related compounds and assays
(MTT, and others) have been found to interact with a number of inhibitors, proteins,
compounds, and even chemotherapy drugs leading to significant over/underestimation of cell
viability by the assay.89,94–96 For example, honey’s reducing sugars and phenolic compounds
interacted with the MTT assay, reducing MTT into formazan although no cells were present.89
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XTT and its related assays can also not be used with nanomaterials as nanomaterials have been
shown to interact with the dye through dye absorption.78
2.9 Conclusions
From the descriptions of the techniques, it is clear that one technique is not sufficient in
detailing cytotoxic effects of treatments towards cells. As a result, a combination of multiple
techniques is preferred to truly determine the biocompatibility/cytotoxicity of polymers and
other treatments.
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Chapter 3: Exploring the Anomalous Cytotoxicity of Commercially-Available
Poly(N-isopropyl Acrylamide) Substrates
Published by Nguyen, P.A.H.; Stapleton, L.; Ledesma-Mendoza, A.; Cuylear, D.L.;
Cooperstein, M.A.; and Canavan, H.E. in Biointerphases Volume 13, Issue 6, September 2018
Abstract
Poly(N-isopropyl acrylamide) (pNIPAM) is a stimulus-responsive polymer (SRP) that has
been of great interest to the bioengineering community. When the temperature is lowered
below its lower critical solution temperature (LCST, ~32 °C), pNIPAM rapidly hydrates, and
adherent cells detach as intact cell sheets. This cell-releasing behavior in a physiologically
relevant temperature range has led to NIPAM’s use for engineered tissues and other devices.
In a previous study, however, we found that although most techniques used to polymerize
NIPAM yield biocompatible films, some formulations from commercially available NIPAM
(cpNIPAM) can be cytotoxic. In this work, we investigate the reasons underlying this anomaly.
We evaluated the response of a variety of cell types (e.g., bovine aortic endothelial cells,
BAECs; monkey kidney epithelial cells, Vero cells; and mouse embryonic fibroblasts, 3T3s)
after culture on substrates spin-coated with sol-gel (spNIPAM) and commercially prepared
(cpNIPAM). The relative biocompatibility of each cell type was evaluated using observations
of their cell morphology and function (e.g., XTT and Live/Dead assays) after 48 and 96 hours
in culture. In addition, the substrates themselves were analyzed using NMR, goniometry, and
XPS. We find that all the cell types were compromised by 96 hours in culture with cpNIPAM,
although the manner in which the cells are compromised differ; in particular, while Vero and
3T3 cells appear to be undergoing cytotoxic death, BAECs appear to be undergoing apoptotic
death. We believe that this result is due to a combination of factors, including the presence of
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short chain oligomers of NIPAM in the commercially available preparation. This work
provides valuable insights into the cytotoxicity of commercially prepared polymer substrates
for this type of bioengineering work, and therefore into the applicability of use of such surfaces
for human subjects.
3.1 Introduction
Poly(N-isopropyl acrylamide) (pNIPAM or pNIPAAM) is a thermoresponsive polymer that
experiences a phase change when exposed to its lower critical solution temperature (LCST) of
~32°C.1 Above the LCST, pNIPAM is relatively hydrophobic, and the chains of the polymer
are collapsed; below the LCST, pNIPAM is relatively hydrophilic, and its chains are extended.2
Although the magnitude of the change to the polymer’s thickness and wettability is relatively
small, it has great impact on adherent mammalian cells: while cell sheets normally require
enzymatic digestion or mechanical scraping to remove them from the substrates to which they
adhere, they will spontaneously “pop off” from NIPAM substrates as contiguous sheets—
similar to a Post-It™ note—capable of adhering and proliferating elsewhere.3 Due to this
property occurring at relevant physiological temperatures, pNIPAM has attracted a great deal
of attention in cell sheet engineering,4–9 drug delivery,10–12 formation of gold nanoparticles,13
and the development of a thermo-responsive membrane.14
However, before pNIPAM can be extensively used for human applications, it must be
demonstrated that pNIPAM is benign, especially considering that the NIPAM monomer itself
is known to be toxic.15 Although hundreds of papers describe the use of pNIPAM with
mammalian cells, few papers assess its cytotoxicity.16–19 In a recent study, we performed the
first, comprehensive study of NIPAM cytotoxicity.20 In that work, NIPAM monomer, and the
most commonly used NIPAM-derivatized substrates were created using a variety of
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techniques, including free radical polymerization, sol-gels spin coated onto glass, plasma
polymerization, and atom transfer radical polymerization. Using the NIPAM substrates,
endothelial cells, epithelial cells, smooth muscle cells, and fibroblasts were cultured. The
effects of direct contact with monomeric and pNIPAM substrates were evaluated. Monomeric
and commercially available pNIPAM (cpNIPAM) was demonstrated to be the only
formulations cytotoxic toward cell types, with as little as 18% viability for MTS assay
concentration gradient results.20
In this work, the reason behind this anomaly was explored. The pNIPAM-coated surfaces were
first evaluated for their thermoresponse and surface chemistry using contact angle
measurements, cell detachment, and XPS. Having observed that different cell types
experienced slightly different levels of cytotoxicity by Cooperstein, et al., we evaluated the
relative biocompatibility of the substrates toward several cell types: bovine aortic endothelial
cells (BAECs), monkey kidney epithelial cells (Veros), and mouse embryonic fibroblasts
(3T3s). Cellular response was evaluated by observing their cell morphology, as well as through
live/dead and XTT assays. Finally, the leachate (or extract) from the polymerized NIPAM
surfaces was evaluated using NMR. We found that 3T3 (fibroblast) cells exposed to cpNIPAM
substrates had the lowest viability, indicating that the surfaces were cytotoxic and resulted in
more lytic death. However, we also found that BAECs—which appeared to have reasonable
viability using live/dead assays—had unusual cell morphology indicative of apoptotic death.
We hypothesize that the diminished cell viability is caused by a combination of factors,
including the inclusion of short chain length oligomers/NIPAM monomer that disrupts cellular
behavior. Given the interest of researchers in this field, this work provides valuable insights
into the appropriateness of using as-is commercially-prepared polymer substrates without any
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post or pre-processing for this type of bioengineering work, and therefore into the applicability
of this type of NIPAM-derived engineered tissues for human use.
3.2 Materials and Methods
3.2.1 Materials
PNIPAM, with a molecular weight of ~40,000 grams/mol, was purchased from Polysciences,
Inc. (Warringon, PA). N-isopropyl acrylamide (99%) was purchased from Acros Organics
(Geel, Belgium). Tetraethyl orthosilicate (TEOS) and isopropanol were purchased from Sigma
Aldrich (St. Louis, MO). HPLC–grade methanol, HPLC–grade dichloromethane, HPLC-grade
acetone, 200 proof ethanol, and hydrochloric acid (1 Normal) were purchased from Honeywell
Burdick and Jackson (Deer Park, TX).
Square glass cover slips were purchased from Fisher Scientific (Pittsburg, PA). Round glass
cover slips were purchased from Ted Pella (Redding, CA). The silicon chips were obtained
from Silitec (Salem, OR).
Dulbecco’s modified eagle’s medium (DMEM), minimum essential medium with alpha
modification (αMEM), and Dulbecco’s phosphate buffered saline without calcium or
magnesium were purchased from HyCLone (Logan, UT). Bovine aortic endothelial cells
(BAECs) were from Genlantis (San Diego, CA). Fibroblasts (MC3T3-E1, 3T3s) and Vero cells
(CCL-81) were purchased from ATCC (Manassas, VA). Fetal bovine serum (FBS), fungizone
and penicillin/streptomycin were from HyCLone (Logan, UT). Minimum Essential Medium
Non-Essential Amino Acids solution (MEM NEAA) and 0.25% trypsin/EDTA were purchased
from Gibco (Grand Island, NY). Ethidium Homodimer I was purchased from Invitrogen
(Grand Island, NY). Calcein am was purchased from Biotium (Fremont, CA).
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3.2.2 Surface preparation
For surface analysis, silicon chips were cut into .8 cm x 3 cm rectangles for goniometry, and 1
cm x 1 cm squares for X-ray photoelectron spectroscopy (XPS). The surfaces were cleaned
using an ultrasonic cleaner from Magnasonic ultrasonic cleaner (Toronto, Canada), for 15
minutes: dichloromethane, acetone, methanol (sequentially). The chips were then rinsed with
deionized water, dried with Nitrogen, placed in a Petri dish, wrapped in Parafilm, and stored
in a desiccator until used for deposition or goniometry.
Glass cover slides were cleaned for 30 minutes in an acid wash (1:1 solution by volume of
methanol: hydrochloric acid), rinsed with deionized water, dried with nitrogen, placed in a
Petri dish, sealed with Parafilm under nitrogen, and stored in a desiccator until used for cell
culture or solution deposition.
3.2.3 CpNIPAM solution preparation
Isopropanol was poured into a 15 mL centrifuge and its weight was determined. The amount
of cpNIPAM to be dissolved into the isopropanol was calculated based of the weight of the
isopropanol to achieve 1% of pNIPAM by weight or 2% of pNIPAM by weight.66
3.2.4 SpNIPAM solution preparation
Solution preparation using sol-gel (spNIPAM) was performed following a method previously
described.1 35 mg of pNIPAM, 5 mL of deionized water, and 200 uL of hydrochloric acid were
mixed in a 15 mL centrifuge tube and a weight percentage of pNIPAM was determined. In a
separate 15 mL centrifuge tube, 250 µL of TEOS solution (1 TEOS: 3.8 ethanol: 1.1 water:
0.0005 HCl), 43 µL of deionized water, and 600 µL of ethanol were mixed and weighed. The
appropriate amount of the pNIPAM solution was added to achieve the final weight percentage
of pNIPAM of .35%.31
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3.2.5 SpNIPAM and cpNIPAM solution deposition
To spin coat surfaces with pNIPAM, 100 µL of either the spNIPAM or cpNIPAM solution was
evenly distributed onto clean glass slides and Si chips placed on the spin coater, a H6-23 spin
coater from Laurell Technologies (North Wales, Pennsylvania). The surfaces were spun at
2000 rpm for 60 seconds. The surfaces were placed in a Petri dish, sealed with Parafilm under
nitrogen, and stored in a desiccator until used for cell culture or surface analysis.
3.2.6 Surface characterization
Goniometry
Contact angle measurements were performed with an Advanced Goniometer model 300-UPG
from ramè-Hart Instrument Co. (Mountain Lakes, NJ) with an environment chamber and the
DROPimage Standard program. Inverted bubble contact angles were taken in Millipore water
(18MΩ). Angles were obtained at room temperature (21˚C) and at body temperature (37˚C)
using the Temp Controller model 100 – 500 connected to the environmental chamber.
X-ray photoelectron spectroscopy (XPS)
Survey spectra of the pNIPAM surfaces were taken at NESAC/BIO at the University of
Washington on a Surface Science Instruments S-probe spectrometer. This instrument has a
monochromatized Al X-ray source and a low energy electron flood gun for charge
neutralization. X-ray spot size for these acquisitions was 800 x 800 µm. All samples were run
as insulators meaning the electron flood gun was used. Pressure in the analytical chamber
during spectral acquisition was about 5 x 10-9 Torr. Pass energy for survey spectra
(composition) was 150 eV. The pass energy for high-resolution C1s spectra taken at 0 degree
was 50 eV. For the high-resolution Cls spectra all binding energies were referenced to the Cls
C-C bonds at 285.0 eV. A detail scan was run for N and Si to improve quantification. Data
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analysis was carried out using the Service Physics ESCA Analysis A program (Service
Physics, Bend OR).
3.2.7 Cell Culture
For cell culture, BAECs and Vero cells were cultured according to previously established
protocols3 in DMEM supplemented with 10% FBS, 1% penicillin/streptomycin, and 1%
fungizone. For BAECs, 1%MEM NEAA was also added. 3T3s were cultured in αMEM
supplemented with 10% FBS, 1% penicillin/streptomycin, and 1% fungizone. Cells were
incubated at 37˚C in a humid atmosphere with 5% CO2. When confluent, the cells were lifted
from the cell culture flasks with 0.25% trypsin/EDTA and passaged into new flasks from
passage 2 up to 10.
3.2.8 Cell culture on NIPAM substrates
PNIPAM surfaces prepared via plasma polymerization, commercial polymerization and solgel were used for culture of mammalian cell lines according to previously established protocols
in our group.31,32,65,66 These glass slides were placed into 6 well plates and the cells at passage
6 through 9 were seeded at 1.0 x 105 cells directly onto the substrates in regular cell culture
media. The time to confluence was about 2 days. From these substrates, cell detachment was
performed in cold, 4˚C media without added supplements. To initiate the detachment, the
regular cell culture media was replaced with cold non-supplemented media. The well plates
with cells in the cold media were placed on a shaker table. The detachment was allowed to
proceed for the desired amount of time (up to 3 hours) at 4˚C. Images were obtained using 20X
objective on a Nikon Eclipse TS200F inverted microscope with an epi-fluorescence attachment
(Nikon Instruments, Melville, NY) and a SPOT Insight color mosaic digital camera
(Diagnostic Instruments, Sterling Heights, MI), before cell detachment began and at 60 minute
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intervals during cell detachment. The cells were counted from beginning of detachment to the
end of detachment using Image J software.
3.2.9 Preparation of pNIPAM extracts for NMR
Extracts from cpNIPAM, and spNIPAM were obtained at room temperature (20˚C) and body
temperature (37˚C) according to a previously described protocol.66 Briefly, to make extracts,
the previously mentioned pNIPAM surfaces were incubated in deuterated (surface to liquid
volume ratio of 2.16 cm2/mL) for 24 hours at room temperature and body temperature. After
24 hours, the resulting extracts were transferred to centrifuge tube and used for NMR.
3.2.10 Cytotoxicity Testing of NIPAM surfaces
XTT assay
XTT cell viability assay was purchased from Biotium (Fremont, CA). The procedure for XTT
assay was adapted from the procedures provided by the manufacturer.97 A working of XTT
solution was prepared by adding 50uL of activated XTT (Biotium XTT solution + activation
reagent) to 100 uL of cell media. After 48 hours, and 96 hours of incubation on pNIPAM and
control glass substrates, BAECs, 3T3s, and VEROs were removed from the incubator, and cell
media was replaced with working XTT solutions. Cells were incubated for 6 hours then
removed for absorbance measurements at 475 nm, and 660 nm (background) with a
SpectraMax M5 microplate reader (Molecular Device, San Jose, CA). A blank control was
included in empty wells in every plate, in which XTT working solution was added to empty
well plates and incubated for 6 hours.
Viability of all cell lines were calculated utilizing this equation:
% 𝑉𝑖𝑎𝑏𝑙𝑒 𝐶𝑒𝑙𝑙𝑠
=

𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 (475𝑛𝑚) − 𝑆𝑎𝑚𝑝𝑙𝑒 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 (660𝑛𝑚) − 𝑏𝑙𝑎𝑛𝑘 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 (475𝑛𝑚)
𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 (475𝑛𝑚) − 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑(660𝑛𝑚) − 𝑏𝑙𝑎𝑛𝑘 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 (475𝑛𝑚)
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Live/Dead Assay

The procedure for live/dead assay follows those previously completed by Cooperstein, et al.66
Briefly, a combined solution such as those sold by ThermoScientific was created by combining
1µL of 2mM calcein AM and 1µL of 2mM ethidium homodimer to every 1mL of DPBS. Cells
grown on pNIPAM substrates and control glass were removed from incubation at 48 hours,
and 96 hours and cell media were replaced with working live/dead solution. Cells were
incubated at 37°C and 5% CO2 with live/dead solution for 45 minutes, then rinsed with sterile
DPBS prior to imaging. Fluorescent images were taken on a Nikon Eclipse TS200F inverted
microscope at 10X with an epi-fluorescence attachment (Nikon Instruments, Melville, NY)
and a SPOT Insight color mosaic digital camera (Diagnostic Instruments, Sterling Heights,
MI).
3.2.11 Characterization of Extract Solution
Nuclear Magnetic Resonance (NMR)
NMR was used to confirm successful polymerization of the cpNIPAM, and spNIPAM. The
NMR spectra of cpNIPAM, and spNIPAM were taken at the University of New Mexico
(UNM) Nuclear Magnetic Resonance facility with an Advance III NMR spectrometer (Bruker,
Billerica, MA). It is a 300 MHz, standard bore, nanobay instrument. Spectra were obtained on
a 5 mm broadband/proton probe, at room temperature, using CDC13 as a solvent.
3.3 Results and Discussion
In a previous study, our group demonstrated that although the cell types, surface deposition
methods, and ultimate utility of cellular/NIPAM constructs differs between laboratories, the
vast majority of those preparations are biocompatible, and therefore suitable for use in
bioengineering. An anomalous result was that commercially-prepared NIPAM (cpNIPAM)
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used as-is from its manufacturer was relatively more cytotoxic than all other polymerized
forms in our lab (~20%).16 In addition, we found that endothelial cells (BAECs) had increased
sensitivity to commercially-prepared NIPAM after 48 hours. These results were consistent
with other research in our laboratory indicating that cellular sensitivity varies with cell type,
as endothelial cells were more sensitive to polymers than epithelial cells.98
In this work, we further explored these anomalous results. The stimulus-response, chemistry,
and biocompatibility of commercially available NIPAM at two concentrations (1% and 2%)
were evaluated alongside silicon controls, as well as spin-coated sol-gel NIPAM (spNIPAM).
Using contact angle goniometry, cpNIPAM-coated surfaces were first evaluated to
demonstrate their thermoresponse. The surface chemistry (and presence or absence of any
potentially harmful contaminants) was assessed using XPS. The relative biocompatibility of
the substrates toward several cell types was then assessed using endothelial cells (bovine aortic
endothelial cells, BAECs), epithelial cells (monkey kidney epithelial cells, Veros), and
fibroblasts (mouse embryonic fibroblasts, 3T3s). Cellular response was evaluated via live/dead
and XTT assays, as well as observations of cellular morphology. Finally, the leachate (or
extract) from the polymerized NIPAM surfaces was evaluated using NMR.
3.3.1 Polymer Thermoresponse
Contact angle measurements were obtained for each of the substrates prepared to determine
their thermoresponse. The contact angle of a captive air bubble was measured for each
substrate in ultrapure water at either room temperature (~25˚C) or body temperature (37˚C).
Three samples were analyzed on three spots per sample. Three replicates were performed for
each type of pNIPAM coated substrates, resulting in n= 27.

47

Figure 3.1 shows the results of these measurements. Each of the pNIPAM–coated substrates
tested yield higher contact angles at body temperature than at room temperature. On average
there is a 13˚ change between contact angles at body temperature and room temperature (46.6˚
vs. 31.5˚ for 1% cpNIPAM, 55˚ vs. 41.6˚for 2% cpNIPAM, and 34.6˚ vs. 23.7˚ for spNIPAM).

Figure 3.1. Captive bubble contact angle measurements of silicon controls and pNIPAM-coated
surfaces measured at room temperature (25°C) and body temperature (37°C) in ultrapure water. N
= 27.

Although the contact angles differ depending on the surface characterization technique,
previous studies have shown that the specific values at each temperature are not critical to
determine the thermoresponse of the substrate—it is the relative change in wettability that is
crucial to their thermoresponse.6 The relative change in contact angles across the LCST
indicates the desired result: each of the prepared pNIPAM surfaces are thermoresponsive.
Although the standard deviations are greater (up to 12 ˚) than other preparation methods (e.g.,
plasma polymerized NIPAM, ±2),66 this analysis confirms that the films are stimulusresponsive, and of sufficient quality for later cell response assays. The silicon (negative)
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controls showed minimal variation between body temperature and room temperature, which is
also consistent with expected results.
3.3.2 Surface Chemistry
The surface chemistry of these pNIPAM coated substrates was assessed by XPS. Figure 3.2a
and 3.2b show the results of survey and high resolution C1s spectra for all four types of
pNIPAM coated surfaces, as well as the composition of NIPAM as predicted from the
stoichiometry of the monomer.
In Figure 3.2a, it is shown that spNIPAM contains far less C (and far more Si), which is
expected, as the TEOS solution used to create the sol-gel contains organosilanes. In
comparison, the presence of silicon in cpNIPAM films is detected at low concentrations/ not
detected, indicating that the films are sufficiently thin (i.e., <~50-100 nm thick). The cpNIPAM
surfaces have an elemental composition (76.9% C, 11.8% N, 11.0% O, and 1.4% Si; and 77.3%
C, 11.9% N, and 10.8% O, respectively for 1% and 2% cpNIPAM) that is consistent with the
predicted composition of the monomer (~75%C, 12.5% O, and 12.5%N). No other elements
were detected on the cpNIPAM substrates, ruling out the presence of any potentially cytotoxic
contaminants (such as catalysts used to polymerize cpNIPAM).
The spNIPAM composition differs significantly from the theoretical composition (8.8% C, 0%
N, 36.6% O, and 54.6% Si). As previously stated, the increased concentration of silicon and
oxygen are consistent with the presence of TEOS to create the sol-gel (indicating that the
NIPAM and TEOS components have phase separated) but could also arise from the underlying
silicon surface (glass, indicating patchy coverage of the film). The trace amounts of nitrogen
indicates a very small amount of NIPAM. Previous studies done by Bluestein, et al. have
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shown that storage conditions such as time after deposition, temperature and humidity all
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Figure 3.2. a) Surface chemistry of NIPAM-coated surfaces as determined by XPS. In part a), the
atomic % of carbon, oxygen, nitrogen, and silicon are shown for silicon control (middle left, grey),
spNIPAM-coated substrates (middle, blue), cpNIPAM 1%- (right middle, light purple), cpNIPAM
2%-coated (right, dark purple). The theoretical composition of NIPAM as calculated from the
monomer (left, black) is shown for comparison. N = 24. In part b), the high resolution carbon
species (C-C/C-H, C-OH/C-N, and N-C=O) are shown silicon control (middle left, grey),
spNIPAM-coated substrates (middle, blue), cpNIPAM 1%- (right middle, light purple), cpNIPAM
2%-coated (right, dark purple). The theoretical composition of NIPAM as calculated from the
monomer (left, black) is shown for comparison. N = 12.
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significantly affect spNIPAM film stability.32
Specifically, over time, regardless of storage conditions, spNIPAM surfaces begin to lose
thermoresponsive characteristics and delaminate as spNIPAM is physiosorbed and not
a)
chemisorbed onto surfaces.32 Furthermore, storage temperatures greatly
affects this

delamination effect, spNIPAM stored at 25°C in low humidity experiences the smallest amount
of delamination while spNIPAM stored at 37°C in low humidity experiences the largest
amount of delamination. As our samples are sent from the University of New Mexico to the
University of Washington, and often awaits one week prior to XPS, it is likely that our XPS
results of spNIPAM are associated with delamination. It is important to note that other than
XPS, all other experiments utilizing spNIPAM is completed immediately after fabrication.
Figure 3.2b shows the high resolution C1s spectra for spNIPAM, 1%cpNIPAM, and
2%cpNIPAM, as well as the silicon control and the theoretical composition of the monomer.
The high resolution analysis shows that the spNIPAM films have a thin amount of NIPAM as
the expected carbon species is present at appropriate concentrations (72.5% C-C/C-H, 20.0%
C-OH/C-N, and 7.5% % N-C=O), consistent with those found with spNIPAM.31,32,66,99
CpNIPAM films have the expected carbon species at appropriate concentrations (65.5% CC/C-H, 19.3% C-OH/C-N, and 15.2% N-C=O), consistent with the predicted composition of
the monomer (~66.7%C, 16.7% O, and 16.7%N).
Together, these data indicate that the cpNIPAM-coated surfaces consist of NIPAM that is of
sufficient quality to achieve cellular adhesion and popoff, and no contaminants are present that
would affect its biocompatibility. Representative survey spectra and high resolution C1s
spectra of silicon controls, spNIPAM, 1% cpNIPAM and 2% cpNIPAM can be found in
Figures 3.3 and 3.4.
51

Figure 3.3. Representative XPS spectra of silicon controls, spNIPAM, 1% cpNIPAM, and 2%
cpNIPAM.
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Figure 3.4. Representative high resolution C1s spectra of silicon control, spNIPAM, 1%
cpNIPAM, and 2% cpNIPAM.

SpNIPAM coated surfaces warranted further testing, as such, spNIPAM, 1% cpNIPAM and
2% cpNIPAM and glass controls all underwent cell detachment experiments (results found in
Figure 3.5) utilizing BAECs. After incubation for 48 hours, pNIPAM-derivatized substrates
and glass control substrates underwent detachment studies at 4°C, utilizing serum-free media.
Cells were observed and imaged every 60 minutes over 3 hours, then analyzed with Image J
cell counter. Control glass substrates had difficulties detaching cells as expected (detachment
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occurred -3%, -0.4%, and 5.6% at 60 minutes, 120 minutes, and 180 minutes respectively).
spNIPAM detached 30.5% of cells, 32.3% of cells and 34.7% of cells at 60 minutes, 120
minutes, and 180 minutes respectively. 1% cpNIPAM detached 12.2% of cells, 13.4% of cells
and 14.7% of cells at 60 minutes, 120 minutes, and 180 minutes respectively. 2% cpNIPAM
detached 9.4% of cells, 14.3% of cells and 19.1% of cells at 60 minutes, 120 minutes, and 180
minutes respectively.
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Figure 3.5. BAECs detachment from pNIPAM surfaces. After 48 hours in culture, BAECs are
exposed to serum free media at 4°C and observed over 180 minutes. Control (blue) are cells grown
on clean glass.

Although many articles have been published using pNIPAM substrates to achieve cell
detachment, rarely do the authors publish the yields they achieved using their method. We
previously showed that spNIPAM yields detachment of ~35%, and cells would detach in
islands instead of a sheet.31 In this work, we find that the detachment of cells from spNIPAM
and cpNIPAM are consistent with previous results found in our group, which is far greater than
54

those achieved by controls such as glass (5%). As such, we conclude that all surfaces contain
a thin layer of NIPAM, enough for cell adherence and detachment and that there are no
contaminates in our NIPAM films that could lead to cytotoxicity effects.
BAECS

VEROs

3T3s

Glass
(control)

spNIPAM

1%
cpNIPAM

2%
cpNIPAM

Figure 3.6. Live/dead assay of BAECs (blue), VEROs (orange), and 3T3s (grey) incubated on glass
(control, left), spNIPAM-coated substrates (left middle), 1% cpNIPAM-coated substrates (right
middle), and 2%-cpNIPAM-coated substrates (right) after 48 hours in culture. Red = dead; green =
live. Scale bar indicates 200 μm. N = 9.
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3.3.3 Cytotoxicity Testing
In order to determine the relative biocompatibility of the substrates, live/dead and XTT assays
were performed on endothelial cells (BAECs), epithelial cells (Vero cells), and fibroblasts
(3T3s) that were cultured on NIPAM substrates for either 48 hours or 96 hours. (See Figures
3.6 and 3.7). Live/dead assays are considered a semi-quantitative assay that stain the cell
membrane of live cells green, whereas non-viable cells are dyed red due to the breakdown of
their membrane.
Figures 3.6 and 3.7 shows representative images of those cells cultured in normal media on
glass (control, top row), on spNIPAM (top middle), 1% cpNIPAM (bottom middle), and 2%
cpNIPAM (bottom). At 48 hours (Figure 3.6), BAEC cells grown on each substrate appear to
be viable and identical to those grown on the glass coverslip controls. In comparison, the Vero
cells and 3T3s grown on cpNIPAM appear to have some cell death (indicated by red). By 96
hours (Figure 3.7), approximately half of the Vero cells grown on cpNIPAM (1 and 2%) are
dead. There is also evidence of cell death in the 3T3s grown on these substrates. In contrast,
there is relatively little evidence of cell death from BAECs grown on sp- and cpNIPAM
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substrates; however, where there is cell death (as evidenced by red spots), there is a large zone
of inhibition toward growth.
BAECS

VEROs

3T3s

Glass
(control)

spNIPAM

1%
cpNIPAM

2%
cpNIPAM

Figure 3.7. Live/dead assay of BAECs (blue), VEROs (orange), and 3T3s (grey) incubated on glass
(control, left), spNIPAM-coated substrates (left middle), 1% cpNIPAM-coated substrates (right
middle), and 2%-cpNIPAM-coated substrates (right) after 96 hours in culture. Red = dead; green =
live. Scale bar indicates 200 μm. N = 9.
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Figure 3.8. XTT metabolic assay of BAECs (blue), VEROs (orange), and 3T3s (grey) incubated
on glass (control, left), spNIPAM-coated substrates (left middle), 1% cpNIPAM-coated substrates
(right middle), and 2%-cpNIPAM-coated substrates (right) after 48 hours in culture. Red line
indicates 70% viability, below which the substrates are considered cytotoxic. ** indicates p<0.05
in a student t-test between sample vs control. N = 9.

XTT assays are quantitative metabolic assays that determine the percentage of cells that are
viable as determined by their ability to reduce tetrazolium salt and produce formazan
derivatives. Figures 3.8 and 3.9 shows the results of XTT assays of all cell types toward the
spNIPAM and cpNIPAM films. The red line on Figures 3.8 and 3.9 is set to 70% viability,
which is the level below which surfaces are considered to be cytotoxic toward cells. At 48
hours (Figure 3.8), all three cell types grown on spNIPAM-coated surfaces have >70%
viability, indicating that spNIPAM would be considered nontoxic. At the same time point, 3T3
cells grown on cpNIPAM-coated surfaces have 47% and 32% viability (for 1% and 2%
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cpNIPAM, respectively), indicating that this substrate is cytotoxic toward 3T3 cells.
Interestingly, by 96 hours (Figure 3.9), it would appear that all of the NIPAM substrates, as
well as the glass control, are biocompatible towards all three cell types (as evidenced by
viability >70%). However, this could be an artifact of the XTT assay, which is unable to
accurately assess cell viability of highly confluent cells, and even some dead cells are capable
of reduction.100

Figure 3.9. XTT metabolic assay of BAECs (blue), VEROs (orange), and 3T3s (grey) incubated
on glass (control, left), spNIPAM-coated substrates (left middle), 1% cpNIPAM-coated substrates
(right middle), and 2%-cpNIPAM-coated substrates (right) after 96 hours in culture. Red line
indicates 70% viability, below which the substrates are considered cytotoxic. ** indicates p<0.05
in a student t-test between sample vs control. N = 9.

3.3.4 Cell Morphology
In parallel with the cytotoxicity assays, the morphology of the BAEC, Vero, and 3T3 cells
grown on the sp- and cpNIPAM substrates were assessed using brightfield microscopy after
48 hours (Figure 3.10) and 96 hours (Figure 3.11). The observations of cell morphology
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results, when considered alongside the differences in cytotoxicity, are particularly striking:
from the live/dead and XTT assays, it would appear that cpNIPAM is most cytotoxic to 3T3
cells, and that BAECs and Vero cells are relatively unaffected. However, close inspection of
the morphology of the cells tells a different story.
The cells grown on control samples (glass coverslips) are shown in the top row for both figures.
It can be observed that the Vero cells grow to confluence the most rapidly (center column) on
each substrate. Also of interest is that the morphology of the Vero and 3T3 cells grown on
spNIPAM and cpNIPAM surfaces are consistent with that of controls (especially at the shorter
time frame).
By 96 hours, however, distinct abnormalities appear in the cells grown on cpNIPAM substrates
(1% and more so on 2%). Close inspection of the BAEC cells shows that distinct “bubbles” or
“holes” have formed within the cell bodies (See Figure 3.10 and 3.11). In an unrelated set of
experiments exploring cellular death after exposure to oligomers, our group showed that cells
entering apoptotic death—rather than lytic death—will first form these “bubbles.” (We
hypothesize that they are neither bubbles nor holes, but are vacuoles containing cellular
material).98 Furthermore, other groups have demonstrated similar results from HeLa cells that
are undergoing lysis by lysosomes, which appear remarkably similar to those found in our
live/dead images of Vero cells and 3T3s.101 Apoptosis may explain why the XTT and live/dead

60

assays underestimate the cytotoxicity, as those techniques are better suited toward detecting
death by cell lysis.
BAECs

VEROs

3T3s

Glass
(control)

spNIPAM

1%
cpNIPAM

2%
cpNIPAM

Figure 3.10: Bovine aortic endothelial cells (BAECs, left)), VEROs (middle), and 3T3s (right)
cultured directly on glass control substrate (top), spNIPAM-coated glass (top middle), 1%
cpNIPAM- (bottom middle), and 2% cpNIPAM-coated glass (bottom). Images obtained at 48
hours after deposition to observe cell morphology. Red circle indicates “pore” or “bubble”
formation. Scale bar indicates 200 μm. N = 9.
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Furthermore, although the results from XTT at 96 hours indicate high cell viability (in Figure
3.9), it is clear from observation of the live/dead images in Figure 3.7 and the morphology
images at the same time point in Figure 3.11 that there are large areas on cpNIPAM substrates

BAECS

VEROs

3T3s

Glass (control)

spNIPAM

1% cpNIPAM

2% cpNIPAM

Figure 3.11. Bovine aortic endothelial cells (BAECs, left)), VEROs (middle), and 3T3s (right)
cultured directly on glass control substrate (top), spNIPAM-coated glass (top middle), 1%
cpNIPAM- (bottom middle), and 2% cpNIPAM-coated glass (bottom). Images obtained at 96 hours
after deposition to observe cell morphology. Red circle indicates “pore” or “bubble” formation.
Scale bar indicates 200 μm. N = 9.
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that either have dead cells (such as Vero cells on 1% cpNIPAM) or have no confluence
(BAECs on 1% and 2% cpNIPAM).
Conversely, the 3T3 cells grown on cpNIPAM substrates do not appear to have a “bubbled”
appearance, although their morphology is also quite abnormal. For example, many of the 3T3s
in Figures 3.10 and 3.11 on 1% and 2% cpNIPAM substrates are no longer stellate in
appearance, but are rounded and without projections. As the 3T3 cells are the ones found to be
least viable by XTT assay at 48 hours, this may indicate that the 3T3 cells are dying via lysis
(rather than apoptosis).
From the collected morphology and viability assays, we conclude that exposure to cpNIPAM
affects cell viability for all cell types at shorter time periods (48 hours). While some cell types
obviously show diminished viability (i.e., 3T3 cells), other cell types undergo changes that will
ultimately result in death, potentially by apoptosis. Furthermore, although XTT analysis
indicates that cell viability recovers at longer time frames, such results should be viewed with
some skepticism, as the appearance of the cells appears compromised (potentially entering
apoptosis).
3.3.5 Nuclear Magnetic Resonance to Determine Extent of Polymerization
Given that the cpNIPAM-coated substrates appeared to lack any kind of contaminant that
would explain the cell death and abnormal morphology results explained above, extracts from
the films themselves were analyzed to determine if there was anything leaching from the films
that explained diminished cell viability. NMR was used to determine the structure of cpNIPAM
and spNIPAM, including the determination of whether any (potentially toxic) NIPAM
monomer was present in the films.
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Figure 3.12 shows three NMR spectra: the spNIPAM polymer (top), 1% cpNIPAM extract
(middle), and the NIPAM monomer (bottom). The structure of the NIPAM monomer is inset,
with the pertinent moieties labeled (alkenes and isopropyl amines). The peaks labeled a, b, and
c in the region from 5.5 to 6.5 ppm indicates the location where the hydrogen adjacent to
double-bonded carbons appears in the NIPAM monomer. These peaks are unique to the
NIPAM monomer.66

Figure 3.12. 1H NMR spectra of extracts from spNIPAM (top), cpNIPAM (middle), and NIPAM
monomer (bottom). The hydrogen atoms of pertinent moieties (alkenes, a-c) and pendant
isopropyl amine (d-e) of the monomer are identified in the monomer’s structure (inset). Note that
most are also present in the cpNIPAM sample.

All three peaks are clearly visible in the NIPAM monomer spectrum, but are missing from the
NMR spectrum of spNIPAM; the disappearance of these peaks indicates successful
polymerization of the polymer. In contrast, the NMR spectrum of cpNIPAM contains the 3
peaks unique to the NIPAM monomer. Although these 3 peaks are not of the same intensity in
cpNIPAM’s spectrum as they are in the spectrum for the NIPAM monomer, they are present.
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These results indicate that polymerization of cpNIPAM was incomplete, and some unreacted
monomer still exists in the leachate. Given the known cytotoxicity of the NIPAM monomer,
this may explain to the increased cytotoxicity of cpNIPAM. These results are consistent with
previous results that have demonstrated that short oligomers and monomers of otherwise
benign polymers can be quite cytotoxic, as their shorter chains allow the polymer to penetrate
into the cell membrane, and disrupt cellular processes.
3.4 Conclusions
Ever since it was demonstrated that intact cell sheets could be harvested from pNIPAM
substrates in the mid-1990’s, there has been interest in the polymer’s use for applications such
as tissue engineering, biological sensors, and drug delivery systems. One of the factors limiting
the development of tissues and devices engineered for use with the human body has been the
question of whether polymerized NIPAM had the same cytotoxic effects as the monomer itself.
The limited number and haphazard comparison studies that had previously been performed
using pNIPAM formulations were not sufficient to answer the question of whether pNIPAM
was sufficiently benign for human use. Recently, our group published the first, comprehensive
study of NIPAM polymerized using a variety of different techniques, exposed to multiple cell
types, and assayed with a variety of tests intended to determine biocompatibility (or
cytotoxicity). In that study, we identified one anomalous result: commercially available
NIPAM (cpNIPAM) appeared to be cytotoxic.
In this work, we performed a study to determine the source behind the cytotoxicity of
cpNIPAM in comparison to other commonly-used techniques. Having confirmed that all
pNIPAM-derivatized surfaces had the correct thermoresponse (by contact angle goniometry
and cell release statistics), and the correct surface chemistry (by elemental analysis via XPS),
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the pNIPAM substrates were used for cell culture up to 96 hours. Using live/dead assays, we
demonstrated that the cpNIPAM is statistically more cytotoxic than the other polymerized
forms studied. Furthermore, we found that although 3T3 cells appear to be the most sensitive
to cpNIPAM toxicity as per live/dead and XTT assays, each of the cell types are actually
compromised by the substrate, and experience decreased viability. Finally, the absence of
contaminants in the pNIPAM leachates (and the presence of unreacted monomer in the
commercially available powder used to coat the surfaces with cpNIPAM) indicates that the
source of the cpNIPAM toxicity is the presence of short, mobile chains of NIPAM monomer
interfering with cellular function.
These results suggest that the anomalous result previously observed regarding the cytotoxicity
of cpNIPAM is due to the presence of unreacted monomer. Therefore, for researchers using
NIPAM-derivatized substrates, we recommended that they synthesize their own substrates
using the methods (e.g. plasma polymerization, sol-gel polymerization, electrospun pNIPAM)
proven to be non-toxic here and in our previous studies. Further studies should evaluate
whether additional post-processing of surfaces (e.g., washing commercial coatings) would
improve cell viabilities. Additionally, these results suggest that cell viability assays such as
XTT or live/dead should always be accompanied by careful observation of the cellular
morphology itself, as the assays may underestimate the cytotoxicity of the substrates if
apoptotic death has been triggered.
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Chapter 4: Ex vivo Human Chondrocyte Toxicity Following Exposure to
Tranexamic Acid
Manuscript in preparation for publication in Journal of Arthroplasty by Nguyen, P.A.H.;
Garbrecht, E.; Elghazali, N.; Canavan, H.E.; Salas, C.; and Decker, M.
Abstract
Tranexamic acid (TXA) is an agent used to reduce blood loss by inhibiting the breakdown of
fibrin clots. Originally, TXA was approved for use in humans in extreme situations such as
prevention of bleeding in hemophiliacs, as well as to treat extremely heavy menstrual bleeding.
Over time, however, TXA has been adapted for use in other settings including orthopedic
procedures to prevent excess blood loss in arthroplasties, spine, and trauma surgeries. Within
total and revision hip and knee arthroplasty literature, it is well established that TXA has
reduced operative blood loss and post-operative transfusion requirements. However, topical or
intra-articular TXA in the setting of a partial arthroplasty would expose native cartilage to
TXA. The impact of topical TXA on human chondrocyte viability has not been well
established.

In this study, we investigate the effect of a range of commonly utilized

concentrations of topical or intra-articular TXA on human chondrocytes ex vivo. We evaluated
chondrocyte viability qualitatively and quantitatively using live/dead assay and cell counts.
Chondrocytes from osteochondral plugs were exposed to TXA for 48 hours, with viability
evaluated from 0 days after treatment to 6 days following treatment. We found that up to 2
days following TXA exposure, the osteochondral plugs were viable (no cytotoxicity was
found). However, 4 days after treatment, all concentrations of TXA (even the lowest dose of
20g/L led to extensive cell death in osteochondral plugs. As a result, TXA should be considered
cytotoxic at all of the levels tested in this study (20+g/L). Extreme caution should be used prior
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to using TXA at these doses in orthopedic procedures until further studies can be performed to
determine the safest dose.
4.1 Introduction
Tranexamic acid (TXA) was originally approved for use in humans for extreme situations such
as prevention of bleeding in hemophiliacs, as well as to treat extremely heavy menstrual
bleeding.102 TXA acts to reduce blood loss by inhibiting the breakdown of fibrin clots.
Specifically, TXA reversibly binds plasminogen, therefore inhibiting fibrinolysis, and
stabilizing fibrin clots. Since its approval as a synthetic agent, TXA has found additional uses
during surgeries, and in instances of spontaneous or trauma induced hemorrhage.103
The use of TXA in orthopedic procedures has been shown to prevent excessive blood loss in
surgical subspecialties including arthroplasty, spine and trauma surgeries.104–106 Within
primary total knee and hip arthroplasty literature, it is well established that TXA has reduced
operative blood loss and post-operative transfusion requirements.107–115 Similar advantages
have been seen in revision hip and knee arthroplasty surgeries.116–118 Although studies showed
similar results regarding decreased intra-operative blood loss and decreased post-operative
transfusion, dosing and delivery methods vary widely. Currently there is no consensus
regarding the dose or delivery method of TXA in total joint arthroplasty. In patients with
average risk for venous thromboembolism (VTE), increase in the rate of VTE has not been
observed with the administration of TXA.119 Patients with history of VTE, stroke, and cardiac
stents have been considered high risk for VTE and systemic or intravenous TXA has been
avoided. In these high-risk patients, some have advocated for the use of topical or intraarticular TXA as a safe alternative.120
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With the clear benefits of TXA demonstrated in primary total joint replacement procedures, its
use in partial joint replacement would seem beneficial. However, topical or intra-articular TXA
in the setting of a partial arthroplasty would expose native cartilage to TXA. The impact of
topical TXA on human chondrocyte viability has not been well established. In this study, we
investigate the effect of a range of commonly utilized concentrations of topical or intraarticular TXA on human chondrocytes ex vivo. We hypothesized that TXA would be
chondrotoxic and demonstrate both a concentration and time-dependent effect on
chondrotoxicity.
4.2 Materials and Methods
4.2.1 Materials
Test specimens were obtained through the New Mexico Donor Services for this study.121
Dulbecco’s Modification of Eagle’s Medium/F-12 (DMEM/F12) 1:1 media was purchased
from Sigma-Aldrich (St. Louis, MO). Fetal Bovine Serum (FBS), fungizone, and
penicillin/streptomycin (P/S) were purchased from HyCLone (Logan, UT). Dulbecco’s
Phosphate Buffer Saline (DPBS) was purchased from VWR Life Sciences (Sanburn, NY).
Calcein AM and ethidium homodimer was obtained from a viability assay kit from Biotium
(Fremont, CA). Pharmaceutical grade tranexamic acid was obtained from Sigma Aldrich (St.
Louis, Missouri).
4.2.2 Osteochondral plug harvest and storage
Human osteochondral plugs were harvested from decedent procured through the local Donor
Services. The decedent was a middle-aged male, with plugs harvested within 48 hours after
passing using the osteoarticular allograft transfer system (OATS) (Arthrex, Naples, FL).
Osteochondral plugs were sterilely obtained from the knee joint (to include distal femur and
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proximal tibia). Osteochondral plugs were visually confirmed to have intact healthy-appearing
articular cartilage. Any plugs that were obtained from areas devoid of intact articular
cartilage were discarded. We obtained 24 osteochondral plugs which were sterilely collected
and transferred into FBS solution and then taken to the lab for PBS wash and rescue period.
Osteochondral plugs were washed with DPBS before being stored in standard 50/50
Dulbecco’s Modified Eagle’s Medium/F12 nutrient mixture with 10% fetal bovine serum
(FBS), 1% penicillin/streptomycin (P/S), and 1% fungizone at 37° C for 2 hours prior to
treatment.
4.2.3 TXA biocompatibility test
Osteochondral plugs were exposed to 0.9% normal saline (NS) or exposure to tranexamic acid
at 20g/L, 30g/L, and 40g/L (500 mg, 750mg, and 1000mg diluted in 25mL cell media).
Osteochondral plugs were exposed either to: 1) treatment utilizing a 1-minute lavage with NS,
or 2) a 48-hour soak of TXA (see Figure 4.1). The choice between option 1 vs. 2 was
dependent on the thickness of the cartilage; plugs had signs of early arthritis (i.e., thinner
cartilage) were used for TXA exposure, as these were the instances where TXA were most
likely used in surgery.106,114 Day 0 was defined as the time point after completion of exposure.
4.2.4 Live/dead assay
The procedure for performing a live/dead assay followed those previously completed by
Cooperstein, et al.66 To create the live/dead assay, a combined solution such as those sold by
ThermoScientific was mixed by combining by adding 1µL of calcein AM (1mM stock
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Figure 4.1. TXA/NS treatment of osteochondral plugs. Plugs are obtained using OATS, transferred
into FBS, washed, and placed in cell media for 2 hours, and exposed to a normal saline 1-minute
lavage, or a 48-hour soak in tranexamic acid dissolved in cell media.

solution), and 1 µL of ethidium homodimer-1 (2mM) to 1 mL of DPBS. Osteochondral plugs
were maintained in cell media and removed for viability tests at specified times after exposure
completion: day 0 (immediately after exposure), day 2 (2 days after exposure), day 4 (4 days
after exposure), and day 6 (6 days after exposure). Plugs were then rinsed, dissected, and cell
media was replaced with working live/dead solution. Cells were incubated at 37º C and 5%
CO2 with live/dead solution for 60 minutes and then rinsed with sterile DPBS prior to imaging.
Fluorescent images were taken on a Nikon Eclipse TS200F inverted microscope at 10X with
an epifluorescence attachment (Nikon Instruments, Melville, NY) and a SPOT Insight color
mosaic digital camera (Diagnostic Instruments, Sterling Heights, MI). Acquired images were
then enhanced using Fiji (Image J Software). Images of dead cells (red) were enhanced to
increase its’ brightness and contrast. This allows dead cells to show in merged images where
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otherwise the green stained live cells would be brighter. As a result, several merged images
contain red hues.
After imaging, cells were analyzed and counted using Fiji (Image J Software), following a
previously established protocol.122 Briefly, all images were converted from color to an 8-bit
grayscale image. Then, the “Find Maxima” function was used, and “noise tolerance” was set
to 15. The formulas used for quantification were:
1. 𝑇𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠 = # 𝑜𝑓 𝐿𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠 + # 𝑜𝑓 𝐷𝑒𝑎𝑑 𝐶𝑒𝑙𝑙𝑠
# 𝑜𝑓 𝐿𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠

2. % 𝐿𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠 = 𝑇𝑜𝑡𝑎𝑙 𝐶𝑒𝑙𝑙 𝑁𝑢𝑚𝑏𝑒𝑟 ∗ 100
Following live/dead counts and evaluation of % live cells, ANOVA was completed at each day
across all treatments. If ANOVA was found to be significant, a post-hoc test of Tukey’s HSD
was used to evaluate which treatments were significantly different. Furthermore, an ANOVA
was completed within each treatment comparing the differences over time, with a post-hoc test
of Tukey’s HSD to evaluate which days, in comparison to day 0, were statistically different.
4.3 Results and Discussion
Live/dead viability assays were performed on days 0, 2, 4, and 6 following osteochondral plug
harvest and treatment of NS, and TXA. Figure 4.2 shows representative images of live (left,
green), dead (middle, red), and merged images (right) of osteochondral plugs at day 0. In
Figure 4.2, chondrocytes exposed to NS appear to remain viable, with little cell death. In
comparison, chondrocytes exposed to all concentrations of TXA demonstrate some level of
cell death, although viability remains high at day 0.
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Figure 4.2. Live (left), dead (middle), and merged (right) images of live/dead stain of osteochondral
plugs at day 0 after treatment of NS, 20g/L TXA, 30g/L TXA, and 40g/L TXA. Scale bar = 300µm.

Representative images of live/dead images of osteochondral plugs exposed to 30g/L of TXA
over time can be seen in Figure 4.3. At day 0 and day 2, little cell death can be seen. However,
beginning day 4, a large number of cells were dead. By day 6, the majority of cells were dead.
The indiscriminate green staining is likely a result of calcein AM’s interaction with cytosolic
esterases’ within the cells that can leak out as cells die.83
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Figure 4.3. Live (left), dead (middle), and merged (right) images of live/dead stain of
osteochondral plugs at 0 days, 2 days, 4 days, and 6 days after treatment of 30g/L TXA. Scale
bar = 300µm.

A quantitative evaluation of the live/dead data was completed for all experimental conditions
over days 0, 2, 4, and 6 using Fiji’s capability to count cells. Figure 4.4 and 4.5 shows the
results of our live/dead counts over all time periods of NS and TXA treatments respectively.
The red line on Figure 4.4 and 4.5 is set to 70% viability, which is the level below which
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Figure 4.4. % Live cells of 0 days (blue). 2 days (orange). 4 days (grey), and 6 days
(yellow) after treatment of NS. The red line is set to 70% viability, below which treatments
are considered cytotoxic.123 ** indicates p-values are <0.05 using Tukey’s HSD test.
treatments are considered to be cytotoxic toward cells by ISO-10993.123 Figure 4.4 shows that
chondrocytes are viable ex vivo following NS wash treatment even at 6 days after exposure
(cell viability >70% for all time points, 94.6% ± 8.9% (day 0), 79.2% ± 13.8% (day 2), 90.9%
± 7.3% (day 4), and 83.3% ± 9.0% (day 6)). Figure 4.5 shows that TXA is borderline toxic at
day 0 for all TXA concentrations (cell viabilities of 70.2% ± 5.6% at 20g/L, 79.0% ± 13.6% at
30g/L, and 78.6% ± 11.6% at 40g/L). 2 days after exposure, chondrocyte viability continues
to be borderline toxic at 69.2% ± 15.0% at 20g/L TXA, 67.4% ± 14.1% at 30g/L TXA, and
67.5% ± 17.3% at 40g/L of TXA. However, beginning at 4 days after exposure to treatment,
viability decreases to 14.9% ± 12.1% at 20g/L TXA, 21.4% ± 16.3% at 30g/L TXA, and 24.8%
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Figure 4.5. % Live cells of 0 days (blue). 2 days (orange). 4 days (grey), and 6 days
(yellow) after treatment of 20 g/L TXA, 30g/L TXA, and 40g/L TXA to osteochondral
plugs. The red line is set to 70% viability, below which treatments are considered
cytotoxic.123 ** indicates p-values are <0.05 using Tukey’s HSD test.
± 15.2% at 40g/L of TXA. This trend continues 6 days after exposure, with viabilities of 14.2%
± 13.2% at 20g/L TXA, 22.5% ± 9.9% at 30g/L TXA, and 22.4% ± 8.6% at 40g/L of TXA.
Based on ANOVA comparing the average % of live cells over time within each treatment
group, all treatment groups were statistically significant. As a result, a Tukey’s HSD post-hoc
test was used to compare average % live cells between time points to determine which time
points are statistically different.
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ANOVA of day 0, comparing the different treatments were statistically significant with a pvalue of 1.87*10-8, indicates that some of our treatments were significantly different from each
other. Further analysis using Tukey’s HSD test (as seen in Table 4.1) shows that in comparison
to normal saline, all treatment conditions of TXA were statistically significant.
group 1

group 2

mean

q-stat

lower

upper

p-value

Normal Saline

TXA 20 g/L

24.36

9.98

15.27

33.46

6.78E-09**

Normal Saline

TXA 30 g/L

15.58

6.38

6.48

24.67

1.52E-04**

Normal Saline

TXA 40 g/L

15.96

6.53

6.86

25.05

1.02E-04**

TXA 20 g/L

TXA 30 g/L

8.79

3.60

-0.31

17.88

0.06

TXA 20 g/L

TXA 40 g/L

8.41

3.44

-0.69

17.50

0.08

TXA 30 g/L

TXA 40 g/L

0.38

0.16

-8.71

9.48

0.99

Table 4.1. Tukey’s HSD test comparing treatment conditions at day 0. Standard error = 2.44. **
indicates p-values are <0.05 using a Tukey’s HSD test.

Continued analysis on day 2 using ANOVA comparing the different treatments showed a
statistically insignificant p-value of 0.07. No post-hoc test was followed as this indicates that
although there are some differences between NS and the treatment groups on day 2, they were
not statistically significant. The following days, day 4 and day 6, after treatment ANOVA
showed p-values of 3.39*10-28, and 2.71*10-32, respectively. The post-hoc tests of days 4 and
group 1

group 2

mean

q-stat

lower

upper

p-value

Normal Saline

TXA 20 g/L

76.07

24.50

64.50

87.64

2.55E-14**

Normal Saline

TXA 30 g/L

69.55

22.40

57.98

81.11

2.55E-14**

Normal Saline

TXA 40 g/L

66.17

21.31

54.60

77.73

2.55E-14**

TXA 20 g/L

TXA 30 g/L

6.52

2.10

-5.05

18.08

0.45

TXA 20 g/L

TXA 40 g/L

9.90

3.19

-1.66

21.47

0.12

TXA 30 g/L
TXA 40 g/L
3.38
1.09
-8.18
14.95
0.87
Table 4.2. Tukey’s HSD test comparing treatment conditions at day 4. Standard error = 3.10. **
indicates p-values are <0.05 using a Tukey’s HSD test.
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6 can be seen in Tables 4.2 and 4.3. At both time points, our results indicate the TXA treated
samples are significantly different from our negative control of normal saline.
group 1

group 2

mean

q-stat

lower

upper

p-value

Normal Saline

TXA 20 g/L

69.95

28.95

60.95

78.95

2.55E-14**

Normal Saline

TXA 30 g/L

61.60

25.49

52.60

70.59

2.55E-14**

Normal Saline

TXA 40 g/L

61.66

25.52

52.66

70.66

2.55E-14**

TXA 20 g/L

TXA 30 g/L

8.35

3.46

-0.65

17.35

0.078274

TXA 20 g/L

TXA 40 g/L

8.29

3.43

-0.71

17.29

0.081869

TXA 30 g/L

TXA 40 g/L

0.07

0.03

-8.93

9.07

0.999997

Table 4.3. Tukey’s HSD test comparing treatment conditions at day 6. Standard error = 2.42. **
indicates p-values are <0.05 using a Tukey’s HSD test.

Qualitative results during dissection showed degradation of osteochondral plugs over time with
exposure to TXA. By day 4 and day 6 after treatment, osteochondral plugs were increasingly
difficult to dissect following the same protocols as established by previous experiments.
Furthermore, initial exposure to TXA rapidly dropped the cell media’s pH, as indicated by a
color change in the cell media from red to yellow (due to the presence of phenol red in the cell
media). Although osteochondral plugs were rinsed between every cell media change for plugs
exposed to tranexamic acid due to pH changes, cell media was changed every 24 hours due to
a change in cell media color (red=>yellow) every 24 hours throughout the experiment. This
acidity is likely the cause of the decline in cell viability found in osteochondral plugs exposed
to tranexamic acid. These observations were not found in samples exposed to NS treatment.
The principle finding of our study is that human chondrocytes exposed to common
concentrations of topical TXA demonstrated marked cell death when compared to controls.
Other authors have investigated chondrocyte viability after exposure to TXA. Tuttle et al.,
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investigated murine and bovine chondrocyte viability after exposure to TXA. Their work
showed bovine and murine chondrocyte viability after exposure to TXA at 25g/L for 48 hours
similar to that of controls.124 The viability of the murine and bovine chondrocytes was tested
immediately after completion of 48 hour exposure.
We hypothesized that there could be delayed cell death after TXA exposure, so our cells were
followed up to 6 days after completion of 48-hour exposure. We observed significant decline
in human chondrocyte viability at 4 days and 6 days, suggesting delayed cell death after
exposure to TXA. Parker et al. investigated human chondrocyte viability after exposure to
TXA and found that exposure of TXA concentrations of 10-20g/L for 3 hours on a 3D human
chondrocyte laden gelatin-methacryloyl hydrogel model did not show any significant
differences in cell viability compared to controls.125 The basis for 3-hour exposure was
established in a study evaluating the diffusion of TXA from the knee joint by Ahlbery, et al.126
The pharmacokinetics of TXA were found to be similar to that of serum in their study. The
TXA was administered and concentration was measured prior to any surgical insult of the knee
joint, therefore the TXA was likely acting in its solute, or unbound, form. We believe that once
TXA binds to plasminogen in the joint it behaves differently from its unbound state. Literature
shows that protein, or protein bound solutes, diffuse from a joint at a much slower rate. Wallis
et al. demonstrated that the effusion times of radiolabel protein (albumin) had an average
elimination half-life of ~32 hours in non-rheumatoid patients.127 After surgical insult, it would
be presumed that plasminogen would be present for binding of TXA and retard its diffusion
from the joint. This was also shown in a clinical study by Sa-ngasoongsong, et al.128 After
total knee arthroplasty, dilute concentrations of TXA were placed in the joint along with a
drain which was clamped. The drains were unclamped at varying time points post-operatively
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and concentrations of TXA measured. The concentrations were variable throughout patients,
but similar concentrations were seen at 0 hours to 12 hours. If the half-life within the joint was
3 hours, one would expect that concentration at 12 hours would very low. However, this was
not observed in their study. Given these findings, we believe protein bound TXA, which would
be expected in the setting of postoperative hemarthrosis, has a half-life in the joint around 3648 hours. We exposed human chondrocytes to TXA for 48 hours, which demonstrated a
delayed but significant chondrotoxicity at all concentration of TXA.
Topical TXA concentrations also varied widely in studies assessing the impact of TXA.
Protocols in total knee arthroplasty for intra-articular or topical administration of TXA use a
wide variety of doses (250 mg to 3 g), but actual intra-articular concentrations are variable and
inconsistent and appear to fall between 15-100g/L.123 Picetti et al., has found that 10-15 g/L of
TXA result in substantial inhibition of fibrinolysis, but effectiveness regarding operative blood
loss or post-operative transfusion was not evaluated in the review study.129 We feel obtaining
such a specific concentration in an operative setting within the joint would be very difficult,
given the differences of joint volume in the setting of postoperative hemarthrosis among
patients. In a metanalysis, Panteli et al. found that a dose of more than 2 grams of TXA trended
toward decreased post-operative transfusion rates.109 This suggests that a higher concentration
may be needed for clinical effectiveness. Although when topical or intra-articular TXA is used
in the setting of post-operative hemarthrosis, it is difficult to predict final concentration which
would be highly variable among patients.
Based on our results, we believe that commonly used doses of intra-articular and topical TXA
in arthroplasty surgery would be toxic to chondrocytes. It is paramount to preserve and protect
cartilage in unicompartmental or partial joint arthroplasties. At this time, we would recommend
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against using standard protocols for topical or intra-articular TXA in the setting of native
cartilage.
4.4 Conclusions
The original FDA-approved use for TXA is for heavy menstrual bleeding and short-term
prevention of excessive bleeding in patients with hemophilia.102 Specifically, TXA has been
often used in tooth extraction in patients with hemophilia. It has been demonstrated that TXA
reduces the amount of blood loss, post-operative bleeding, and need for additional clotting
factors. 102
Unapproved use of oral, topical, and intravenous TXA has become more common. TXA is
now frequently used in surgical operations such as total knee arthroplasties, total hip
replacement surgeries, and other orthopedic surgeries. As with the results when used for
hemophiliacs and other FDA-approved uses, TXA has been shown to decrease the need for
blood transfusions and reduce the risk for hemorrhage.102,114,128,130 In these surgeries, TXA has
been administered via intravenous, topical, and injected methods.
Although TXA is becoming more used in orthopedic surgeries to prevent bleeding, to date,
only one study appears to have focused on its effect on native human cartilage, including
chondrocytes.125 (Another study by Tuttle et. al. focused on effects on murine and bovine
cells.) Parker, et al. assessed TXA’s toxicity to isolated chondrocytes from anterior cruciate
ligaments (ACL) from a donor. The chondrocytes were cultured in vitro 2-dimensionally as
well as 3-dimensionally within a hydrogel, after which they were exposed to TXA and
observed for cytotoxicity. They showed that concentrations above 20 g/L (such as those
recommended in intra-articular applications) appear cytotoxic to cells, resulting in atypical
morphology, reduced adhesion, and metabolic activity. At 20 g/L and below, the dose is
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considered either cytotoxic or borderline toxic (~42-79%) metabolically, though the effect is
dose- and time-dependent.
Our study is therefore the first to evaluate the cytotoxicity of TXA ex vivo. Chondrocytes from
osteochondral plugs were exposed to TXA for 48 hours, with viability evaluated from 0 days
after treatment to 6 days after treatment. We found that up to 2 days following TXA exposure,
the osteochondral plugs were viable (no cytotoxicity was found). However, beginning at 4 days
after treatment, all concentrations of TXA (including 20g/L, the level previously deemed
biocompatible by Parker, et al.) led to extensive cell death in osteochondral plugs. As a result,
TXA should be considered cytotoxic at all of the levels tested in this study (20+g/L). Extreme
caution should be used prior to using TXA at these doses in orthopedic procedures until further
studies can be performed to determine the safest dose.
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Chapter 5: Ex vivo Human Chondrocyte Toxicity Following Exposure to
Commonly Used Antibiotics and Antiseptics
Manuscript in preparation for publication in Journal of Bone & Joint Surgery (JBJS) by
Nguyen, P.A.H.; Garbrecht, E.; Elghazali, N.; Canavan, H.E.; Salas, C; and Decker, M.
Abstract
Nosocomial (hospital-acquired) infections are currently listed as the 4th leading cause of death
in the USA.131 As open wounds are one potential entryway for bacteria, fungi, and other
potentially harmful microorganisms to enter into the patient’s bloodstream, chlorhexidine,
povidone-iodine (PI), bacitracin, and vancomycin have been used in orthopedic procedures as
preventative measures against infection and as adjuvant treatments in the setting of existing
infection. With the common use of these solutions and topical powders during orthopedic
surgeries, articular cartilage is likely to be exposed to these solutions/substances. In this work,
we examine the impact that dilute solutions of chlorhexidine, povidone-iodine, bacitracin, and
vancomycin have on chondrocytes of the knee using live/dead assay. Our research shows that
vancomycin, povidone-iodine, bacitracin, and chlorhexidine are cytotoxic toward human
chondrocytes when used under the concentrations currently recommended for surgical use.
Therefore, their use under these conditions should be re-evaluated.
5.1 Introduction
Nosocomial (hospital-acquired) infections are currently listed as the 4th leading cause of death
in the USA.131 As open wounds are one potential entryway for bacteria, fungi, and other
potentially harmful microorganisms to enter into the patient’s bloodstream, antiseptic
solutions, antibiotic solutions, and topical antibiotics are commonly used in a variety of
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orthopedic procedures as preventative measures against infection and as adjuvant treatments
in the setting of existing infection (see Table 5.1).
Name

Treatment Type

Method of
Exposure

Purpose of Use

Vancomycin

Antibiotic

Intra-articular
Injection

Prevents post-operative
infection; treats total
knee arthroplasty (TKA)
infection

Bacitracin

Antibiotic

Irrigation

Prophylaxis

Chlorhexidine

Antiseptic

Irrigation

Prophylaxis

Povidone-Iodine
(PI)

Antiseptic

Irrigation

Prophylaxis

TXA

Antifibrinolytic

Intra-articular
Injection

Reduces bleeding post
operation

Normal Saline (NS)

N/A

Irrigation

Remove debris

Table 5.1. Classification and use of commonly used solutions in TKA to prevent infections
prophylactically.
5.1.1 Antibiotics
Antibiotics are the antimicrobial-active substance of choice as they can kill and/or prevent the
reproduction of bacteria. Vancomycin was approved by the FDA as an oral antibiotic in the
1950s, and bacitracin was approved as a topical antibiotic in the 1940s. Once the FDA approves
a drug, healthcare providers are then responsible to judge and evaluate its need in nonapproved
use. As a result, many healthcare providers including surgeons began using antibiotics and
antiseptics during surgery in the 1990s/2000s despite not being approved by the FDA for this
purpose.
Numerous in vivo studies of topical vancomycin powder have been performed in the setting of
spine surgeries. After review of this literature, Kanj et al.132 stated that a patient is 4 times more
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likely to experience a deep post-operative infection after orthopedic spine surgery than a
counterpart who received prophylactic topical vancomycin. In a pilot study within orthopedic
trauma surgery, intra-wound vancomycin powder in periarticular tibia fractures has shown
reduction in infection rates from 17 to 10%, although this was not statistically significant.7
During orthopedic trauma surgeries, many surgeons use a bacitracin solution for irrigation of
open fractures.46 However, no large randomized control trials specific to orthopedic surgery
have studied the effectiveness of a bacitracin irrigation solution to prevent infection. In fact,
some studies have recommended discontinuing use of bacitracin since the benefits are
unproven and there are concerns regarding increased antimicrobial resistance.43
In their study of instrumented posterior spinal fusion of the thoracolumbar spine,13 Sweet et al.
found that application of 2 grams of vancomycin significantly reduced post-operative wound
infection. Evaluation of the wound at day 0 showed that the concentration of vancomycin
within the wound was an average of 1457mg/L; by day 3, the concentration of vancomycin
was 128mg/L on day 3. For this reason, we used similar concentrations (1000mg/L, 400mg/L,
and 160mg/L) of vancomycin.
5.1.1 Antiseptics
Similar to the use of antibiotics, antiseptics such as povidone-iodine were initially approved
by the FDA for topical application on skin. As with vancomycin and bacitracin, surgeons began
to use antiseptics during surgeries in 2010 to prevent hospital-acquired infections. In the
arthroplasty literature, a dilute (0.35%) povidone-iodine (PI) lavage has been shown to
decrease the risk of infection in primary total joint arthroplasty from 0.97% to 0.15%.133 Dilute
PI lavage (1.0%) is also commonly used to treat periprosthetic joint infections.134 For this
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study, PI was evaluated from 0.25 to 1% to evaluate the potential biocompatibility of this
antiseptic.
Chlorhexidine is also commonly used in arthroplasty surgeries as an adjuvant treatment.
Campbell et al. found that pulse lavage with 0.002% chlorhexidine did not result in significant
chondrocyte cell death for up to 7 days after exposure, although higher concentrations resulted
in early (day 1 and 2) chondrocyte cell death.11 Campbell et al. also showed that that 0.002%
results in effective decontamination of Staphylococcus aureus, which is one of the bacterial
strains of most concern. For these reasons, this study includes chlorhexidine as a positive
control to evaluate our methodology.
An in vitro study has shown that dilute chlorohexidine is able to eradicate Staphylococcus
epidermidis from biofilms,44 although there are no studies showing an in vivo advantage or
effectiveness of the use of dilute chlorhexidine.
5.1.3 Other treatments
Also listed in Table 5.1 are the use of normal saline (NS), which is currently used to clean
debris and blood from the joint during surgery and is used in this study as a negative control.
In addition, TXA (which was addressed in Chapter 4) has been used as an antifibrinolytic to
prevent bleeding.
5.1.4 Evidence of antibiotics, antiseptics, and other treatments in the literature
There are few large randomized control trials within the orthopedic literature that support the
use of these adjuvant treatments even though they are commonly used.46,132,135 With the
common use of these solutions and topical powders during orthopedic surgeries, articular
cartilage is likely to be exposed to these solutions/substances. In this work, we examine the
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impact that dilute solutions of chlorhexidine, povidone-iodine, bacitracin, and vancomycin
have on chondrocytes of the knee.
5.2 Materials and Methods
5.2.1 Materials
Test specimens for this study were procured through New Mexico Donor Services. 121
Dulbecco’s Modification of Eagle’s Medium/F-12 (DMEM/F12) 1:1 media was purchased
from Sigma-Aldrich (St. Louis, MO). Fetal bovine serum (FBS), fungizone, and
penicillin/streptomycin (P/S) were purchased from HyCLone (Logan, UT). Dulbecco’s
phosphate buffer saline (DPBS) was purchased from VWR Life Sciences (Sanburn, NY).
Calcein AM and ethidium homodimer were obtained from a viability assay kit from Biotium
(Fremont, CA). Pharmaceutical grade vancomycin and bacitracin was obtained from SigmaAldrich (St. Louis, Missouri). Chlorhexidine was obtained from CareFusion (San Diego, CA).
Normal saline (NS) was obtained from B.Braun (Melsungen, Germany). Povidone-iodine was
obtained from Aplicare (Meriden, CT).
5.2.2 Osteochondral plug harvest and storage
Osteochondral plugs were obtained from a middle-aged male within 48 hours after passing
using the OATS (osteoarticular allograft transfer system) from Arthrex (Naples, Florida).
Osteochondral plugs were sterilely obtained from the knee joint (to include distal femur and
proximal tibia). Osteochondral plugs were visually confirmed to have intact articular surface;
any areas with osteoarthritis (devoid of intact articular cartilage) were discarded. We obtained
~135 osteochondral plugs. The plugs were transferred into FBS solution, and then taken to the
lab for PBS wash and rescue period.
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Osteochondral plugs were washed with DPBS before being stored in standard 50/50
Dulbecco’s Modified Eagle’s Medium/F12 nutrient mixture with 10% fetal bovine serum
(FBS), 1% penicillin/streptomycin (P/S), and 1% fungizone at 37° C for 2 hours prior to
treatment.
5.2.3 Antiseptics/antibiotics biocompatibility test
Osteochondral plugs were randomized to the following treatments: 0.9% NS as the live control;
chlorhexidine at 0.01%, and 0.5%; povidone-iodine (PI) at 0.25%, 0.50%, and 1.00%;
bacitracin at 10K units/L, 50K units/L, and 100K units/L; and vancomycin at 4mg, 10mg, and
25mg (diluted in 25mL cell media) resulting in 160mg/L, 400mg/, and 1,000mg/L.
Osteochondral plugs were exposed to treatment utilizing 1 of 2 techniques: a 1-minute lavage,
or a 48-hour soak to simulate intra-wound application of vancomycin (i.e., the procedure
previously described in Figure 4.1).
Treatments were made from stock solutions and diluted using DPBS. Bacitracin concentrations
were determined and calculated using the international standard concentration for bacitracin
of 51.2 units/mg as determined by Humphrey, et. al.136
5.2.4 Live/dead Assay
The procedure for live/dead assay follows those previously completed by Cooperstein, et al.66
Briefly, a combined live/dead solution such as those sold by ThermoScientific was made by
adding 1µL of calcein AM (1mM stock solution), and 1 µL of ethidium homodimer-1 (2mM)
to 1 mL of DPBS. Osteochondral plugs were maintained in cell media and removed for
viability tests at specified times after exposure: day 0 (immediately after exposure), day 2 (2
days after exposure), day 4 (4 days after exposure), and day 6 (6 days after exposure). For
bacitracin, viability tests were completed at day 0, day 3 (3 days after exposure), and day 6 (6
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days after exposure). Plugs were then rinsed, dissected, and cell media was replaced with
working live/dead solution. Cells were incubated at 37º C and 5% CO2 with live/dead solution
for 60 minutes and then rinsed with sterile DPBS prior to imaging. Fluorescent images were
taken on a Nikon Eclipse TS200F inverted microscope at 10X with an epifluorescence
attachment (Nikon Instruments, Melville, NY) and a SPOT Insight color mosaic digital camera
(Diagnostic Instruments, Sterling Heights, MI). Acquired images were then enhanced using
Fiji (Image J Software). Images of dead cells (red) were enhanced to increase brightness and
contrast. This allows dead cells to show in merged images where they otherwise would be
overshadowed by live cells stained in green. As a result, some of the merged images are
oversaturated and appear to contain red hues.
After imaging, cells were analyzed and counted using Fiji (Image J Software), following a
previously established protocol.122 In short, all images were converted from to color to an 8bit grayscale image. Then, the “Find Maxima” function was used, and “noise tolerance” was
set to 15.
The formulas used for quantification were:
1. 𝑇𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠 = # 𝑜𝑓 𝐿𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠 + # 𝑜𝑓 𝐷𝑒𝑎𝑑 𝐶𝑒𝑙𝑙𝑠
# 𝑜𝑓 𝐿𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠

2. % 𝐿𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠 = 𝑇𝑜𝑡𝑎𝑙 𝐶𝑒𝑙𝑙 𝑁𝑢𝑚𝑏𝑒𝑟 ∗ 100
Following live/dead counts and evaluation of % live cells, ANOVA was completed at each day
across all treatments. A post-hoc test of Tukey’s HSD was used to evaluate which treatments,
in comparison to normal saline, were significantly different. Furthermore, an ANOVA was
completed within each treatment comparing the differences over time, with a post-hoc test of
Tukey’s HSD to evaluate which days, in comparison to day 0, were significantly different.
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5.3 Results and Discussion
Live

Dead

Merged

NS (Live
Control)

0.01%
Chlorhexidine

0.5%
Chlorhexidine

Figure 5.1. Live (left), dead (middle), and merged (right) images of live/dead stain of osteochondral
plugs at day 0 after a 30-second lavage treatment of NS (top), 0.01% Chlorhexidine (middle), and
0.5% Chlorhexidine (bottom). Scale bar = 300µm.

The live/dead viability assay was performed at days 0, 2, 4, and 6 (0, 3, and 6 for bacitracin)
after osteochondral plug harvest and treatment of normal saline (NS), vancomycin,
chlorhexidine, povidone-iodine (PI), and bacitracin. Figure 5.1 shows representative images
of live (left), dead (middle), and merged images (right) of osteochondral plugs at day 0 for NS,
and chlorhexidine controls. After treatment with NS, the chondrocytes appear to be viable,
with little cell death (see top row of Figure 5.1, which is primarily green, with very little red
fluorescence). In comparison, both concentrations of chlorhexidine (0.01%, middle row; and
0.5%, bottom row of Figure 5.1), appear to induce cell death. The higher concentration (0.5%
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chlorhexidine, bottom row), appears more cytotoxic, as evidenced by the red fluorescence.
These results shows that our treatment and staining was successful, with similar results to the
one previous study published in the literature utilizing chlorhexidine at similar concentrations
on salvaged contaminated grafts.47

a)

Figure 5.2. a) % Live cells at day 0 (blue). 2 (orange). 4 (grey), and 6 (yellow) after treatment of
a) NS and b) 0.01% chlorhexidine, and 0.5% chlorhexidine to osteochondral plugs. The red line is
set to 70% viability, below which treatments are considered cytotoxic.123 ** indicates p-values are
<0.05 using a Tukey’s HSD test.

In Figure 5.2, a quantitative evaluation of the live/dead data was completed for NS and
chlorhexidine conditions over days 0, 2, 4, and 6 using cell counting. 122 The red line in Figure
5.2 is set to 70% viability, which is the level at which treatments are considered to be cytotoxic
toward cells by ISO-10993.123 ** indicates p-values are <0.05 using Tukey’s HSD in
comparison to day 0. Figure 5.2a shows that osteochondral plugs are viable ex vivo following
NS wash treatment even 6 days after treatment (cell viability >70% for all time points). Figure
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5.2b shows that chlorhexidine at 0.01% is mildly toxic, with cell viabilities of 76.1% ± 23.9%
(day 0), 56.1% ± 16.5% (day 2), 60.7% ± 11.7% (day 4), and 75.2% ± 15.1% (day 6). Cell
viability drops significantly at two and four days after exposure. However, after day 4, there
appears to be a trend towards recovery, possibly due to the doubling of healthy cells within the
culture medium. This may explain our findings that by day 6, chondrocytes treated with 0.01%
chlorhexidine are similar to those found at day 0 (no significant change observed).
In contrast, at the higher concentration of chlorhexidine (0.5%), the chondrocytes at each time

b)

Figure 5.2. b) % Live cells of day 0 (blue). 2 (orange). 4 (grey), and 6 (yellow) after treatment of a)
NS and b) 0.01% chlorhexidine, and 0.5% chlorhexidine to osteochondral plugs. The red line is set
to 70% viability, below which treatments are considered cytotoxic.123 ** indicates p-values are <0.05
using a Tukey’s HSD test.

point have cell viabilities below 50% (35.0% ± 13.0% (day 0), 29.8% ± 14.9% (day 2), 36.3%
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± 14.9% (day 4)). By day 6, virtually all of the chondrocytes exposed to 0.5% chlorhexidine
are dead (0.7% ± 2.1%).
Figure 5.3a shows representative images of live (left), dead (middle), and merged images
(right) of osteochondral plugs after exposure to povidone-iodine (PI) at increasing
concentrations (0.25% PI, 0.50% PI, and 1.0% PI. 0.25% PI) at day 0. At the lowest
concentration of PI, there appears to be little cell death; however, at medium and high dosages
a)
Live

Dead

Merged

0.25% PI

0.50% PI

1.0% PI

Figure 5.3. a) Live (left), dead (middle), and merged (right) images of live/dead stain of
osteochondral plugs at day 0 after treatment of 0.25% PI (top), 0.5% PI (middle), and 1.0% PI
(bottom). Scale bar = 300µm.
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(0.50% and 1.0%) of PI the larger number of red cells fluorescing indicates greater
cytotoxicity.
b)

Figure 5.3. b) % Live cells of day 0 (blue). 2 (orange). 4 (grey), and 6 (yellow) after a 30 second
lavage treatment of 0.25% PI, 0.5% PI, and 1.0% PI to osteochondral plugs. The red line is set to
70% viability, below which treatments are considered cytotoxic.123 ** indicates p-values are <0.05
using a Tukey’s HSD test.

Figure 5.3b confirms these observations using a quantitative evaluation of the live/dead data
for PI conditions over days 0, 2, 4, and 6 using cell counting.122 Similar to Figure 5.2, the red
line on Figure 5.3b is set to 70% viability, which indicates the level below which treatments
are considered to be cytotoxic toward cells by ISO-10993.123 Figure 5.3b shows that—despite
the appearance of viability in Figure 5.3a—even at the low concentrations of PI (0.25%), PI
appears to already be borderline cytotoxic to chondrocytes at day 0 (71.8% ± 15.7%). Longterm evaluation of PI at 0.25% shows significant drop in cell viability to 33.1% ± 13.9% by
day 2, 45.2% ± 17.7% by day 4, and 12.0 ± 12.0% by day 6.
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Similar drops in viabilities are found at higher concentrations of PI. Higher concentrations of
PI (0.5% and 1.0%) are considered toxic even at day 0 (34.3% ± 14.4% and 27.2% ± 15.9%
respectively), 0.50% PI continues to have cytotoxic effects at 2 days (21.9% ± 14.4%), 4 days
(31.5% ± 24.2%), and 6 days (12.6% ± 8.2%) after exposure. Similarly, 1.0% appears cytotoxic
to osteochondral plugs 2 days (29.0% ± 15.4%), 4 days (33.8% ± 18.6%), and 6 days (13.2%
± 15.2%) after exposure.
Figure 5.4 shows the results of live/dead imaging and cell counts after 0, 2, 4, and 6 days after
treatment with vancomycin. Representative images stained with live (left) and dead staining
(middle), and merged images (right) of osteochondral plugs are presented in Figure 5.4a at
day 0 for 160mg/L, 400 mg/L and 1000 mg/L of vancomycin. Vancomycin appears to be
cytotoxic toward the chondrocytes with toxicity increasing with higher concentration.
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a)
Live

Dead

Merged

160mg/L
Vancomycin

400mg/L
Vancomycin

b)

1000mg/L
Vancomycin

Figure 5.4 a) Live (left), dead (middle), and merged (right) images of live/dead stain of
osteochondral plugs at day 0 after treatment of 160mg/L vancomycin (top), 400mg/L vancomycin
(middle), and 1000mg/L vancomycin (bottom). Scale bar = 300µm.

Figure 5.4b shows the quantitative results of live/dead counts over days 0, 2, 4, and 6 of
vancomycin treatments. The red line on Figure 5.4b indicates 70% viability, below which
treatments are considered cytotoxic to cells. Figure 5.4b confirms that all three concentrations
(160mg/L, 400mg/, and 1,000mg/L g) of vancomycin concentrations are toxic to chondrocytes
at all time points tested (days 0, 2, 4, and 6). Exposure to 160mg/L of vancomycin led to
chondrocyte viabilities of 44.3% ± 14.3% (day 0), 24.0% ± 10.2% (day 2), 47.4% ± 11.6%
(day 4), and 30.2% ± 21.0% (day 6). Drops in viabilities were statistically significant in
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comparison to day 0 at day 2, and day 6. Treatment to 400mg/L of vancomycin had
chondrocyte viabilities of 22.6% ± 12.1% (day 0), 30.1% ± 11.3% (day 2), 43.1% ± 17.5%
(day 4), and 22.4% ± 13.5% (day 6). At 1,000mg/L, vancomycin led to chondrocyte viabilities
of 27.3% ± 14.9% (day 0), 22.7% ± 16.7% (day 2), 3.7% ± 5.6% (day 4), and 7.8% ± 11.9%
(day 6). At all concentrations, cell viability is low, with no significant recovery 6 days after
treatment (unlike cells exposed to chlorhexidine).
b)

Figure 5.4. b) % Live cells of day 0 (blue). 2 (orange). 4 (grey), and 6 (yellow) after a 48-hour soak
of 160mg/L, 400mg/L, and 1000mg/L vancomycin to osteochondral plugs. The red line is set to
70% viability, below which treatments are considered cytotoxic.123 ** indicates p-values are <0.05
using a Tukey’s HSD test.
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Figure 5.5 shows the results of live/dead imaging and counts at days 0, 3, and 6 after exposure
to bacitracin. Figure 5.5a are representative images live (left), dead (middle), and merged
images (right) of osteochondral plugs at day 0 for 10K units/L 50K units/L, and 1000 units/ L
of bacitracin. At day 0, bacitracin appears to be the most biocompatible, with less cell death
observed after exposure compared to the other antibiotics/antiseptics/treatments in this chapter
and Chapter 4. Bacitracin also appears to have an optimal dosage, as more live cells are
observed at 10K units/L and the most cell death is observed at 100K units/L.
a)
Live

Dead

Merged

10K
Bacitracin

50K
Bacitracin

100K
Bacitracin

Figure 5.5. a) Live (left), dead (middle), and merged (right) images of live/dead stain of
osteochondral plugs at day 0 after treatment of 10K units/L bacitracin (top), 50K units/L bacitracin
(middle), and 100K units/L bacitracin (bottom). Scale bar = 300µm.
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Figure 5.5b shows the results of live/dead counts over days 0, 3, and 6 of bacitracin treatments.
Figure 5.5b confirms the findings in Figure 5.5a. At day 0, all concentrations of bacitracin
appear biocompatible, with cell viabilities >70% (10K/L bacitracin: 94.0% ± 6.0%, 50K/L
bacitracin: 89.1 ± 10.9%, 100K/L bacitracin - 77.8% ± 15.1%). However, cell viability drops
b)

Figure 5.5 b) % Live cells of day 0 (blue). 2 (orange). 4 (grey), and 6 (yellow) after a 30 second
lavage treatment of 10K units/L, 50K units/L, and 100K units/L of bacitracin. The red line is set to
70% viability, below which treatments are considered cytotoxic.123 ** indicates p-values are <0.05
using a Tukey’s HSD test.

dramatically at day 3 (~60% for all concentrations). In fact, viabilities for the 10K/L bacitracin
drops to 20.8% ± 10.4% 3 days after exposure and continues to drop to 12.8% ± 10.1% 6 days
after exposure. Similar trends are found in 50K/L bacitracin and 100K/L bacitracin with drops
to 24.9% ± 14.0%, and 20.8% ± 8.9% 3 days after exposure; and 14.6% ± 16.0% and 19.3% ±
13.6% 6 days after exposure.
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Based on ANOVA comparing the average % of live cells over time within each treatment
group, all treatment groups were statistically significant. As a result, a Tukey’s HSD post-hoc
test was used to compare average % live cells between time points to determine which time
points are statistically different.
ANOVA analysis of the data from day 0 shows that cell viability following the different
treatments were statistically significant with a p-value of 1.22*10-68. Analysis at day 0 using
Tukey’s HSD test (as seen in Table 5.2) shows that in comparison to normal saline, cell
viability following treatment with almost all of the possible treatments (the highest dosage of
bacitracin, 100K units/L; as well as all concentrations of vancomycin, chlorhexidine, and PI),
group 1

group 2

mean

q-stat

lower

upper

p-value

Normal Saline

Vancomycin
160mg/L

50.32

15.99

35.60

65.03

2.02E-14**

Normal Saline

Vancomycin
400mg/L

72.00

22.89

57.29

86.72

2.02E-14**

Normal Saline

Vancomycin
1000mg/L

67.31

21.39

52.60

82.02

2.02E-14**

Normal Saline

Bacitracin 10K 0.64

0.20

-14.08

15.35

1

Normal Saline

Bacitracin 50K 5.47

1.74

-9.24

20.18

0.99

Normal Saline

Bacitracin
100K

16.83

5.35

2.12

31.54

0.01**

Normal Saline

Chlorhexidine
0.01%

18.46

5.87

3.75

33.17

2.81E-3**

Normal Saline

Chlorhexidine
0.5%

59.56

18.93

44.85

74.27

2.02E-14**

Normal Saline

Povidone
Iodine 0.25%

22.80

7.25

8.09

37.52

4.36E-05**

Normal Saline

Povidone
Iodine 0.50%

60.28

19.16

45.56

74.99

2.02E-14**

Normal Saline

Povidone
Iodine 1.0%

67.37

21.41

52.66

82.09

2.02E-14**

Table 5.2. Tukey’s HSD test results of day 0 comparing treatments to normal saline.
Standard error = 3.15. ** indicates p-values are <0.05 using a Tukey’s HSD test.
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was significantly different than those exposed to normal saline. The high q-stat values (~1) and
extremely high p-values (<0.05) for bacitracin at day 0 at low and medium dosage indicate that
cell viability after treatment with bacitracin at these amounts does not significantly affect the
viability of cells, and therefore, this antibiotic is biocompatible at these dosages.
Continued analysis on days 2, 4, and 6, showed similar results to day 0. ANOVA comparing
the different treatments showed statistically significant results at all times. At day 2, the pvalue was 3.12*10-29. At day 4 and 6 the p-values were 4.97*10-35, and 1.10*10-63 respectively.
The post-hoc tests of days 2-6 can be seen in Tables 5.3-5.5. It should be noted that bacitracin
was not part of the analysis for days 2, and 4 as bacitracin was not evaluated at these time
periods but was evaluated at day 3 instead due to minimal availability of samples. At all time
points, all treatment groups (excluding 0.01% chlorhexidine at day 6) were significantly

group 1

group 2

mean

q-stat

Lower

upper

p-value

Normal Saline

Vancomycin
160mg/L

55.23

16.42

40.26

70.20

2.02E-14**

Normal Saline

Vancomycin
400mg/L

49.08

14.59

34.11

64.05

2.00E-14**

Normal Saline

Vancomycin
1000mg/L

56.49

16.79

41.52

71.46

2.04E-14**

Normal Saline

Chlorhexidine
0.01%
23.16

6.89

8.19

38.13

9.52E-05**

Normal Saline

Chlorhexidine
0.5%
49.43

14.69

34.45

64.40

2.05E-14**

Normal Saline

Povidone
Iodine 0.25%

46.08

13.70

31.11

61.05

2.07E-14**

Normal Saline

Povidone
Iodine 0.50%

57.27

17.03

42.30

72.25

2.04E-14**

Normal Saline

Povidone
Iodine 1.0%

50.24

14.93

35.27

65.22

2.04E-14**

Table 5.3. Tukey’s HSD test results of day 2 comparing treatments to normal saline.
Standard error = 3.36. ** indicates p-values are <0.05 using a Tukey’s HSD test.
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different from normal saline, indicating that our results seen in treatments are different from
our negative control of normal saline.

group 1

group 2

mean

q-stat

lower

Upper

p-value

Normal Saline

Vancomycin
160mg/L

43.56

12.01

27.43

59.70

6.07E-13**

Normal Saline

Vancomycin
400mg/L

47.82

13.19

31.68

63.96

2.48E-14**

Normal Saline

Vancomycin
1000mg/L

87.28

24.07

71.14

103.41

2.04E-14**

Normal Saline

Chlorhexidine
0.01%
30.21

8.33

14.08

46.35

8.34E-07**

Normal Saline

Chlorhexidine
0.5%
54.62

15.06

38.49

70.76

2.02E-14**

Normal Saline

Povidone
Iodine 0.25%

45.73

12.61

29.60

61.87

6.88E-14**

Normal Saline

Povidone
Iodine 0.50%

59.45

16.40

43.31

75.59

2.04E-14**

Normal Saline

Povidone
Iodine 1.0%

57.17

15.77

41.03

73.31

2.02E-14**

Table 5.4. Tukey’s HSD test results of day 4 comparing treatments to normal saline.
Standard error = 3.63. ** indicates p-values are <0.05 using a Tukey’s HSD test.

From our initial evaluation of chondrocytes immediately after exposure to 0.25% PI, 0.01%
chlorhexidine, and all concentrations of bacitracin, each of these antibiotics and antiseptics
show promise as clinically effective and non-toxic antiseptics/antibiotics in orthopedic
procedures. However, further evaluation at longer time periods shows that of all
antiseptic/antibiotic treatments, only 0.01% chlorhexidine remains non-toxic to ex vivo
osteochondral plugs. Other conditions, including all concentrations of vancomycin (160mg/L,
400mg/L, and 1000mg/L), and high concentrations of PI (0.50%, and 1.0%) are toxic to
chondrocytes at all time points. As expected, osteochondral plugs that were exposed to normal
saline remained alive with high viabilities even 6 days after exposure, indicating that our
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method of maintenance was not the cause of cell death and the toxic effects seen in
chondrocytes are likely a result of exposure to antiseptics and antibiotics.

group 1

group 2

mean

q-stat

lower

upper

p-value

Normal Saline

Vancomycin
160mg/L

53.95

17.51

39.54

68.37

3.77E-15**

Normal Saline

Vancomycin
400mg/L

61.74

20.03

47.32

76.15

3.77E-15**

Normal Saline

Vancomycin
1000mg/L

76.33

24.77

61.91

90.74

3.77E-15**

Normal Saline

Bacitracin
10K

71.36

23.16

56.95

85.78

3.77E-15**

Normal Saline

Bacitracin
50K

69.46

22.54

55.05

83.88

3.77E-15**

Normal Saline

Bacitracin
100K

64.82

18.81

48.71

80.94

3.77E-15**

Normal Saline

Chlorhexidine
0.01%
8.94

2.90

-5.48

23.35

0.66

Normal Saline

Chlorhexidine
0.5%
83.37

27.05

68.95

97.78

3.77E-15**

Normal Saline

Povidone
Iodine 0.25%

72.09

23.39

57.68

86.51

3.77E-15**

Normal Saline

Povidone
Iodine 0.50%

71.53

23.21

57.12

85.95

3.77E-15**

Normal Saline

Povidone
Iodine 1.0%

70.86

22.99

56.45

85.28

3.77E-15**

Table 5.5. Tukey’s HSD test results of day 6 comparing treatments to normal saline. Standard error
= 3.08. ** indicates p-values are <0.05 using a Tukey’s HSD test.

5.4 Conclusions
In this work, the relative biocompatibility of several antibiotics (vancomycin, bacitracin) and
antiseptics (povidone-iodine, chlorhexidine) toward chondrocytes harvested from human
knees was evaluated using live/dead assays. These antibiotics and antiseptics were initially
approved for use with humans by the FDA for either topical or oral usage and have more
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recently been used in orthopedic procedures to prevent joint infection following hip and knee
arthroplasty.
Our research shows that vancomycin, povidone-iodine, bacitracin, and chlorhexidine are
cytotoxic toward human chondrocytes when used at (and even under) the concentrations
currently recommended for surgical use. Therefore, their use under these conditions should be
re-evaluated. Given the increasing numbers of joint replacement surgeries experienced by
patients (at earlier ages), exposing sensitive cells such as osteochondrocytes’ to cytotoxic
agents could mean a faster return to osteoarthritis for patients, with a shorter time span between
revisions. Lower concentrations should be evaluated for their safety and efficacy prior to
continued use in the surgical arena.
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Chapter 6: Investigation of the in-vitro cytotoxicity of PEG 3350 with human
gastrointestinal cells.
Manuscript in preparation for publication by Nguyen, P.A.H.; Cuylear, D.; and Canavan, H.E.
Abstract
Colorectal cancer (CRC) is the fourth most common type of cancer and the fourth leading
cause of cancer-related deaths in the United States, with an estimated 200,000 new cases each
year. A method to reliably screen for and prevents CRCs exist, and it is known as a
colonoscopy. A colonoscopy is a procedure that allows gastroenterologists to visualize and
remove the polyps that lead to 75 to 80% of CRC. A colonoscopy is recommended every few
years, beginning at the age of 50, dependent on your risk of CRC. Although individuals may
be compliant to their first screening, as many as 40% will not return for any future screenings,
dramatically increasing their risk for CRC. It is believed that low patient compliance is due to
the preparation experienced by the patient prior to the exam. The preparation is a 4-L consisting
of polyethylene glycol 3350 and other salts that help clear out the colon. PEG was initially
developed in the mid-1800s by Laurenco and Wurtz through the polymerization of ethylene
oxide with alkali metal hydroxide or zinc chloride. By the 1930s, PEG was commercialized;
and PEG became used in a variety of areas including pharmaceuticals such as topical reagents,
lubricants, cosmetics, and detergents. With limited additional in vitro studies on Chinese
Hamster cells utilizing PEG with molecular weight of 6000-7000 and small in vivo studies on
men, PEG 3350 became the primary colonoscopy preparation reagent. In this study, we
investigate the relative cytotoxicity of primary human stomach cells (HSCs), human small
intestine cells (HSIs), and human colon cells (HCCs) after exposure to increasing
concentrations of PEG 3350 (1%, 5%, 10%, 15%, and 20%) over multiple time periods (2, 6,
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12, 24, and 48 hours). Cell viability was investigated using cell morphology, live/dead assay,
and XTT assay. Though long considered to be a biocompatible polymer due to its acceptance
by the FDA, PEG 3350 does appear to negatively affect the morphology and viability of human
stomach and intestinal cells. Exposure to 5% PEG 3350 and 10% PEG 3350 cannot be
considered cytotoxic at relevant time frames to all cell lines within the human digestive system,
cytotoxic effects are seen with small changes in cell morphology as well as a decrease in cell
viability as measured by XTT in all cell types. Importantly, one of the primary complaints
about the GI preparation method is that the solution can be improperly mixed due to its high
viscosity. In such cases, it is possible that higher concentrations (up to 20%) could be
experienced in the GI tract of a patient. These results indicate that, contrary to the belief on the
safety of PEG 3350, cytotoxic effects may be experienced from the current preparation method.
6.1 Introduction
6.1.1 Colorectal Cancer (CRC) and Colonoscopy
Colorectal cancer (CRC) is the fourth most common type of cancer and the fourth leading
cause of cancer-related deaths in the United States, with an estimated 200,000 new cases each
year.137 The rate at which people are diagnosed with colorectal cancer has dropped by 32%
from 2000-2013.138 Death rates have dropped by 34% over the same time period.138 This
positive improvement in health is seen to be a direct result of more individuals participating in
a reliable screening and prevention method for CRC called a colonoscopy.138 A colonoscopy
is a procedure that allows gastroenterologists to visualize and remove the polyps that lead to
75 to 80% of CRC.139 Colonoscopy has therefore become the screening test of choice, as it
offers the advantage of simultaneously being a diagnostic and preventive tool by allowing
immediate detection and removal of polyps.140
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Despite the proven efficacy of colonoscopy as a screening tool, CRC remains one of the leading
causes of death in the USA and other developed nations. The persistence of deaths due to CRC
is due, in part, to low patient compliance adhering to the screening tool. Although individuals
may be compliant to their first screening, as many as 40% will not return for any future
screenings, dramatically increasing their risk for CRC.141,142 In the case of colonoscopy, it is
not the exam itself that causes issues, as the procedure is traditionally performed while the
patient is under “twilight” (vs. general anesthesia) conditions that limit the awareness or
discomfort experienced by the patient.
6.1.2 Patient Compliance and User Experience (UX)
It is believed that low patient compliance is due to the preparation experienced by the patient
prior to the exam. The night prior to receiving the screening, patients must prepare their
gastrointestinal (GI) tract by consuming the standard 4-liter poly(ethylene glycol)-electrolyte
lavage solution (PEG-ELS) that has been approved and accepted for use by the Food & Drug
Administration (FDA).
Approximately 34% of patients who undergo the procedure report moderate to significant
discomfort with the preparation,143,144 with patients describing the preparation as foul tasting,
with side effects including nausea, vomiting, abdominal bloating, abdominal pain, and rectal
irritation. In addition, a small percentage of patients, particularly women, elderly persons, and
physically smaller patients, experience more severe side effects, including dehydration, loss of
consciousness, and nephrotoxicity (reversible kidney failure) due to this preparation.145,146
These effects are most likely compounded by the fact that the dosage is not optimized for
individual patients (i.e., all patients receive the same dose, regardless of gender, mass, etc.). In
addition, one of the complaints of the mixture noted above is that the PEG-ELS solutions tend
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to not be homogenous, so the dosage experienced may vary greatly from the estimated ~5.2%
(w/w).
As discussed in Chapter 1, the FDA approval process is both lengthy and expensive; therefore,
it is unlikely that the key to improved patient compliance is through new materials. Instead,
we chose to explore how the “user experience” (UX, in design language)/ patient and medical
practitioner experience of products such as GoLytely™ and other PEG-ELS solutions might
be improved by varying the dosage and/or delivery system used for PEG.
6.1.3 History of Colonoscopy
In the 1970s prior to the usage of PEG in colonoscopy preparation, clinical trials for
colonoscopy screening method focused on using high concentrations of sodium chloride
solutions. This method proved quite effective; however, it was shown to have significant side
effects over longer periods of time, due to the negative effects it had on sodium/potassium
transport in the ilium and colon.30
6.1.4 History of PEG
PEG was initially developed in the mid-1800s by Laurenco and Wurtz through the
polymerization of ethylene oxide with alkali metal hydroxide or zinc chloride.30,147 By the
1930s, PEG was commercialized; and PEG became used in a variety of areas including
pharmaceuticals such as topical reagents, lubricants, cosmetics, and detergents.30,147
While PEG was initially used as a biomaterial nearly 100 years ago, it was transitioned into
the current FDA structure with minimal evaluation of its toxicity in vitro or in vivo. Shintani
et. al showed that one specific strain of PEG, PEG86-1, is a biocompatible polymer in vitro at
different molecular weights.148 Pontecorvo showed PEG 6000-7750 promoted cell growth in
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Chinese hamster hypoxanthine guanine phosphoribosyltransferase-deficient (HGPRT-), strain
wg cells and mouse thymidine kinase-deficient (TK-), strain 3T3 cells149. After these studies
were completed, no other studies have fully examined the short and long-term effects of low
and high concentrations of PEG, in particular PEG 3350, on human cell lines. To date, no
research thoroughly determines the cytotoxic effects of PEG 3350 on cells pertinent to the
human gastrointestinal tract.
6.1.5 Incorporation of PEG into Colonoscopy
In response to such limitations, Davis et al. conducted a study using PEG alongside other
electrolytes to evaluate the effect PEG had on the water and electrolyte absorption and
secretion in the gastrointestinal tract.150 This method was deemed appropriate because it
showed no evidence of volume overload or electrolyte imbalance in a human model. Thus, the
preparation solution “GoLytely™” was created.151 Further research completed by Hammer et
al. concluded that PEG 3350 was enough to increase the amount of stool a patient produces
needed to perform the procedure and as such, PEG 3350 became the primary colonoscopy
preparation reagent.152
6.1.6 Current Work
In this study, we investigate the relative cytotoxicity of primary human stomach cells (HSCs),
human small intestine cells (HSIs), and human colon cells (HCCs) after exposure to PEG 3350.
The cells have been observed after exposure to increasing concentrations of PEG 3350 (1, 5,
10, 15, and 20% (w/w)) mixed with cells’ respective cell media, over multiple time periods (2,
6, 12, 24, and 48 hours). The cellular response of the three cells lines were analyzed by
observing their cell morphology as well as through live/dead™ and XTT assays.
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6.2 Materials and Methods
6.2.1 Materials
Over the counter poly(ethylene glycol), with a molecular weight of 3350 g/mol (PEG 3350),
was purchased from EQUATE (Ahmadi, Kuwait).
Primary human (Homo sapiens) stomach (Hs.738/Int), small intestine (HIEC-6), and colon
cells (CCD-18Co) were purchased from ATCC (Manassas, VA). Dulbecco’s Modification of
Eagle’s Medium, 1X (DMEM) with 4.5 g/L glucose, L-glutamine and sodium pyruvate was
purchased from Corning (Manassas, VA) for human stomach cells. Opti-MEM I (1X) reduced
serum medium with HEPES, 2.4 g/L sodium bicarbonate, and L-Glutamine was purchased
from Life Technologies Corporation (Grand Island, NY) for human small intestine cells.
Eagle’s Minimum Essential Medium (EMEM) with Earle’s salt, L-Glutamine, and sodium
bicarbonate was purchased from Sigma-Aldrich (St. Louis, MO) for human colon cells.
Fetal bovine serum (FBS), fungizone, and penicillin/streptomycin (P/S) were purchased from
HyClone (Logan, UT). HEPES buffer (1M solution) was purchased from Mediatech, Inc.
(Manassas, VA). GlutaMAX-I (100X) was purchased from Life Technologies Corporation
(Grand Island, NY). Epidermal growth factor (Human, Recombinant) (EGF) was purchased
from Discovery Labware, Inc. (Bedford, MA). A 0.25% trypsin/ethylenediamine tetra-acetic
acid (EDTA) was purchased form Gibco (Grand Island, NY). Dulbecco’s phosphate buffer
solution (DPBS) was purchased from VWR Life Sciences (Sanburn, NY).
Ethidium Homodimer I (Eth-D) and was purchased from Invitrogen (Grand Island, NY) and
calcein AM purchased from Biotium (Fremont, CA). XTT Cell Viability Assay Kit was
purchased from Biotium (Fremont, CA). 200 proof ethanol and deuterated oxide were
purchased from Burdick and Jackson (Deer Park, TX).
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6.2.2 Cell culture
Cells were cultured according to manufacturer’s suggestion with some adaptations made by
our research group to optimize the cells’ performance.153–155 Briefly, human stomach cells
(HSCs) were cultured in DMEM, supplemented with 10% FBS, 1% P/S, and 1% fungizone.
Human small intestine cells (HSIs) were cultured in Opti-MEM, supplemented with 30 ng/mL
EGF, 10% FBS, 1% P/S, and 1% fungizone. Human colon cells (HCCs) were cultured with
EMEM supplemented with 10% FBS, 1% P/S, and 1% fungizone. All cell lines were incubated
at 37º C in an 80-100% humid atmosphere with 5% CO2. When 80% confluent, the cells were
detached from the cell culture flask using 0.25% trypsin/EDTA and redeposited into new
flasks. Tests were conducted on cells from passage 2 up to 10.
6.2.3 Preparation of cell media/PEG 3350 solutions
PEG 3350 was weighed to make 1%, 5%, 10%, 15%, 20% (w/w) solutions for cell growth.
Before adding the various weight volumes of PEG 3350 to the cell media, we exposed PEG
3350 to UV-light (~254nm) for five minutes to ensure the polymer continues to be sterile and
cytotoxicity are not a result of bacterial contamination. After UV-light exposure, PEG 3350
was added to cell media (DMEM 1X, Opti-MEM, and EMEM) to make the 1%, 5%, 10%,
15%, and 20% (w/w) solutions.
6.2.4 PEG 3350 direct contact test
The cellular response to direct contact of PEG 3350 was evaluated by observing the cells’
morphology. Cells were seeded at 1.0 x 105 cells per well in a 48-well plate then given 24
hours to adhere and grow prior to exposure to experimental protocol. At that time, the normal
cell media were exchanged for cell media with PEG 3350 (1-20% w/w), negative (cell media
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without PEG 3350), and positive controls (a 70% ethanol solution). Exposure times were 2,
6, 12, 24, and 48 hours.
6.2.5 Cell morphology
After exposure at specified time points, images for all the cell lines were obtained using 20x
objective lens on a Nikon Eclipse TS200F inverted microscope (Nikon Instruments, Melville,
NY) and a SPOT Insight color mosaic digital camera (Diagnostic Instruments, Sterling
Heights, MI).
6.2.6 Live/dead assay
The procedure for live/dead assay follows those previously completed in our group and
outlined by Cooperstein et al.66 A combined solution similar to those produced by
ThermoScientific was made by adding 1 µL of 2 mM calcein AM, and 1 µL of 2 mM ethidium
homodimer to every 1 mL of DPBS. After exposure to experimental protocol, cells were
removed from incubation and cell media, cell media with PEG 3350, and ethanol were replaced
with working live/dead solution. Cells were incubated at 37º C and 5% CO2 with live/dead
solution for 45 minutes and then rinsed with sterile DPBS prior to imaging. Fluorescent images
were taken on a Nikon Eclipse TS200F inverted microscope at 20X with an epifluorescence
attachment (Nikon Instruments, Melville, NY) and a SPOT Insight color mosaic digital camera
(Diagnostic Instruments, Sterling Heights, MI).
6.2.7 XTT metabolic assay
XTT cell viability was purchased from Biotium (Fremont, CA). The procedure for XTT was
adapted from the procedures provided by the manufacturer.156 A working solution of XTT was
prepared by adding 50 µL of activated XTT (Biotium solution + activation reagent) to every
10 mL of XTT solution. XTT solution and cell media were used at a 1:1 ratio. After cells were
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media/ethanol/experimental conditions were replaced with working XTT solution. Cells were
incubated for six hours with working XTT solution and then removed for absorbance
measurements at 475 and 600 nm (background) with a SpectraMax M5 microplate reader
(Molecular Devices, San Jose, CA). A blank control was included, in which XTT working
solution was added to the column and incubated for six hours for sample background
measurements.
Viability was calculated with this equation:
% 𝑉𝑖𝑎𝑏𝑙𝑒 𝐶𝑒𝑙𝑙𝑠
=

𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 (475 𝑛𝑚) − 𝑆𝑎𝑚𝑝𝑙𝑒 𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 (660 𝑛𝑚)
∗ 100
𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 (475 𝑛𝑚) − 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 (660 𝑛𝑚)

6.2.8 XTT data analysis
A one-way analysis of variance (ANOVA) was used to determine whether any statically
significant differences occurred between treatments at each time point. Accompanied by
ANOVA, a Levene’s homogeneity of variances test, and a Kolmogorov-Smirnov were
completed to ensure the assumptions of ANOVA were true. If the assumption of homogeneity
could not be rejected, a follow up using the Welch test was completed. A Tukey’s HSD test
was used post-hoc following ANOVA to test the statistical significance between treatment
groups at each time point. Statistical analysis was completed utilizing RealStats Excel-Add In.
6.3 Results and Discussion
6.3.1 Cell Morphology
The relative cytotoxicity of PEG 3350 toward mammalian gastrointestinal tract cells was
examined via observation of cellular morphology after exposure to increasing concentrations
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of PEG 3350 (1%, 5% [the current therapeutic dosage], 10%, 15% and 20%) at multiple time
points (2, 6, 12, 24, and 48 hours exposure) using bright-field microscopy.
These time frames were chosen as they are the relative time points at which food travels
through the different parts of the digestive system in a healthy human (see Table 1).

157–161

Specifically, solid and mixed foods are present in the stomach from 0-6 hours, the small
intestine from 3-6 hours, and the colon from 4-72 hours (average times are 30-40 hours). 157–
161

Figure 6.1 shows human stomach cells (HSCs) exposed to 1%, 5%, 10%, 15%, and 20% PEG
Course of digestion

Time Elapsed

50% of stomach contents emptied

2.5-3 hours

Total emptying of the stomach

4 to 6 hours

50% emptying of the small intestine

2.5 to 3 hours

Total emptying of the small intestine

3 to 6 hours

Transit through the colon

30 to 40 hours

Table 6.1. Average transit times in healthy humans following the ingestion of a standard
meal (i.e. solid, or mixed foods). 157–161
3350 at 2, 6, 12, 24, and 48 hours. The results of cellular response to PEG 3350 were compared
to negative control (exposed to DMEM only, absent PEG 3350), as well as a positive control
(a 70% ethanol solution). Examination of negative controls showed that the HSCs grew well
at all time points, with spindle-shaped cells adhering to the culture substrate. Minimal cell
detachment indicated by lighter, circular-shaped cells was observed in the negative control
(DMEM) even at the longest time points.
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In comparison, the positive control sample (far right column, 70% EtOH) had fewer adherent
(spindle-shaped) cells, and more detached cells (circular shaped). The rounded cell shape
indicated that the positive control (70% ethanol) was toxic toward the cells. In particular, short
exposure time (2 hours) to the positive control showed a significant amount of cell death.
Although the positive control surfaces did not appear (due to cell morphology) to completely
kill the HSCs at all time points, they are likely dead, despite their spindle-shape. The lack of
morphological changes seen after exposure to ethanol is due to EtOH’s known capabilities and
use as a fixative agent for mammalian cells.162
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Time

Cell
Media 1% PEG
(Negative
Control)

5% PEG

10% PEG

15% PEG

20% PEG

70%
EtOH
(Positive
Control)

2 hr.

6 hr.

12 hr.

24 hr.

48 hr.

Figure 6.1. Cell morphology of human stomach cells. Bright field microscopy images of HSCs exposed to 1%, 5% 10%, 15%, and 20% PEG after
26, 12, 24, and 48 hours. From left to right, cell media control (negative), 1%, 5% 10%, 15%, and 20% PEG, and 70% EtOH (positive control). Red
circles = intracellular bubbles. Red arrows = rounded cells, changed cell morphology. Scale bar = 200µm. N = 18.
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HSCs exposed to 1% PEG 3350 (second column) continued to grow to confluency over time
and did not appear to differ from their counterparts in the negative control (DMEM) from 224 hours. At 48 hours, HSCs grown in negative controls appear to be more rounded and less
confluent than the negative control. At the therapeutic dosage of 5% PEG 3350, even more
significant differences were observed. The cells’ morphology at 5% PEG exposure was not the
usual stellate shape (such as those in the negative controls at all time points). Instead, the cells
in the “therapeutic dosage” of 5% PEG began to have a rounded appearance as early as 2 hours.
After 24 hours, cells exposed to 5% PEG 3350 appeared to have intracellular “bubbles” or
“holes” within the cell bodies (indicated by red circles). By 48 hours, the 5% PEG 3350
appeared to have more rounded cells (likely dead, indicated by red arrows) in comparison to
the 1% solution, despite the 5% solution also continuing to grow spindle-shaped live cells.
Furthermore, the remaining spindle-shaped live cells appear to contain intracellular “bubbles”.
These intracellular “bubbles” appear to be similar to those seen on fibroblasts exposed to
cpNIPAM in Chapter 2. We believe that these “bubbles” are a result of cells forming vacuoles
as it goes down the apoptotic pathway.
Cells exposed to 10% PEG 3350 had a decrease in number of cells as well as an increase in
rounded shaped cells, indicative of death with similar formation of intracellular “bubbles”.
Observation of the cells exposed to 15% and 20% PEG 3350 (columns 5 and 6) appeared to
have died within 2 hours of exposure and were detached from the cell culture plate. Later time
points indicated similar results with no spindle-shaped cells seen. It appears that even at the
current therapeutic dosage of ~5%, PEG 3350 can be cytotoxic to human stomach cells such
as those in the human gastrointestinal system.
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Figure 6.2 shows HSCs grown in different concentrations of PEG 3350 over increasing
amounts of time. The cellular response to PEG 3350 was compared to the negative control
(OPTI-MEM only, absent PEG 3350) and positive control (a 70% ethanol solution) similar to
the analysis of HSCs. Examination of the response to the control samples indicated that the
negative control grew accordingly with minimal cell death.
At low concentrations, cell morphology indicates that HSIs are tolerating the 70% EtOH
(positive controls, far right column) unfavorable conditions because the cells morphology was
similar to those found in the cell media (negative control, far left column) from 2-12 hours.
Beginning at 24 hours, the morphology of the positive control changed from the stellate shape
to a rounded appearance. Again, this is expected due to EtOH’s known capabilities as a fixative
agent.162
The cellular response to exposure to 1% PEG 3350 (second column) was similar to those found
for the HSCs. The appearance of the cells did not differ from the negative control. From 2-48
hours at exposure to the therapeutic dosage at 5% PEG 3350, cells continued to appear healthy,
with stellate formation similar to those found in the negative control.
Cell morphology changed dramatically after exposure to 10% PEG 3350. After 2 hours of
exposure, the cells appeared to be less spindled shaped and more rounded (red arrows). As
time increased, the cells became more circular and detached from the culture substrate. By 48
hours of exposure to 10% PEG 3350, no stellate-shaped cells were seen. Similar patterns of
cell deaths were seen in HSIs exposed to 15% PEG 3350. By 24 hours of exposure, no visible
stellate-shaped cells were present. No changes to HSIs viability were seen in 15% PEG 3350
exposure times of 48 hours. Exposure to 20% PEG 3350 appear to lead to cell death in HSIs
within 2 hours as no stellate-shaped cells were found at this time.
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Time

Cell
Media 1% PEG
(Negative
Control)

5% PEG

10% PEG

15% PEG

20% PEG

70%
(Positive
Control)

EtOH

2 hr.

6 hr.

12 hr.

24 hr.

48 hr.

Figure 6.2. Cell morphology of human small intestine cells. Bright field microscopy images of HSIs exposed to 1%, 5% 10%, 15%, and 20% PEG
after 26, 12, 24, and 48 hours. From left to right, cell media control (negative), 1%, 5% 10%, 15%, and 20% PEG, and 70% EtOH (positive control).
Red arrows = rounded cells, changed cell morphology. No circles, as no intracellular bubbles were seen. Scale bar = 200µm.
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Figure 6.3 shows the cell morphology of HCCs exposed to 1%, 5%, 10%, 15%, and 20% PEG
3350 over 2, 6, 12, 24, and 48 hours. The cellular response to PEG 3350 was compared to the
negative control (EMEM only) and the positive control (a 70% ethanol solution). Examination
of the response of the control samples indicated that the cells grown in EMEM with FBS
(negative control) grew well at all time points, as expected. Similarly, the 70% EtOH (positive
control) had few stellate-shaped cells, with large amounts of dead cells leading to blurriness at
all time points.
The cellular response to exposure to 1% PEG 3350 exposure was similar to those found for
HSCs and HSIs, such that the appearance of cells did not differ from the negative control. After
exposure to 5% PEG 3350, the cell morphology significantly changed through 2 to 12 hours.
However, the live cells that were present recovered from the initial toxicity effects, grew to
confluency, and appeared to be elongated and stellate like those found in the negative control
by 24 hours of exposure. However, longer periods of exposure to 5% PEG 3350, such as 48
hours, saw a decrease in cell number and the remaining cells appeared to be more rounded with
the appearance of some intracellular “bubbles” (as indicated by red circles).
After exposure to 10% PEG 3350, cells became more rounded and decreased in confluency
even at the shortest exposure time of 2 hours. As exposure time increased, the negative effects
increased with less stellate shaped cells, and more rounded shaped cells until 48 hours, where
no stellate shaped cells were seen. Similar results were seen at exposure to 15% PEG 3350,
however, no stellate shaped cells were seen, as early as 24 hours. Exposure to 20% PEG 3350
led to cell death as early 2 hours of exposure, with no stellate shaped cells found at this time.
Cell detachment from the culture substrate occurred throughout the remaining time points.
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Time

Cell
Media 1% PEG
(Negative
Control)

5% PEG

10% PEG

15% PEG

20% PEG

70%
EtOH
(Positive
Control)

2 hr.

6 hr.

12 hr.

24 hr.

48 hr.

Figure 6.3. Cell morphology of human colon cells. Bright field microscopy images of HCCs exposed to 1%, 5% 10%, 15%, and 20% PEG
after 26, 12, 24, and 48 hours. From left to right, cell media control (negative), 1%, 5% 10%, 15%, and 20% PEG, and 70% EtOH (positive
control). Red arrows = rounded cells, changed cell morphology. No circles, as no intracellular bubbles were seen. Scale bar = 200µm. N = 18.
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Overall, cell morphology showed that HCCs and HSCs were sensitive to PEG 3350 at
therapeutic dosage (at 5% PEG 3350). HCCs’ and HSCs’ reactions were within physiologically
relevant time frames, with HCCs’ being affected as early as 24 hours, and HSCs’ being affected
as early as early as 2 hours. Intracellular “bubbles” were seen in HSCs and HSIs at multiple
time points and multiple concentrations, likely indicative of early cell death via apoptosis.
6.3.2 Live/dead assay
Figure 6.4 shows human stomach cells stained with calcein AM and Eth-D following exposure
to 1%, 5%, 10%, 15%, and 20% PEG 3350 over 2, 6, 12, 24, and 48 hours. As with Figure 1,
the negative control (DMEM only, absent PEG 3350) and positive control (a 70% ethanol
solution) are presented at the far left and far right columns, respectively. Between, cells
exposed to increasing concentrations of PEG from 1 to 20% are presented. Top to bottom are
the time points from 2-48 hours.
Figure 6.4 shows that the cells exposed to minimal PEG 3350 (toward the left of the figure)
for shorter time periods (toward the top of the figure) were the healthiest, as indicated by large
amounts of green (live) cells. In addition, the cells’ morphology appeared to be spindle-shaped,
similarly to those exposed to cell media. Conversely, increasing concentrations of PEG 3350,
and increasing exposure time resulted in more cell death, as shown by less green (live)
fluorescence and more red (dead) fluorescence. The results of cellular response to PEG 3350
were compared to cell media (negative control) as well as to the 70% EtOH (positive control).
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Time

Cell Media 1% PEG
(Negative
Control)

5% PEG

10% PEG

15% PEG

20% PEG

70% EtOH
(Positive
Control)

2 hr.

6hr.

12 hr.

24 hr.

48 hr.

Figure 6.4. live/dead images of human stomach cells. Fluorescence microscopy images of HSCs exposed to 1%, 5% 10%, 15%,
and 20% PEG after 26, 12, 24, and 48 hours. From left to right, cell media control (negative), 1%, 5% 10%, 15%, and 20% PEG,
and 70% EtOH (positive control). The green dye indicates alive cells; red dye indicates dead cells. Scale bars = 300µm. N=18.
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The results indicate that exposure to very low concentrations (1%) of PEG 3350 resulted in
similar outcomes to the cell media (many live cells, with normal appearance), which is not
indicative of cell death. However, after exposure to the therapeutic dosage (5%) PEG 3350 for
2 hours, the number of live cells decreased significantly, and the cells’ morphology changed
as well. Exposure to intermediate concentrations (10% and 15%) PEG 3350 resulted in similar
outcomes with the exceptions that cell death (red dye) was apparent within 24 hours and that
few live cells were visible. Complete cell death was seen after 48 hours of exposure to 10%
and 15% PEG 3350. 20% PEG 3350 showed almost complete cell death at our shortest
exposure time of 2 hours similar to those found in our positive controls.
The results from the live/dead assay indicate similar results found in our comparisons of cell
morphology (Figure 6.1). Together with the previous results, this outcome indicates that very
high concentrations of PEG 3350 resulted in extensive cell death within a physiologically
relevant time range (2 hours). Furthermore, even lower concentrations of PEG (the therapeutic
5%) resulted in immediate changes to cell viability and morphology after 2 hours of exposure
in HSCs.
Figure 6.5 shows human small intestine cells stained with calcein AM and Eth-D following
exposure to 1%, 5%, 10%, 15%, and 20% PEG 3350 over 2, 6, 12, 24 and 48 hours. As with
Figure 6.4, the negative control (Opti-MEM only, absent PEG 3350) and positive control (a
70% ethanol solution) are presented at the far left and far right columns, respectively. Between,
cells exposed to increasing concentrations of PEG from 1 to 20% are presented. Top to bottom
are the time points from 2-48 hours.
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Time

Cell
Media 1% PEG
(Negative
Control)

5% PEG

10% PEG

15% PEG

20% PEG

70%
EtOH
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Control)

2 hr.

6hr.

12 hr.

24 hr.

48 hr.

Figure 6.5. Live/dead images of human small intestine cells. Fluorescence microscopy images of HSCs exposed to 1%, 5% 10%, 15%, and
20% PEG after 26, 12, 24, and 48 hours. From left to right, cell media control (negative), 1%, 5% 10%, 15%, and 20% PEG, and 70% EtOH
(positive control). The green dye indicates alive cells; red dye indicates dead cells. Scale bars = 300µm. N=18.
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In comparison to the cell media (negative control), exposure to 1% PEG 3350 did not result in
cell death. Even with exposure to the therapeutic (5%) concentration of PEG 3350, the cells
appeared to grow similar to the negative control (confluent, alive). The differences in cellular
response were not observed until exposure to 10% PEG 3350. At lower time points (2-12
hours), minimal cell death was seen. however, cell number is markedly decreased in
comparison to those exposed to cell media control beginning at 24 hours. Exposure to 15%
PEG 3350 had a dramatic decrease in confluency after 2 hours, with cell morphology less
stellate, and rounder than those found in the cell media control. Cell death became apparent
after 6 hours of exposure and on. Exposure to 20% PEG 3350 exposure produced the same
results as seen for the cells exposed to 15% PEG 3350.
Figure 6.6 shows human colon cells stained with calcein AM and Eth-D following exposure
to 1%, 5%, 10%, 15%, and 20% PEG 3350 over 2, 6, 12, 24, and 48 hours. As with Figure
6.7, the negative control (EMEM only, absent PEG 3350) and positive control (a 70% ethanol
solution) are presented at the far left and far right columns, respectively. Between, cells
exposed to increasing concentrations of PEG from 1 to 20% are presented. Top to bottom are
the time points from 2-48 hours.
In comparison to the cell media (negative) control, exposure to 1% PEG lead to no obvious
cytotoxicity effects observed in HCCs from the live/dead assay. The cells continue to grow to
confluency, and cells remain stellate shaped and viable even after 48 hours of exposure to 1%
PEG. However, beginning at the therapeutic dose of 5%, exposure to PEG 3350 leads to
decrease in human colon cell number beginning at 12 hours. Even so, cells remain stellate
shaped with no increase in dead cells as indicated by red stain at all time points until 48 hours
(in which a small number of dead cells was observed).
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Time

Negative
Control

1% PEG

5% PEG

10% PEG

15% PEG

20% PEG

Positive
Control

2 hr.

6hr.

12 hr.

24 hr.

48 hr.

Figure 6.6. Live/dead images of human colon cells. Fluorescence microscopy images of HSCs exposed to 1%, 5% 10%, 15%, and
20% PEG after 26, 12, 24, and 48 hours. From left to right, cell media control (negative), 1%, 5% 10%, 15%, and 20% PEG, and 70%
EtOH (positive control). The green dye indicates alive cells; red dye indicates dead cells. Scale bars = 300µm. N=18.
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Exposure to higher concentrations of PEG 3350 such as 10% lead to an even bigger difference
in comparison to the cell media (negative) control. There is a decrease in the
number/confluency of HCCs’ as early as after 2 hours of exposure. Not only that, a larger
number of dead cells can be seen as soon as 12 hours, and this pattern continues until 48 hours.
Similar patterns to exposure to 10% PEG 3350 are seen in HCCs exposed to 15% PEG 3350:
there is a clear decrease in cell number/confluency. However, cells begin to die off at a shorter
exposure time of 6 hours.
Unlike our findings utilizing cell morphology, it appears as if there are a number of live cells
remaining after 2 hours of exposure to 20% PEG 3350. However, the total number of live cells
is lower in comparison to the cell media (negative) control. By 6 hours, the majority of cells
appear to die off and by 24 hours, the majority of cells are dead. No recovery is detected after
48 hours of exposure.
6.3.3 XTT metabolic assay
To confirm our findings, an XTT metabolic assay was performed on all the cell type from 248 hours to increasing concentrations of PEG 3350. Figure 6.7 shows the results of HSCs
exposed to increasing PEG concentrations at subsequent time points. The red bar in this figure
marks 70% viability, below which solutions are considered to be cytotoxic toward cells.163 **
indicates p<0.05 between treatment condition vs positive control at every time point using
Tukey’s HSD.
Exposure to 1% PEG 3350 leads to a small decrease in cell viability at multiple time points,
including at 12 and 48 hours. Even so, cell viability remains >70% at all time points (after 2
hours cell viability was 97.6±5.3%, after 6 hours cell viability was at 104.3±8.7%, after 12
hours cell viability was 82.6±7.2%, after 24 hours cell viability was 92.0±11.2%, and after 48
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hours cell viability was 80.1±5.3%). Furthermore, these changes in cell viability are not
statistically significant in comparison to the cell media (negative) control at all time points
from 2-24 hours. At 48 hours, the difference was statistically significant, in which the p-value
was 1.49*10-6. However, viability is >70%. As a result, exposure to 1% PEG 3350 can be
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Figure 6.7. XTT metabolic assay of human stomach cells. XTT metabolic assay results from

HSCs exposed to increasing concentrations of PEG 3350 over time. Red line indicates 70%
cell viability, below which the solution is cytotoxic. ** indicates p<0.05 between treatment
condition vs positive control at every time point using Tukey’s HSD. N= 6.
considered non cytotoxic to HSCs at all time points. This confirmed previous observations that
exposure to 1% PEG 3350 is non-cytotoxic to HSCs as seen in from the cell morphology
(Figure 6.1) and live/dead results (Figure 6.2).
Interestingly, similar cell viabilities were found in HSCs exposed to the current therapeutic
dose at 5% PEG 3350. Cell viabilities were >70% at all time points, specifically they were
91.4±15.7% after 2 hours, 103.8±18.2% after 6 hours, 92.0±10.7% after 12 hours, 97.3±5.0%
after 24 hours, and 100.8±10.1% after 48 hours. Due to the cell high viabilities and standard
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deviations, the differences between our cell media control and exposure to 5% PEG 3350 was
not statistically significant at all time points. As such, based on XTT assay – exposure to 5%
PEG 3350 is not considered to by cytotoxic to HSCs from 2-48 hours. This is similar to our
findings utilizing cell morphology, but different from our findings using live/dead assay. This
may be a result of differences in what the assays are measuring. As XTT assay rely on a
mitochondrial reduction to convert the tetrazolium to formazan.94,156 If exposure to 5% PEG
3350 increases the enzymatic activity of the remaining cells, then the XTT assay will report a
high cell viability even if there are less cells than those found in the media control.
By comparison, exposure to 10% PEG 3350 resulted in decreased cell viability within 12 hours
of exposure. Specifically, exposure to 10% PEG 3350 lead to cell viabilities of 90.0±8.4% after
2 hours, 91.6±6.7% after 6 hours, 55.5±5.9% after 12 hours, 62.0±7.7% after 24 hours, and
79.3±6.8% after 48 hours. Changes in viability after exposure to 10% PEG 3350 was not
statistically significant until 12 hours and beyond. Although there are drops in cell viability,
the stronger cells appear to recover from the initial cell death. As such, exposure to 10% PEG
3350 can be considered borderline toxic to HSCs long term, although shorter exposure times
lead to cytotoxic effects.
Exposures to 15% PEG 3350 is where clear cytotoxicity effects are seen, with cytotoxicity
found as early as after 6 hours of exposure. Exposure to 15% PEG 3350 leads to HSC viabilities
of 104.4±7.7% after 2 hours, 69.5±10.5% after 6 hours, 51.3±5.5% after 12 hours, 65.2±5.5%
after 24 hours, and 55.7±10.7% after 48 hours. Decreases in cell viability do not recover and
remain <70% at all time points after the first decrease after 6 hours of exposure. Furthermore,
this decrease is statistically significant from the cell media (negative) control beginning at 6
hours, with p-values of 6.0*10-5 at 6 hours, 4.0*10-3 at 12 hours, 1.6*10-8 at 24 hours, and
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6.7*10-7 at 48 hours. 15% PEG 3350 is cytotoxic towards HSCs at exposure times of 6 hours
and beyond.
XTT assay results of HSCs exposed to 20% PEG 3350 shows similar findings to those found
at exposure to 15% PEG 3350 and previous findings about 20% PEG 3350 using cell
morphology and live/dead assay. HSC has viabilities of 89.0±12.9% after 2 hours, 45.6±12.2%
after 6 hours, 40.0±10.2% after 12 hours, 40.9±4.6% after 24 hours, and 42.7±4.7% after 48
hours exposure to 20% PEG 3350. Again, decreases in cell viability do not recover and remain
<70% at all time points after the first decrease after 6 hours of exposure. This decrease is
statistically significant from the cell media (negative) control beginning at 6 hours, with pvalues of 2.5*10-10 at 6 hours, 6.3*10-5 at 12 hours, 1.5*10-13 at 24 hours, and 2.0*10-14 at 48
hours. Exposure to 20% PEG 3350 is cytotoxic towards HSCs beginning at 6 hours and
beyond.
The ethanol (positive) control confirms that the XTT assay is reliable as cell viabilities are
>70% at all time points as expected. Exposure to ethanol leads to HSC viabilities of
46.3±12.9% after 2 hours, 31.7±12.2% after 6 hours, 13.0±10.2% after 12 hours, 46.0±4.6%
after 24 hours, and 37.7±4.7% after 48 hours exposure. This difference is statistically
significant in comparison to the media (negative) control at all time points.
The XTT assay on HSCs show that, in general, although HSCs appear to experience some
morphological differences at concentrations as low as 5% PEG 3350, metabolically, they do
not behave differently and continue to metabolize ATP at a similar rate. In contrast, exposure
to higher concentrations of PEG are statistically different from our negative control (DMEM)
in a time period as short as 6 hours. ANOVA between the different treatment groups was
significant at all time points.
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The XTT metabolic assay was also performed on all HSIs and HCCs. Figure 6.8 shows the
results of HSIs exposed to increasing PEG concentrations for increasing time periods. The red
bar in this figure marks 70% viability, below which solutions are considered to be cytotoxic
toward cells.163 ** indicates p<0.05 between treatment condition vs positive control at every
time point using Tukey’s HSD.
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Figure 6.8. XTT Metabolic assay of human small intestine cells. XTT metabolic assay results from
HSIs exposed to increasing concentrations of PEG 3350 over time. Red line indicates 70% cell
viability, below which the solution is cytotoxic. ** indicates p<0.05 between treatment condition vs
positive control at every time point using Tukey’s HSD. N= 6.

Similar to the results found with HSCs, exposure to 1% PEG 3350 had no cytotoxic effects on
HSIs. Cell viabilities of HSIs exposed to 1% PEG 3350 were 85.4±9.1% after 2 hours,
91.2±5.7% after 6 hours, 98.4±22.5% after 12 hours, 86.5±10.3% after 24 hours, and
96.2±11.5% after 48 hours. The fluctuations in cell viability of HSIs exposed to 1% PEG 3350
were not statistically different from those found in the cell media (negative) control at all time
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points. 1% PEG 3350 can be considered non-cytotoxic to HSIs for exposure times up to 48
hours.
Exposure to 5% PEG 3350 leads to a decrease in metabolic activity in HSIs, though viability
remains high, >70%. HSIs exposed to 5% PEG 3350 has viabilities of 77.8±17.6% after 2
hours, 81.1±8.5% after 6 hours, 88.7±19.6% after 12 hours, 85.5±14.4% after 24 hours, and
82.5±10.1% after 48 hours. There is a small drop in viability initially, however, the remaining
cells continue to grow and recover from the initial cytotoxic effects. This initial drop is
statistically different from the cell media (negative) control indicating the effects are likely a
result of exposure to PEG 3350. However, 5% PEG 3350 cannot be considered cytotoxic to
HSIs as viability is >70% at all time points.
Similar results to 5% PEG 3350 are found with HSIs exposed to 10% PEG 3350. Exposure to
10% PEG 3350 leads to viabilities of 66.1±8.0% after 2 hours, 77.3±6.0% after 6 hours,
86.8±13.9% after 12 hours, 87.4±21.5% after 24 hours, and 74.2±14.8% after 48 hours in HSIs.
This initial drop is significant in comparison to the cell media control. As the cell viability is
borderline 70%, exposure 10% PEG 3350 can only be considered borderline cytotoxic to HSIs.
Exposure to 15% PEG 3350 and 20% PEG 3350 causes clear cytotoxic effects in HSIs
metabolism as soon as 2 hours, with cell viability <70%. HSIs exposed to 15% PEG 3350 has
viabilities of 53.5±21.9% after 2 hours, 32.4±11.2% after 6 hours, 54.4±17.1% after 12 hours,
21.9±12.5% after 24 hours, and 8.6±5.7% after 48 hours. HSIs exposed to 20% PEG 3350 has
viabilities of 29.9±5.8% after 2 hours, 49.0±11.5% after 6 hours, 45.5±22.2% after 12 hours,
15.8±12.2% after 24 hours, and 7.6±1.9% after 48 hours. At all time points, the difference in
HSIs’ viability after exposure to 15% PEG 3350 and 20% PEG 3350 is statistically different
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from those found in the cell media (negative) control. Both concentrations of PEG 3350 are
cytotoxic to HSIs as early as 2 hours after exposure.
Figure 6.9 presents the % cell viability utilizing an XTT assay of HCCs after exposure to
increasing concentrations of PEG 3350 at 2 hours, 6 hours, 12 hours, 24 hours, and 48 hours.
As with Figure 6.3 and 6.6, the red line in Figure 6.9 indicates 70% viability, below which
solutions are cytotoxic toward cells. Similar to previous morphological and live/dead results,
exposure to 1% PEG 3350 is non-cytotoxic towards HCCs at all time points. Cell viabilities
were >70%, 116.5±14.7% after 2 hours, 82.3±13.3% after 6 hours, 88.8±6.8% after 12 hours,
93.4±6.2% after 24 hours, and 89.6±12.5% after 48 hours. Although cell viability decreases
significantly at 6 hours, HCCs’ viability remains above what is considered cytotoxic. At the
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Figure 6.9. XTT Metabolic assay of human colon cells. XTT metabolic assay results from HCCs

exposed to increasing concentrations of PEG 3350 over time. Red line indicates 70% cell
viability, below which the solution is cytotoxic. ** indicates p<0.05 between treatment
condition vs positive control at every time point using Tukey’s HSD. N= 6.
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therapeutic dosage of 5% PEG, cells exposed to the shortest time period of 2 hours had a higher
viability, but longer time periods of 6-48 hours show a significant decrease in viability that is
at borderline toxicity at levels. HCCs exposed to 5% PEG 3350 has viabilities of 105.4±9.7%
after 2 hours, 66.8±22.5% after 6 hours, 79.5±5.3% after 12 hours, 88.6±2.8% after 24 hours,
and 68.0±9.3% after 48 hours. The decrease in viability at 6 hours is significant with a p-value
of 1.3*10-3 in comparison to the cell media (negative) control. Even so, cell viability of HCCs
are ~70% or greater at all time points, which indicates that PEG 3350 is borderline cytotoxic
in which some cytotoxic effects can be seen but is not deemed cytotoxic by the ISO-10993.
HCCs’ exposure to higher concentrations of PEG 3350 leads to clearer signs of cytotoxicity.
10% PEG 3350 leads to HCCs’ viability drop over time, with clear cytotoxicity seen beginning
at 24 hours. Specifically, HCCs exposed to 10% PEG 3350 has viabilities of 91.7±8.4% after
2 hours, 65.7±10.9% after 6 hours, 82.7±17.9% after 12 hours, 50.4±22.1% after 24 hours, and
15.9±5.3% after 48 hours. Tukey’s HSD pairwise comparison shows that the difference
between our cell media (negative) control and exposure to 10% PEG 3350 were significant at
6, 24, and 48 hours. This shows that there was a significant decrease in cell viability after initial
exposure, but resilient cells were able to grow and withstand the initial cytotoxic effects.
However, over time, even the resilient cells did not tolerate the growth conditions, and
cytotoxic effects returned at longer term exposure times of 24 and 48 hours. Short term
exposure of HCCs to 10% PEG 3350 leads to cytotoxic effects that can be overcome. Long
term exposure (24 hours+) of HCCs to 10% PEG are cytotoxic.
Similar to results in cell morphology and live/dead, HCCs exposed to 15% PEG 3350 and 20%
PEG 3350 are found to be cytotoxic utilizing the XTT assay. HCCs exposed to 15% PEG 3350
has viabilities of 44.9±10.7% after 2 hours, 27.9±20.8% after 6 hours, 21.6±5.7% after 12
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hours, 8.5±2.3% after 24 hours, and 10.2±4.9% after 48 hours. HCCs exposed to 20% PEG
3350 has viabilities of 50.8±9.7% after 2 hours, 14.6±0.8% after 6 hours, 16.1±2.5% after 12
hours, 9.5±3.3% after 24 hours, and 15.3±6.6% after 48 hours. At all time points, the difference
in HCCs’ viability after exposure to 15% PEG 3350 and 20% PEG 3350 is statistically different
from those found in the cell media (negative) control with viabilities of <70%.Both
concentrations of PEG 3350 are cytotoxic to HSIs as early as 2 hours after exposure.
In HSCs, XTT assay results indicate that cells remain viable until they are exposed to PEG3350
at concentrations of 10% or greater for long periods of time, often beyond the time it takes for
foods to pass though the stomach. However, morphological changes, decrease in confluency,
and the number of live cells could be seen at the therapeutic dosage of 5% as early as 2 hours
and continue to 48 hours. Specifically, pore formation – or intracellular “bubble” formation
can be seen in HSCs at the therapeutic dosage of 5% at 2 hours. As seen in Chapter 2, this is
possibly apoptotic (programmed cell death) response of fibroblastic cell types to cytotoxic
conditions.
HSIs exposed to XTT assay show no cytotoxicity following exposure to 1% PEG 3350.
However, exposure to 5% and 10% PEG 3350 lead to borderline cytotoxic effects, in which
viabilities’ hover ~70%. At concentrations of >15% PEG 3350, cell viability significantly
decreases, and PEG 3350 is considered cytotoxic. Similar results are found using cell
morphology and live/dead where some changes in cell morphology and cell viability is seen at
the therapeutic dose of 5% and 10% PEG 3350. However, it isn’t until 15% PEG 3350 and
higher in which confluency, cell morphology, and live/dead assay clearly shows a cytotoxic
effect. This shows that HSIs are more resistant to cytotoxic effects caused by exposure to PEG
3350 than HSCs.
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Exposure of HCCS to increasing concentrations of PEG 3350 have similar outcomes to those
found with HSIs. However, foods and drinks remain in the colon for much longer than HSIs.
As a result, it is important to note that although viability hovers ~70% for the therapeutic
dosage of 5% from 20-40 hours, going above it and exposing HCCs to 10% PEG 3350 or
greater for 20-40 hours will cause cytotoxicity. Similar trends are found using cell morphology
and live/dead assay where lower concentrations lead to cell death and morphological changes.
6.4 Conclusions
Though long considered to be a biocompatible polymer due to its acceptance by the FDA, PEG
3350 does appear to negatively affect the morphology and viability of human stomach and
intestinal cells. Although exposure to 5% PEG 3350 and 10% PEG 3350 cannot be considered
cytotoxic at relevant time frames to all cell lines within the human digestive system, cytotoxic
effects are seen with small changes in cell morphology as well as a decrease in cell viability as
measured by XTT in all cell types.
The cytotoxic effects were observed at the current therapeutic dosage of an assumed perfectly
mixed solution of 5%. Importantly, one of the primary complaints about the GI preparation
method is that the solution can be improperly mixed due to its high viscosity. In such cases, it
is possible that higher concentrations (up to 20%) could be experienced in the GI tract of a
patient.
These results indicate that, contrary to the belief on the safety of PEG 3350, cytotoxic effects
may be experienced from the current preparation method. Furthermore, these results may
explain why some patients (especially women, children, the elderly, and others with low body
mass) experience more negative symptoms from GI preparation than healthy adult men. To
prevent such negative outcomes, the current dosage should be re-evaluated, and ensured to
137

always be less than 5%. It will be essential to develop a method for providing accurate dosage
utilizing height, weight, and other physical characteristics related to the patient and correlate
it with the data of PEG 3350 to improve patient compliance and outcomes following a
colonoscopy preparation.
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Chapter 7: Developing a pH responsive hydrogel for the delivery of PEG 3350
within the human gastrointestinal tract
Manuscript in preparation for publication by Nguyen, P.A.H.*; Cuylear, D.*; Mounho, S.; and
Canavan, H.E.
*indicates equal author contribution
Abstract
Oral administration of drugs is the most ideal choice of drug delivery due to its simplicity,
convenience, and high rate of patient acceptance. However, orally delivered drugs are exposed
to a relatively inhospitable environment that can affect pharmaceutical absorption.
Furthermore, drugs travelling through the gastrointestinal tract will experience different transit
times and environmental conditions leading to early breakdown. Many drugs such as PEG
3350 (discussed in Chapter 6) used for osmotic laxatives are often described as “foul tasting,”
making them difficult to ingest. These factors frequently lead to reduction in patient
compliance. Hydrogels are ideal as drug delivery systems due to their ability to protect drugs,
proteins, and peptides from the environment – preventing drugs from being degraded prior to
delivery at their ideal site. Natural polymers are optimal candidates for hydrogels as they are
known to be non-toxic and are currently already FDA approved for use in food products.
Hydrogels have been fabricated out of these known natural polymers such as alginate, and
chitosan. In this work, we use chitosan, and sodium alginate using a one-step procedure to
create a system that will allow for the delivery of PEG 3350 into the stomach. We confirmed
that elemental composition of the hydrogels via XPS. Hydrogel networks’ stability following
exposure to solutions of physiologically relevant pH, as well as gastric simulation fluid were
confirmed via rheology. Hydrogels are pH-responsiveness and PEG release at physiologically
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relevant conditions (as evidenced by weight change, spectrometry of rhodamine-labelled
PEG). We showed that the leachate from the hydrogels contains only PEG (not any other
component of the hydrogel, or contaminants) using NMR. Finally, we showed that the optimal
concentration of PEG to be loaded hydrogels for drug delivery is 15% PEG (w/w).
When compared to the traditional technique for GI prep (GoLytely™), this technique affords
several distinct advantages, such as the ability to precisely and predictably tailor the dosage of
PEG to the needs of the patient, preventing the potentially cytotoxic effects seen in Chapter
6.
7.1 Introduction
Oral administration of drugs is the most ideal choice of drug delivery due to its simplicity,
convenience, and high rate of patient acceptance.164 Patient non-compliance is often associated
with injections of protein and peptide molecules, whereas oral administration improves the
bioavailability of poorly water soluble drugs and reduces adverse effects associated with
chemotherapy.165,166 Furthermore, oral drug formulations have benefits both for the physician
and the industry, including flexible dosing schedules, reduced demands on staff, reduced costs
through fewer hospital or clinic visits, and less expensive production.166–168
However, orally delivered drugs are exposed to a relatively inhospitable environment that can
affect pharmaceutical absorption. Drugs travelling through the gastrointestinal tract will
experience different transit times and environmental conditions (determined by the pH, the
water content, and the presence of enzymes and live bacteria, see Figure 7.1.)169,170 Exposure
to these conditions can result in deactivation of protein medications and cell death of probiotics
– decreasing the bioavailability of drugs in the GI tract.166,171,172 In addition, many drugs such
as PEG 3350 (discussed in Chapter 6) used for osmotic laxatives are often described as “foul
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tasting,” making them difficult to ingest. This frequently leads to reduction in patient
compliance.

Figure 7.1. Morphology of the human gastrointestinal tract and pH values in different parts of the
tract. 172, 173

To overcome these problems, researchers have been focusing on stimulus-responsive
hydrogels that are capable of responding to pH,173–176 ionization,171,177–179 temperature,180,181
glucose,182,183, etc. Hydrogels are three-dimensional hydrophilic networks composed of homopolymers or copolymers absorbing large quantities of water without dissolution. Hydrogels
have attracted much attention in recent years for drug delivery due to their softness,
hydrophilicity, superabsorbancy, viscoelasticity, biodegradability, biocompatibility and their
similarity with extracellular matrix.176 Furthermore, hydrogels are ideal as drug delivery
systems due to their ability to protect drugs, proteins, and peptides from the environment –
preventing drugs from being degraded prior to delivery at their ideal site.182
However, current formulations capable of producing great site-specificity have depended on
the use of synthetic molecules that are toxic at high concentrations.182,184,185 Other systems
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depend on nanomaterials that have been found to be digested prior to arrival at the site.186
Natural polymers are ideal candidates for hydrogels as they are known to be non-toxic and are
currently already FDA approved for use in food products. Hydrogels have been fabricated out
of these known natural polymers such as alginate,187–190 and chitosan.187,191,192

Alginate is a water-soluble
natural

biopolymer

extracted from brown algae
and

composed

of

a)

alternating blocks of 1-4 αL-guluronic

and β-D-

mannuronic acid residues
(see Figure 7.2a). This
polymer forms hydrogels in

b)

presence of divalent cations
like Ca2+, Ba2+, Sr2+, and
Zn2+ and this characteristic
allows

preparing

drug

loaded

beads.193,194

The

mechanism of this gelation

c)
Figure 7.2. a) Chemical structure of alginate. The figure
shown is a polymer chain of 2 guluronic acid (G)
monomers and 2 mannuronic acid (M) monomers, with (14) linkages, b) “Egg-box” structure of alginate gels formed
by chelation of Ca2+, and c) Chemical structure of chitosan.
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process involves the exchange of sodium ions from the guluronic acids with the divalent
cations, stacking these guluronic groups to form an “egg box structure” as seen in Figure
7.2b.193 Chitosan is a linear polysaccharide composed of D-glucosamine and N-acetyl-Dglucosamine units linked by β-(1-4) glycosidic linkages (see Figure 7.2c).189,191 Chitosan is
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commonly found in chitin shell of crustaceans such as crab and shrimp. To obtain chitosan,
ground shells are deproteinated and demineralized by sequential treatment with alkali and acid,
after which the extracted chitin is deacetylated to chitosan by alkaline hydrolysis at high
temperatures. Production of chitosan from these sources is inexpensive and easy.193
Furthermore, chitosan is a biocompatible, biodegradable, and nontoxic that is already
commonly used in food and is approved by the FDA.193 All of these properties make it an ideal
candidate as a natural polymer for use in hydrogels and other materials.

Alginate shrinks in low pH (<3) systems and is soluble at higher pH (>6), making this polymer
ideal for targeted small intestine delivery. This effect is a result of alginate’s carboxyl group’s
pKa which is 3.5. This allows the carboxyl to become less viscous as pH increases. Chitosan
exhibits a pH-sensitive behavior as a weak poly-base and dissolves easily at low pH (<3) while
it is insoluble at higher pH ranges. Together, they create a more stable system at pH ranges of
4-6, that is pH responsive at low pH such as those found in the stomach yet dissolves at higher
pH such as those found in the small intestine.195 Cross-linking of alginate and chitosan in a
hydrogel provide materials useful for medical and pharmaceutical applications as the obtained
system is characterized by enhanced stability compared to those obtained with a single
polymer.195 The two polymers form the polyelectrolyte complex via the ionic interaction
between the carboxyl residues of alginate and the amino residues of chitosan.195

Hydrogels can be produced by two different methods: utilizing a two-step procedure or a onestep procedure.196 In the two-step method, calcium alginate hydrogel beads are produced by
dropping a solution of alginate into a gelling bath containing calcium ions. The beads are then
transferred into a chitosan solution to form a membrane on the surface of the hydrogels. In the
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one-step procedure, droplets of alginate solution fall into an aqueous solution containing both
the gelling agent for alginate (e.g., calcium ions) and chitosan.197

In this work, we use chitosan, and sodium alginate using the one-step procedure to create a
system that will allow for the delivery of PEG 3350 into the stomach. Our approach is to make
a set of hydrogels that are palatable, safe, and can encapsulate poly(ethylene glycol) (PEG)
3350 and deliver them to the stomach and small intestine within the gastrointestinal system to
achieve its function as an osmotic laxative while reducing commonly found side effects in
current preparations.
7.2 Materials and Methods
7.2.1 Materials
Poly(ethylene glycol), with a molecular weight of 3350 g/mol (PEG 3350), was purchased
from EQUATE (Ahmadi, Kuwait). Sodium alginate from cultivated sea kelp was purchased
from Cape Crystal (Far Hills, NJ). Chitosan was purchased from BulkSupplements.Com
(Henderson, NV). Calcium Chloride was purchased from Will Powder (Miami Beach, FL).
Acetic Acid – 100% was purchased from KMG Electronic Chemicals Inc. (Fort Worth, TX).
10.0 N Sodium hydroxide and 1.0 N Hydrochloric acid were purchased from Millipore Sigma
(Burlington, MA). Deuterated acetic acid (Acetic acid-d4) was purchased from Sigma-Aldrich
(St. Louis, MO). 100 ml Burette was purchased from VWR (Radnor, PA). Sodium
taurocholate, Pepsin (1:10,000), lecithin and sodium chloride were purchased from VWR
(Radnor, PA). Rhodamine labeled-PEG 3350 was purchased from Creative PEGWorks
(Durham, NC). NMR tubes were purchased from Wilmad Labglass (Vineland, NJ)
7.2.2 Sodium alginate and PEG 3350 solution
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Sodium alginate was weighed to 1% (w/v) and added to milli-q water. The alginate solution
was given time (~one night) to dissolve. After the alginate solution dissolved, PEG 3350 was
weighed to make 1%, 5%, 10%, 15%, and 20% (w/w) and added to the 1% (w/v) alginate
solution, independently.
7.2.2 Chitosan purification
Chitosan was purified from a previous protocol with some adaptations made by our research
group.198 Briefly, chitosan was dissolved with 0.1M acetic acid, then precipitated using sodium
hydroxide, then rinsed with Millipore water. This process is repeated 3x to create purified
chitosan. Purified chitosan was weighed out to make a 0.1% (w/v) and added to milli-q water.
Calcium chloride was weighed out to make a 3% (w/v) solution and was added to the
chitosan/milli-q water solution. Acetic acid was added to the solution and adjusted to make a
0.005 M solution.
7.2.3 Hydrogel formation
50 mL of the purified chitosan solution was added to a beaker. ~15-20 mL of the sodium
alginate/PEG 3350 solution was added to a 100 mL burette. The sodium alginate/PEG 3350
solution stayed in the burette for ~15 minutes to allow the air bubbles to rise out of the solution.
The sodium alginate/PEG 3350 solution was titrated into the chitosan solution. The formed
hydrogel complex stayed in solution for 30 minutes to ensure full cross-linking of the
components. After 30 minutes, the hydrogels were taken from the solution and rinsed in milliq water three times before taken for XPS, rheology, and other experiments.
7.2.4 X-ray photoelectron spectroscopy (XPS)
Hydrogels were lyophilized with Labconco’s 2.5 Plus Freezone lyophilizer (Kansas City, MO)
for 24 hours prior for use in XPS. Survey spectra of the lyophilized hydrogels were taken at
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the Department of Chemistry and Biotechnology at Swinburne University of Technology using
a Kratos Axis Nova instrument (Kratos, UK). This instrument has a monochromatized Al Xray source (source energy of 1486.69 eV) at a power of 150W. All samples were run as
insulators meaning the electron flood gun was used. Pass energy for survey spectra
(composition) was 160 eV with a step size of 1eV. High resolution spectra were collected at a
pass energy of 20eV and a step size of 0.1eV. For the high-resolution Cls spectra all binding
energies were referenced to the Cls C-C bonds at 285.0 eV. A detail scan was run for N, C,
and O to improve quantification. Data analysis was carried out using Casa XPS. A number of
constraints were placed due to high resolution C1s spectra between sample differences.
Constraints of FWHM for C-C was 0.5, 13, C-N/C-O was 0.5, 13.5, and for O-C-O/C=O was
0.3, 8.5
7.2.5 Rheology
All rheological studies were conducted using a rotational stress rheometer MCR 300 (Paar
Physica) by parallel plate geometry with 1 mm gap. The experiments were carried out mainly
in the two following modes:
Amplitude sweep oscillations in the range of strains from 0.01% to 200% at the constant
angular frequency of 10.0 rad/s (~1.59 Hz). The deviation from linear viscoelastic behavior in
this experiment is named the large-amplitude-oscillation-shear regime of deformations
determining the strain for the frequency sweep measurements.
Frequency sweep measurements were taken from 600 rad/s to 0.5 rad/s at 2.0% strain of
hydrogels. Hydrogels were exposed pH = 1, pH = 4, pH = 7, or GSF for 30 minutes prior to
each run. 3 runs were completed per hydrogel type and pH/GSF condition.
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7.2.6 Degradation of hydrogels
In order to test the degradation stability, the hydrogels were placed in individual wells
containing 500 uL of pH solutions 1-8, fasted state gastric simulation fluid (GSF), and small
intestine simulation fluid (SISF). These solutions were chosen to simulate the variety of
conditions that hydrogels could be exposed to in drinks as well as those found in the stomach,
and small intestine. At the time of the experiment, the well-plates containing the hydrogels
were at room temperature, and weight was measured in 30-minute intervals until reaching 60
minutes (GSF and SISF) or 120 minutes (pH = 1-8). The degradation of the hydrogels was
then investigated measuring the weight change in % using Equation (7.1) where Wf and Wi are
the final weight and initial weight respectively.
𝑊𝑒𝑖𝑔ℎ𝑡 𝑐ℎ𝑎𝑛𝑔𝑒 (%) = 100 + (

𝑊𝑓 −𝑊𝑖
𝑊𝑖

∗ 100) (Equation 7.1)

Acidic pH solutions were made by adding hydrochloric acid to milli-q water (pH 1-4). Basic
pH solutions were made by adding sodium hydroxide to milli-q water (pH 5-8). After making
the pH solutions.
7.2.7 Simulated gastric and small intestine fluids
Fasted-state gastric simulation fluid (GSF) and small intestinal simulation fluid (SISF) were
made according to a previous protocol.199 Briefly, fasted-state GSF was made by
supplementing milli-q water with 80 µM sodium taurocholate, 20 µM lecithin, 34.2 mM
sodium chloride, and 0.1 mg/mL of pepsin. The pH of solution was adjusted to 1.6 with
hydrochloric acid. Fasted-state intestinal fluid was made by supplementing milli-q water with
3 mM sodium taurocholate, 0.2 mM lecithin, 19.12 mM maleic acid, 34.8 mM sodium
hydroxide, 68.62 mM sodium chloride. The pH was adjusted to 6.5 by adding sodium
hydroxide.
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7.2.8 Release of PEG functionalized with Rhodamine
PEG-functionalize with rhodamine 6G were encapsulated in increasing concentrations of 1%,
5%, 10%, 15%, and 20% (w/w) using alginate/chitosan and CaCl2. The PEG-rhodamine
hydrogels were then placed into the fasted-state gastric and intestinal simulation fluids (GSF
and SISF) for 120 minutes. At 30-minute intervals, the hydrogels were taken out and the
solution was read using a plate reader with emission set at 450, excitation at 500, and readings
were taken every 10 nm until 700 nm was reached. After the plate reading, the hydrogels were
replaced back into solution for continued analysis. Readings were taken in three conditions,
experimental conditions (exposure to GSF or SISF), control conditions (no hydrogels, blank),
and maximal conditions (hydrogels crushed in GSF and SISF to ensure maximal release). To
determine the amount of % PEG released, Equation (7.2) was used where λE, λC, and λmax
represents the wavelengths found in the experimental conditions (exposure to GSF, or SISF),
control conditions (no hydrogels, blank), and maximal conditions (hydrogels crushed)
respectively.
𝑊% 𝑃𝐸𝐺 𝑅𝑒𝑙𝑒𝑎𝑠𝑒𝑑 = 𝜆

𝜆𝐸 (580)−𝜆𝐶 (580)

𝑚𝑎𝑥 (580)−𝜆𝐶 (580)

∗ 100 (Equation 7.2)

7.2.9 PEG 3350 release in gastric and small intestine simulation fluid
A single hydrogel containing different concentrations of PEG 3350 (1,5,10,15, and 20% [w/w])
were placed in 1 mL of each simulation fluid for 60 minutes. Every 10 minutes the hydrogel
was taken from the simulation fluid and weighed. After being weighed, the single hydrogel
was replaced back into its respective simulation fluid.
7.2.10 NMR characterization of leachate
Single hydrogels of each concentration of PEG 3350 (1,5,10,15,20% [w/w]) were placed in
deuterated acetic acid (pH 2.14) for 120 minutes. Every 30 minutes the hydrogel was taken out
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and placed in new deuterated acetic acid solutions. The leachate (old solution) was transferred
to NMR tubes for analyzation.
NMR was used to confirm release of only PEG 3350 in solution. The NMR spectra of the
leachate were taken at the University of New Mexico (UNM) Nuclear Magnetic Resonance
facility with an Advance III NMR spectrometer (Bruker, Billerica, MA). It is a 300 MHz,
standard bore, nanobay instrument. Spectra were obtained on a 5 mm broadband/proton probe,
at room temperature, using deuterated acetic acid as a solvent.
7.3 Results and Discussion
In the previous chapter, we demonstrated that PEG 3350 at higher concentrations is toxic to
human gut cells at short-term and long-term exposure. Furthermore, we explored the
consequences this has in clinical use. As mentioned, PEG 3350 is commonly used as an
osmotic laxative that is a one-size-fits all solution for many patients who undergo a
colonoscopy preparation. However, patients who are elderly, female, or generally smaller in
stature tend to experience more significant side effects associated with the preparation
including palatability as well as nausea, vomiting, abdominal pain, etc. We hypothesize these
smaller and/or more sensitive individuals are not able to withstand the higher concentration of
PEG 3350 than their gastrointestinal system permits.
In this work, we evaluate a potential solution to the problem by creating and testing pH
responsive hydrogels that can deliver PEG 3350 to the stomach. As the PEG 3350 is
encapsulated in the hydrogel, patients do not have to taste the preparation. Furthermore, this
method allows for the opportunity to search for a weight appropriate dose, in which patients
can get different numbers of hydrogels, based on their weight and height. The hydrogels were
created with increasing concentrations of PEG to identify the ideal amount of PEG that could
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be encapsulated using this method (the concentration of alginate and chitosan were kept
constant). After they were created, the hydrogels were first evaluated using XPS to ensure that
there were no contaminants in our process. Rheological measurements of the hydrogels
following exposure to GSF, pH = 1, 4, and 7 solutions to test its physiological response in
comparison to previous studies. Weight loss measurements of hydrogels were taken to evaluate
drug release following exposure to acidic and basic solutions over 2 hours. This series of
experiments were then followed by weight loss measurements of hydrogels following exposure
to GSF and SISF over 2 hours. Additional studies of drug release were completed with PEG
functionalized with rhodamine to determine the percentage of drug released. Finally, to
confirm that the hydrogel is releasing only PEG, hydrogel leachates were taken following
exposure to deuterated acetic acid and evaluated using NMR.
7.3.1. X-ray photoelectron spectroscopy (XPS)

1% PEG

5% PEG

10% PEG

15% PEG

20% PEG

C

73.5±3.4%

71.9±3.2%

72.2±2.1%

75.8±2.2%

72.3±2.4%

O

15.0±2.2%

18.3±1.0%

19.2±1.4%

20.3±1.9%

21.4±1.3%

Si

4.8±0.6%

0.5±0.4%

0.7±0.2%

1.0±0.2%

0.3±0.5%

Ca

2.5±0.5%

2.8±0.3%

3.1±0.2%

1.7±0.1%

2.7±0.7%

Cl

4.2±1.2%

6.0±3.2%

4.8±0.6%

2.7±0.7%

3.4±1.8%

Table 7.1. XPS survey spectra results of hydrogels loaded increasing concentrations of PEG 1%20% (w/w).

The surface chemistry of these hydrogels was accessed by X-ray photoelectron spectroscopy
(XPS). Figure 7.3a and 7.3b show the results of preliminary data of survey and high resolution
C1s spectra for all five types of hydrogels as the concentration of PEG increases, as well as the
composition of the hydrogels as predicted from the stoichiometry of the outer shell of the
hydrogels.
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Figure 7.3a indicates that our hydrogels loaded with 1% PEG (w/w) contains less O and more
Si than is expected. [Note: as this anomaly is only present in the 1% PEG sample, this is likely
the result of an attempt to crush the lyophilized hydrogels using a mortar and pestle;
contamination of the pestle by silicone and/or PDMS may have led to contamination of these
samples.] As visual inspection of the 1% samples that had been crushed in this manner also
had anomalous appearance, following this initial attempt, all of the remaining hydrogel
samples were not crushed prior to XPS.
The hydrogels loaded with 5% PEG have elemental composition of 71.9% C, 18.3% O, 0.5%
Si, 2.8% Ca, and 6.0% Cl. 10% PEG loaded hydrogels have elemental composition of 72.2%
C, 19.2% O, 0.7% Si, 3.1% Ca, and 4.8% Cl. Hydrogels loaded with 15% PEG and 20% PEG
have elemental compositions of 75.8% C, 20.3% O, 1.0% Si, 1.7% Ca, and 1.3% Cl; and 72.3%
C, 21.4% O, 0.3% Si, 2.7% Ca, and 3.4% Cl respectively. The elemental composition of these
samples are consistent despite increasing PEG concentration, as is evident in Figure 7.3 and
Table 7.1. The only difference that is statistically significant is that of the atomic percentage
of oxygen for the 5% vs. 20% PEG (p = 0.03 when subjected to student t-test); this result is of
interest, as the lower dose (5%) was shown to be tolerated by all cell types in Chapter 6,
whereas the higher dose (20%) was not. Furthermore, the results of all PEG %s are relatively
consistent with that predicted from the stoichiometry of the copolymer (alginate and chitosan)
combination (51.6% C, 0.8% N, 43.7% O, and 4.0% Ca). The difference is likely due to the
presence of adventitious carbon, as well as salt ions introduced during the production process
of the hydrogels. Nitrogen was expected at only trace concentrations (<1.0%), which is at the
detection limit of the instrument for Nitrogen (0.5-1.0%).48
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Figure 7.3. a) Surface chemistry of alginate-chitosan hydrogels loaded with PEG by XPS. In part
a), the atomic % of carbon, oxygen, silicon, calcium and chlroine are shown for hydrogels loaded
with 1% PEG (orange), 5% PEG (grey), 10% PEG (yellow), 15% PEG (light blue), and 20% PEG
(green). The theoretical composition of alginate-chitosan hydrogels as calculated from the
chitosan-alginate outer shell is shown for comparison. N = 3.

Figure 7.3b shows the high resolution C1s spectra for hydrogels loaded with 1% PEG, 5%
PEG, 10% PEG, 15% PEG and 20% PEG. The high-res spectra show that the carbon-carbon
peaks are difficult to deconvolute with large deviations within samples as well as between
samples. Hydrogels loaded with 1% PEG show the carbon species consist of 39.5% C-C,
43.8% C-O/C-N, and 16.8% O-C-O/C=O. Hydrogels loaded with 5% PEG, 10% PEG, 15%
PEG, and 20% PEG show the carbon species breakdown to be 30% C-C, 35% C-O/C-N, and
36% O-C-O/C=O; 33% C-C, 39% C-O/C-N, and 29% O-C-O/C=O; 27% C-C, 49% C-O/CN, and 24% O-C-O/C=O; and 42% C-C, 43% C-O/C-N, and 14% O-C-O/C=O respectively.
Statistically, there is no difference between the molecular environment of carbon for any of the
samples. The C1s carbon environment of the PEG samples differ from the expected theoretical
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values of 83.3% C-O/C-N and 16.7% O-C-O/C=O. This is most likely due to the low sample
number (n) as well as the extremely low %N (<1.0%) mentioned previously that
overemphasize the error computed. It should also be noted that the peak envelope observed for
the C1s data varied widely between samples (see Figure 7.4). These results could be due to
either: a) the dehydration required to achieve high vacuum to perform XPS, or b) the insulating
nature of polymers. (Explained below)
Biological and other samples are known to deform due to dehydration when placed under high
b)
100.0

75.0

Relative %

Expected
1%
5%

50.0

10%
15%
20%
25.0

0.0
C-C

C-O/C-N

O-C-O/C=O

Figure 7.3. b), the high resolution carbon species (C-C/C-H, C-OH/C-N, and N-C=O) are shown
shown for hydrogels loaded with 1% PEG (orange), 5% PEG (grey), 10% PEG (yellow), 15% PEG
(light blue), and 20% PEG (green). The theoretical composition of alginate-chitosan hydrogels as
calculated from the chitosan-alginate outer shell is shown for comparison. N = 3.

vacuum can be seen in Figure 7.5. Lyophilization (freeze-drying) was used to prepare the
hydrogels for analysis in the high vacuum environment. As a result of the rapid dehydration,
the structure of the hydrogel may simply collapse (Figure 7.5, left side), or a fracture may be
introduced (Figure 7.5, right side). The event experienced by the hydrogel (collapse vs.
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fracture) will cause different regions of the hydrogels to be available for sample analysis (as
the escape depth for XPS is ~50-100 Angstroms). In this case there is spillage/leakage of the
encapsulated PEG and, as a result, the PEG core is analyzed. For a collapsed (or non-fractured
hydrogel), the chitosan/alginate shell will be analyzed, resulting in increased %N, C-N, and
C=O detected. For a fractured
hydrogel, the PEG core will be
analyzed, instead, resulting in
increased C-O detected.

We

believe that this is the origin of
spot-to-spot variation within
the samples. [Note: due to the
large

a)

deviations

between

samples and within samples of
the
these

high-resolution
results

spectra,

should

be

considered preliminary data,
and additional experiments may
be

required

prior

to

publication.]

b)
Figure 7.4. Sample C1s spectra of PEG hydrogels of: a) a peak
envelope that could be deconvoluted and b) a peak envelope
that experienced charging

The second source of abnormal
C1s peak envelope appearance

is most likely due to charging of the samples. “Charging” occurs when the rate of electrons
being ejected from the sample surface is higher than the rate of electrons diffusing through the
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material (often insulators such as PEG) and the charge is not compensated.200 As a result, the
ejected photoelectron will feel an electrostatic attraction due to positive charge accumulation
at the specimen’s surface, resulting in a photoelectron slow down and loss of kinetic energy
before being detected by the energy analyzer. Charging leads to the loss of information of the
photoelectron initial state and affects the photoemission spectrum by shifting all the feature to
higher kinetic/binding energies.200 As a result, the C1s peak envelope becomes an unresolved
“hump” which is difficult to deconvolute.
Overall, XPS survey spectra of elemental composition shows no unexpected contamination in
the fabrication process.

Figure 7.5. Schematic of alginate-chitosan hydrogel lyophilized then placed under vacuum for
XPS. Hydrogels are first lyophilized then placed under vacuum for XPS. Vacuum can lead to
hydrogels being fractured, exposing the encapsulated area of the hydrogel for XPS and not only
the outer shell.
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7.3.2 Rheology
To determine hydrogel network stability, the hydrogels’ viscoelastic behavior following a 30minute exposure to different pH solutions (1, 4, and 7) and GSF were analyzed. Frequency
sweeps are needed to observe this behavior as it could better explain hydrogels’ network
stability. However, frequency sweeps generally are observed the behavior of a sample in the
non-destructive deformation range, an amplitude sweep was necessary to determine a nondestructive strain. A amplitude sweep of strain from 0.02% to 200% strain was completed, and
a 2% strain was determined to be ideal, as this was prior to the large-amplitude-oscillationshear regime deformations region for all concentrations (e.g. constant chitosan and alginate
with increasing concentrations of PEG 3350, see Figure 7.6).

156

0.01

15000

A
Storage
modulus (G')

100

0.01

100

20000

C

10000
Storage modulus
(G')

5000

Storage modulus
(G')

10000
5000

Loss modulus
(G'')

0

D

15000

Pascals

Pascals

1

Oscillation Strain (%)

15000

1

Loss modulus
(G'')

0

Oscillation strain %

0.01

Storage modulus
(G')

5000

Loss modulus
(G'')
1

B

10000

Pascals

Pascals

12000
10000
8000
6000
4000
2000
0

Loss modulus
(G'')

0

0.01

100

1

100

Oscillation Strain (%)

Oscillation Strain (%)

10000

E

Pascals

8000
6000

Storage modulus
(G')

4000
2000

Loss modulus
(G'')

0
0.01

1

100

Oscillation Strain (%)

Figure 7.6. Storage modulus and loss modulus results under oscillation strain from 0.2% to
200% of 1% alginate-chitosan hydrogels with a)1% PEG, b) 5% PEG, c) 10% PEG, d) 15%
PEG, and e) 20% PEG.
Frequency sweep experiments were then completed with a 2% strain to determine the stability
of the hydrogel networks following exposure to different conditions pH conditions (pH = 1, 4,
and 7) as well as GSF. The tan(δ) (G’’/G’) for hydrogels loaded with increasing concentrations
of PEG (1% PEG, 10% and 20% PEG) following a 30-minute exposure to GSF, pH = 1, 4, and
7 with varying frequency are shown in Figure 7.7.
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Each of the hydrogel networks remain stable (i.e., G’’/G’ <1.0) following exposure to all
experimental conditions. Closer observation of Figure 7.6 shows that, following a 30-minute
exposure to pH 4 or 7, the G’’/G’ results for all hydrogel concentrations are similar to those
found in the control (exposure to air). Exposure to lower pH conditions (i.e., pH = 1 and GSF)
does affect hydrogels, with the material becoming less stiff, as indicated by the increased
G’’/G’ values. This shows that there is some change to the hydrogel networks following
exposure to low pH conditions, although the gel remains in a gel-like state, and no dissolution
occurs. At the highest concentration of PEG loaded into the hydrogel, the pH response seems
to decrease with G’’/G’ following exposure to GSF and pH = 1, more similar to those found
in samples controls.
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Figure 7.7. Tan(δ) (G’’/G’) vs angular frequency results of hydrogels loaded with increasing concentrations of a) PEG: 1%, b) 5%, and c)
10% following a 30-minute exposure to varying pH solutions of 1, 4, and 7 as well as GSF. Rheological results indicate that hydrogel
networks are stable following exposure to different pH conditions, but is also pH responsive, with an increase in G’/G’’ following exposure to
GSF and pH = 1. N = 3.
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Figure 7.7 Tan(δ) (G’’/G’’) vs angular frequency results of hydrogels loaded with d) 15%, and e) 20% PEG concentrations of following a 30minute exposure to varying pH solutions of 1, 4, and 7 as well as GSF. Rheological results indicate that hydrogel networks are stable following
exposure to different pH conditions, but is also pH responsive, with an increase in G’’/G’ following exposure to GSF and pH = 1. N = 3.
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7.3.3 Weight change of hydrogels in acidic and basic solutions
As the results from rheology indicate that the hydrogels are stable at all concentrations at all
pHs, we then measured the extent to which a weight change was observed for the hydrogels in
acidic and basic conditions. In this way, we could determine whether the hydrogel structures
were intact, but releasing their internal cargo (preferred outcome), or not.
Figure 7.8 charts the degradation results (% of weight change) of 1%, 5%, 10%, 15% and 20%
PEG-loaded hydrogels following placement in pH = 1-8 over the course of 120 minutes.
Overall, the hydrogels were pH-responsive in acidic solutions, with the largest amount of
weight change in acidic pH solutions of 1 and 2. The lower PEG concentration hydrogels (115% PEG) were the most responsive, with the greatest weight change. At pH 1 and pH 2,
hydrogels loaded with 1% PEG 3350 lost ~45% and ~44% of its original weight respectively.
Similar losses were found in 5% PEG 3350, at which hydrogels lost ~47% and ~44% of its
weight in pH 1 and 2, respectively. Higher concentrations of PEG-loaded hydrogels at 10%
and 15% lost 52% and 48% of their weight in pH 1 and 2, and 53% and 51% of its weight in
pH 1 and 2, respectively. In comparison, at the highest PEG concentration (20%), the lowest
% weight loss was detected at pH 1 and 2, where only ~28%, and ~19% loss was detected. At
higher pH of 3-8, <25% of weight loss was detected across all time periods and concentrations.
From these results, it is apparent that although the hydrogel structure remains intact (from
rheology results), for physiological applications, hydrogel complexes loaded with 1-15%
would be most suitable, as they lose ~ 50% of their cargo within the first 60 minutes (relevant
time frame) after being placed in the low pH solution.

161

120.0

100.0

pH = 1

pH = 2

80.0

Weight %

Weight %

100.0

pH = 3
60.0

pH = 4

40.0

pH = 5
pH = 6

20.0

B

120.0

A

pH = 1

pH = 2

80.0

pH = 3
60.0

pH = 4

40.0

pH = 5
pH = 6

20.0

pH = 7
0.0
-50

pH = 7
0.0

pH = 8
0

50

100

150

-50

pH = 8
0

Time (minutes)

50

100

150

Time

C

120.0

Weight %

100.0

pH = 1
pH = 2

80.0

pH = 3
60.0

pH = 4

40.0

pH = 5
pH = 6

20.0

pH = 7
0.0
-50

pH = 8
0

50

100

150

Time (minutes)

Figure 7.8. Change in weight % of hydrogels loaded with increasing concentrations of a) PEG: 1%, b) 5%, and c) 10% following a 30-minute
exposure to varying pH solutions of 1 (blue), 2 (orange), 3 (grey) 4 (yellow), 5 (light blue), 6 (green), 7 (dark blue), and 8 (brown). Hydrogels
in low pH solutions (1 and 2) display high amounts of weight loss while little weight changes higher pH solutions (pH 4 – 8). N=6.
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Figure 7.8 continued. Change in weight % of hydrogels loaded with increasing concentrations d) 15%, and e) 20% following a 30-minute
exposure to varying pH solutions of 1 (blue), 2 (orange), 3 (grey) 4 (yellow), 5 (light blue), 6 (green), 7 (dark blue), and 8 (brown). Hydrogels
in low pH solutions (1 and 2) display high amounts of weight loss while little weight changes higher pH solutions (pH 4 – 8). N=6.
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7.3.4 Hydrogel weight gain/loss in gastric simulation fluid and small intestine simulation
fluid
Next, the hydrogels were exposed to gastric and small intestine simulation fluids in order to
mimic the more complicated physiological milieu. Figure 7.9a shows the amount of PEG 3350
(in %) weight change in hydrogels loaded with PEG (1-20%) following exposure to fastedstated gastric simulation fluid (GSF) over 60 minutes, in 10-minute intervals. A shorter time
interval was chosen due to observations in previous studies where the greatest weight change
was found within the first 60 minutes of exposure to low pH conditions. The GSF, which has
a pH of 1.6, was made and implemented in this experiment to ensure that this hydrogel system
could release the cargo in our intended target – the stomach.
All of the hydrogel systems used in the experiment were responsive to the GSF. The amount
of weight loss decreased as the concentration of PEG-loaded into the hydrogels increased.
Hydrogels loaded with 1% and 5% PEG 3350 performed similarly, losing ~50% of its weight
by 30 minutes with ~60% weight lost by 60 minutes. Hydrogels loaded with 10% PEG 3350
were slightly less responsive, with ~50% of the weight loss reached at 40. By 60 minutes, 54%
of the weight was lost. 15% PEG 3350 loaded hydrogels were unable to lose 50% of its weight
until the 60-minute mark. Finally, 20% PEG loaded hydrogels had the least change in weight,
with only ~30% of its original weight lost. Furthermore, the standard deviations within samples
were largest in 20% PEG loaded hydrogels. These hydrogels did not lose 50% of their weight
by the 60-minute mark. This is indicative that there may be a loading limitation in these
hydrogels, in which 20% PEG decreases efficiency in response, as the hydrogel networks may
not be as tightly cross-linked. Overall, the hydrogels were responsive to the FaGSF and are
promising vessels for drug release in a stomach-like environment.
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A

B

Figure 7.9. Graph of % weight of hydrogels loaded with varying concentrations of PEG (1-20%)
following exposure to a) fasted-state gastric simulation fluid (GSF), and b) small intestinal simulation
fluid (SISF) over 60 minutes. 1% loaded PEG gels are indicated by red, 5% PEG gels are blue, 10%
yellow, 15% black, and 20% green. Hydrogels loaded with the lowest concentrations of PEG 3350
(1%, 5%) lost ~50% of its weight within 30 minutes. N=6.
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Figure 7.9b shows the amount of PEG 3350 that was released into fasted-state intestinal
simulation fluid (SISF). SISF was used for this part of the experiment to evaluate the
hydrogels’ stability within the small intestine (which has a pH of 6.3). The results obtained in
from hydrogels exposed to SISF were significantly different from the previous section, which
were exposed to pH = 1-8 or GSF; instead of losing weight, the hydrogels at all concentrations
of PEG gained a significant amount of weight after being placed in the SISF. Furthermore, as
the concentration of PEG 3350 loaded into the hydrogels increased, the amount of weight
gained by the hydrogels increased.
The hydrogels loaded with lower concentrations of PEG (1 and 5% PEG 3350) gained 23%
and 41% weight over 60 minutes, respectively. At 10%, there was ~56% increase in weight
over 60 minutes. The largest amount of weight gained was found in hydrogels loaded with
15% and 20% PEG 3350, with a weight increase of 113% and 134%, respectively. We
hypothesize that this opposite result is due to a number of causes: 1) compared to GSF, SISF
contains far more sodium, as well as maleic acid, and does not contain pepsin; 2) alginate is
known to shrink at low pH (such as in GSF) and swells at higher pH (such as SISF); 3) chitosan
is soluble at low pH (such as in GSF) and is insoluble at higher pH (such as SISF). It is unclear
which of these differences is the driving factor behind the rapid swelling and weight gain, and
it is most likely that it is a combination of the swelling of alginate, and its interactions with the
other components of SISF. Overall, these results confirm that the hydrogels respond to changes
in pH in physiologically-relevant conditions (such as GSF and SISF), and therefore have great
potential for drug release in the stomach.
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7.3.5 Rhodamine-PEG release

Time
1%
(minutes) PEG

5%
PEG

10%
PEG

15%
PEG

20%
PEG

0

0±10.3

0±1.5

0±1.2

0±0.1

0±0.9

30

13.0±1.9 41.2±1.8 50.6±6.6 54.8±2.5 46.0±6.2

60

17.7±1.2 49.3±3.1 67.5±5.6 69.7±2.1 62.5±12.1

90

18.6±1.4 48.8±3.9 68.9±9.4 72.6±2.2 66.4±12.8

120

19.2±1.2 47.5±4.7 69.0±9.0 70.8±2.7 67.3±14.0

Table 7.2. Percentage of PEG-labeled with rhodamine 6G released following exposure to
gastric simulation fluid over 120 minutes, with 30-minute intervals.

Having demonstrated that the PEG hydrogels are pH-responsive in physiologically relevant
conditions, we obtained PEG that was functionalized with rhodamine 6G so that we could
ensure that PEG is released as a result of the pH change. Rhodamine is an inexpensive dye that
fluoresces red and is easily tracked via spectroscopy.
Tables 7.2 and 7.3 chart the amount of rhodamine labeled-PEG 3350 that was released into
fasted-stated gastric simulation fluid (GSF) and small intestine simulation fluid (SISF),
respectively. Table 7.2 indicates that hydrogels loaded with 1% PEG 3350 released the least
PEG 3350 following exposure to GSF. Hydrogels loaded with 15% PEG 3350 released the
most PEG (70%) following exposure to GSF. Furthermore, the 15% loaded PEG hydrogels
released PEG the fastest, as well (within 30 minutes). However, when the concentration of
PEG was raised to 20%, the hydrogels’ response worsened: they did not release more than 50%
in solution after 30 minutes, and only had 67% in solution after 120 minutes. Therefore, there
appears to be a limitation in how much PEG can be loaded and released into the hydrogels.
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From these results, it appears that 15% PEG loaded hydrogel is ideal in gastric simulation fluid,
delivering the most PEG in the shortest amount of time. In addition, creating hydrogels with a
high concentration of PEG (15% vs. 1%) will reduce the total amount of drug that will need to
be ingested to deliver the optimal dosage of PEG. For the current size of the hydrogels being
studied, this translates to a reduction of the dosage by 15x.
Table 7.3 shows the performance of hydrogels loaded with 1%-20% PEG following exposure
to SISF over 120 minutes. Although the results from the previous section’s weight change data
indicates that the hydrogels swell in SISF, the PEG itself is not retained; it appears that PEG
is released into the SISF solution over time. Similarly to the results in GSF, there is a dosage
effect at work for hydrogels in SISF, with increased PEG concentration yielding increased
release of PEG into SISF. Also similar to results in GSF, 15% PEG hydrogels released the
largest amount of PEG (~70%) in SISF in the shortest time frame (120 minutes). Finally, as
with the results in GSF, 20% loaded PEG hydrogels perform worse than the 15% PEG
hydrogels, releasing only ~50% in 120 minutes.
From these results, it appears that 15% PEG loaded hydrogel is ideal also for small intestine
simulation fluid, delivering the most PEG in the shortest amount of time. However, these
results should be considered preliminary, for several reasons. For example, instead of testing
duplicate PEG-loaded hydrogels to the GSF and SISF solutions in parallel, a more
physiologically relevant test would be to expose them sequentially to GSF followed by SISF
over physiologically-relevant time frames. In this way, the amount of PEG released in the small
intestine following digestion in the stomach could be truly determined.
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In addition, results from the hydrogels exposed to SISF have large standard deviations within
samples. This is likely a result of spectrometer difficulties that occurred within the lab while
this study was completed. Therefore, replicate studies should be performed prior to publication.

Time
1% PEG 5% PEG
(minutes)

10%
PEG

15%
PEG

20%
PEG

0

0±2.8

0±5.1

0±10.5

0±10.7

0±5.1

30

6.4±1.6

-9.4±19.5

37.2±22.8 34.4±20.9 34.5±16.2

60

24.6±4.2

6.0±20.7

47.8±3.8

90

16.2±9.6

4.3±21.1

59.9±25.1 59.2±15.5 49.2±14.6

120

15.6±11.2

29.1±30.6

63.2±31.1 69.0±22.5 54.3±15.7

49.9±16.9 43.8±12.1

Table 7.3. Percentage of PEG-labeled with rhodamine 6G released following exposure to small
intestine simulation fluid over 120 minutes, with 30-minute intervals. N = 6.

7.3.6 Nuclear Magnetic Resonance of hydrogel leachate
The results from the previous sections indicate that the hydrogels respond to change in pH by

releasing PEG. In this section, we studied the leachate from the hydrogels to determine whether
other components are being released into solution, as well.
This was achieved by performing a study in which 1% PEG-loaded hydrogels were exposed
to deuterated acetic acid over a time period of 120 minutes, with 1H NMR data collection of
the solution performed every 30 minutes.
Figure 7.10 shows the expected peaks if alginate201 (top) and/or chitosan202 (middle) was
present. The bottom spectra on Figure 7.10 shows the deuterated acetic acid solution following
exposure to PEG-loaded hydrogels after 120 minutes. The bottom spectra on Figure 7.10
shows peaks at ~3.8 ppm indicative of CH2CH2O-, and ~4.6 ppm indicative of -OH both of
which are indicative of PEG.203 No peaks are observed that would indicate the presence of
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chitosan or alginate in the leachate, however are seen. Similar NMR spectra were obtained
after 30 minutes, 60 minutes, and 90 minutes (data not shown, as they are identical).
This NMR data indicates that only PEG is being released from the hydrogels, and no other
contaminants (including alginate or chitosan), are released following exposure to acidic
conditions such as those found in the stomach.

Figure 7.10 NMR spectrum of pH responsive hydrogel (Alginate w/PEG 3350) in deuterated
acetic acid with pH responsive hydrogel added after 120 minutes (bottom). Other NMR spectras
are those found associated with chitosan (middle), and alginate (top). Results confirm that only
PEG 3350 was in solution with no other components that would give indication of other
components such as alginate and chitosan being released.

7.4 Conclusions
The

softness,

hydrophilicity,

superabsorbancy,

viscoelasticity,

biodegradability,

biocompatibility, and other properties of hydrogels have led to their extensive use as potential
drug delivering agents.176 However, most studies have not sought to improve on the use of
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hydrogels for the delivery of low compliance drugs such as GoLytely™ that are currently used
in colonoscopy preparation.
In our study, we evaluated the use of chitosan-alginate hydrogels as a pH-responsive hydrogel
system to deliver PEG 3350 into the stomach and small intestine. We confirmed that the
elemental composition of the hydrogels is consistent with what was expected from the mixture
using XPS. We also showed that the hydrogel networks are stable following exposure to
solutions of physiologically relevant pH, as well as gastric simulation fluid via rheology.
Furthermore, the hydrogels are pH-responsive and release PEG at physiologically relevant
conditions (as evidenced by weight change, spectrometry of rhodamine-labelled PEG). As
importantly, we showed that the leachate from the hydrogels contains only PEG (not any other
component of the hydrogel, or contaminants) using NMR. Finally, we showed that the optimal
concentration of PEG to be loaded hydrogels for drug delivery is 15% PEG (w/w).
When compared to the traditional technique for GI prep (GoLytely™), this technique affords
several distinct advantages, such as the ability to precisely and predictably tailor the dosage of
PEG to the needs of the patient, preventing the potentially cytotoxic effects seen in Chapter
6. In addition, the ability to create capsules that are stable in neutral pH solutions such as water
means that the technique may prevent the unpredictable viscosity and unpleasant taste that
many patients find unbearable. Finally, all of these components have previously been approved
for use in humans by the FDA and are therefore suitable for use in this system. These results
therefore indicate that this method for delivering PEG 3350 via encapsulation within
chitosan/alginate hydrogels has great potential as an osmotic laxative alternative for those
struggling with the palatability and side effects of the current prep technique.
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Chapter 8: Conclusions and Future Directions
8.1 Conclusions
8.1.1 Unanticipated sources of toxicity within existing protocols
The cytotoxicity of reagents (NIPAM) used in current experimental protocols were
investigated as described in Chapter 3. This work examined the cytotoxic effects of using prepolymerized NIPAM on mammalian cells and evaluated whether its continued use without
purification is beneficial. Although other forms of polymerized NIPAM are non-toxic to cells,
cpNIPAM purchased from retailers should be purified prior to use to prevent unintended
cytotoxic effects. Furthermore, any biomedical devices, and technologies that utilize
cpNIPAM without purification can lead to unexpected cytotoxicity response in tissue culture.
Cytotoxicity was not only found in experimental protocols, but also in medical protocols, as
well. It is often assumed that the use of topical and oral antibiotics and antiseptics is safe, and
that the application of these items directly to wounds will have few side effects during surgery.
As a result, current surgical procedures often encourage the use of antibiotics (e.g., bacitracin,
tranexamic acid, and vancomycin), and antiseptics (e.g., chlorhexidine, and povidone iodine)
to prevent infection (Chapter 5), or as part of the antifibrinolytic process (Chapter 4).
However, in this work, it was demonstrated that each of the antibiotics, antiseptics, and
antifibrinolytic tested are detrimental to chondrocytes (knee joint cells). As these cells are
poorly vascularized, they are less likely to recover as compared to other more vascularized cell
types. In turn, this could lead to more difficult recovery periods following knee surgical
procedures, and over time, osteoarthritis for patients who have had these materials applied
during joint replacement and other surgeries.
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8.1.2 Cytotoxicity despite FDA approval
Although the FDA evaluates the safety of drugs and medical devices prior to their release in
the market, many are used for purposes other than they were originally intended, and often
with unanticipated consequences. In 2003, the Centers for Medicare and Medicaid Services
collaborated with the CDC and 10 other national organizations to develop the Surgical
Infection Prevention Project. This effort resulted in recommendations of prophylactic
antibiotic usage for patients undergoing clean-contaminated surgeries to prevent surgical site
infections.204 Since, antibiotics have become the standard of care and are widely used in a range
of surgeries.
A number of studies were performed to determine the effectiveness of antibiotics for the
prevention of surgical site infections. 132,204–206 Chapter 5 showed that this assumption may be
incorrect as even rapid washing (30 seconds) with antibiotics including bacitracin and
vancomycin lead to delayed cytotoxicity seen in chondritic knee cartilage. Similar assumptions
on the safety of tranexamic acid in surgeries and PEG 3350 were made based on their FDA
approval. Chapter 4 showed that tranexamic acid exposure may not be appropriate as current
recommended concentrations are cytotoxic to knee chondrocytes, delaying healing postsurgery. Chapter 6 showed that PEG 3350 at current therapeutic concentrations changes the
behavior of gut cells including stomach, small intestine, and colon cells. Taken together, these
chapters emphasize the need for careful evaluation of the possible cytotoxic effects of
antibiotics in surgical applications prior to their use.
8.1.3 Biocompatible devices
Chapter 7 outlines the development of a new biocompatible method to deliver colonoscopy
preparations with more control and precision using well known polymers such as sodium
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alginate. Sodium alginate and chitosan have been previously used in food,193 and many studies
have shown their safety to the human gastrointestinal system.207,208 This makes them ideal
candidates as part of a pH-responsive drug delivery hydrogel system.
Chapter 7 characterizes the ideal concentrations and their effectiveness as a potential delivery
vehicle for PEG 3350 and identifies the ideal concentration of PEG 3350 versus sodium
alginate and chitosan to deliver the maximum amount of drug. Studies were completed
evaluating the hydrogels’ pH responsiveness utilizing simple pH solutions as well as simulated
gastrointestinal and small intestinal simulation fluids.
8.2 Future Directions
8.2.1 Assessing the mechanism of death
Cell death typically occurs by necrosis or apoptosis (see Figure 8.1).85 Following injury, a
series of cellular mechanisms called oncosis takes place and eventually lead to necrosis.
Necrosis is characterized by cell and organelle swelling, pyknosis, loss of ion gradients,
increased permeability, loss of cell membrane integrity, and the release of intracellular
contents.85 Apoptosis, on the other hand, is ATP-dependent and characterized by cell
shrinkage, maintenance of plasma membrane integrity, chromatin condensation, and nuclear
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Figure 8.1. Pathways and markers of cell death. Cells typically die on one of two pathways,
necrosis or apoptosis. Different characteristics are listed with the outcomes associated with each
type of cell death. Figure adapted from Cummings et. al. 85

fragmentation.209 It has been shown that the type of death greatly affects response in vivo.
Necrotic cell death typically induces inflammation, while apoptotic death does not.
Inflammation is essential in efficient tissue repair, but large amounts of inflammation has been
shown to delay healing and results in increased scarring. Furthermore, chronic inflammation
is a hallmark of non-healing injuries and wounds, predisposing the tissue to cancer
development.210
It was shown in Chapter 2 that cpNIPAM is cytotoxic and detrimental to cells with cell
morphology differences, specifically the formation of intracellular pores in 3T3 cells. As
mentioned above, necrotic vs apoptotic cell deaths lead to different responses in vivo. These
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differences can significantly affect their uses. For example, if cpNIPAM leads to necrotic cell
death in BAECs and VEROs then its use as a polymer in the medical setting will likely be
limited to materials that are not implanted into humans or taken to be implanted into humans.
Not only that, this may delay NIPAM’s approval in the FDA process as controlling mechanism
of deposition and polymer formation greatly affects cell behavior. Future studies should be
repeated on these cell lines to assess and better understand their mechanism of death as this
could affect their use in vivo changing the current standards of care.
Multiple methods could be used to evaluate the mechanism of death. Many previous studies
rely on the use of the Comet assay, an assay that looks at fragmented DNA stained with a
fluorescent dye, such ethidium bromide, and the length of the tail of DNA from the cell
corresponds to the degree of apoptosis.211 Caspase assays that detect for apoptosis by the
presence of caspases 2, 3, 6, 7, 8, 9, and 10 are another effective method. These are fluorescent
assays that will fluoresce or chemically luminesce under the presence of caspases. 211
Luciferase, an ATP detecting assay could also be used to assist in differentiating the type of
cell death. Here, presence of ATP will cause Luciferase to luminesce. High levels of
luminescence are indicative of cells undergoing apoptotic death following exposure to a
cytotoxic polymer.100 Annexin V, an apoptosis detecting assay, could also be used in
combination with other assays. Healthy cells contain phosphatidylserine, a phospholipid,
within their membranes. Annexin V is a protein that binds to phosphatidylserine but is not cell
permeable. Thereby, cells that are alive are not affected by Annexin V. However, during
apoptosis, cell membranes will lose asymmetry and phosphatidylserine will be exposed to the
surface, allowing Annexin V to bind.
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Using these assays in combination such as using both Luciferase and Annexin V on BAECs,
3T3s, and VEROs following exposure to cpNIPAM substrates and leachates will allow us to
determine the mechanism of cell death and understand the mechanism in which NIPAM
monomers and short chain polymers cause cytotoxicity in multiple cell types thereby
improving the fundamental understanding of pNIPAM.
Similar follow up studies using these assays could be completed with PEG 3350 as pore
formation was also found in HSCs following exposure to PEG 3350 in Chapter 6.
Understanding the mechanism of death of PEG 3350 in HSCs vs HSIs and HCCs will help
explain why PEG 3350 causes more severe side effects in groups with generally smaller
statures such as women and elderly individuals.212 This will help improve the current
understanding regarding PEG’s cytotoxicity and can lead to an improvement in the standard
of care, allowing physicians to further study on an effective, but non-toxic dose for these
populations that require PEG 3350 in their medical care.
Follow ups on the mechanism in which antifibrinolytics such as TXA (in Chapter 4) are
leading to cytotoxic effects seen on chondrocytes is also necessary. Current evaluations
without pH measurements showed a change in media pH from red to yellow indicative of an
acidic environment (pH <6.8) after 24 hours of exposure to TXA. Although it was not explored,
and media was changed every 24 hours, the reaction continued even after TXA was removed
and cells were maintained in a media environment.
It is known that environmental changes greatly affect cell viability,62 and it is possible that the
acidic conditions are toxic to chondrocytes found in the osteochondral plugs. To better
understand if the observed cytotoxic effects are caused by environmental changes or due to
exposure to TXA, a study could be completed using a bioreactor in which fresh media is fed
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through and waste media is emptied out automatically (see Figure 8.2).213 This will allow
clinicians to better understand the effects TXA has on chondrocytes viability and aid clinicians
in

their

non-approved

use

of

previously approved FDA drugs.
8.2.2 Search for a potential “safe”
and effective concentration of
antibiotics and antiseptics
Antibiotics and antiseptics have
become an essential part of surgical
Figure 8.2. Schematic of stirred tank bioreactor setup for
osteochondral plugs in which cell media is fed through
then harvested/removed after use. Obtained from Cole et.
al. 213

procedures

including

knee

arthroplasties. However, it has not
been established whether a specific

antiseptic, a combination of agents, etc. are better suited to prevent the formation of biofilms
or other infections.43 To further complicate the matter, although the WHO and CDC
recommend the use of dilute betadine for irrigation of wounds during orthopedic procedures,
the optimal volume, frequency, and duration is unknown. Other antiseptics and antibiotics
along with saline and ringers lactate solutions have also been proposed as potential irrigation
solutions but a “gold standard” does not exist due to a lack of clinical studies. 43
Further studies on ideal concentration, volume, and frequency of antibiotics and antiseptic use
in surgeries should be completed. Evaluation of the effective concentration and assessing
cytotoxicity with chondrocytes should be completed, allowing us to determine a safe and
effective surgical dosage.
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8.2.3 Depth of penetration of antibiotics, antiseptics, and antifibrinolytics and additional
techniques to evaluate cytotoxicity
A study evaluating the depth of penetration of the antibiotics, antiseptics, and antifibrinolytics
will allow for better understanding of how deep these reagents are able to penetrate into the
chondrocytes.
Our current study evaluates the plugs in a 2-dimensional environment utilizing a fluorescent
microscope, dependent on creating small slices of osteochondral plugs for fluorescent imaging.
Future studies could use a confocal microscope to evaluate the depth at which these reagents
are able to penetrate into chondrocytes by cutting the osteochondral plug in 100 µm dimensions
horizontally. Subsequent staining utilizing a live/dead assay could be carried out followed by
visualization under a confocal microscope (see Figure 8.3). This will allow the confocal
microscope to image the plug in a 3D format and give a clearer picture.

Figure 8.3. Current osteochondral plug processing and imaging (left) that shows attempts to
determine the cytotoxicity using a 2D microscope. Red indicates the direction in which samples
were cut and prepared for imaging, prior to live/dead staining and microscopy. Right are
recommendations on future directions in which osteochondral plugs should be cut horizontally
at 100µm height prior to staining and confocal microscopy.

Furthermore, confirmation of cytotoxicity should be completed with another assay such as an
XTT assay to evaluate its metabolic activity to ensure that the visual live/dead images and
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counts correlate with true cytotoxicity effects seen as a result of osteochondral plug exposure
to antibiotics, antiseptics, and antifibrinolytics. Osteochondral plugs could be exposed to
antibiotics, antiseptics, and antifibrinolytics for similar time frames prior to being placed in
cell media with XTT assay and incubated. Plugs would then be removed prior to readings being
taken for evaluation of metabolic activity – which often correlates directly with cell viability.
8.2.4 Encapsulation of PEG with electrolytes
Hydrogel studies have focused on encapsulation and release of PEG 3350 for delivery of
colonoscopy preparations. However, GoLytely™ does not only contain PEG 3350. Along with
227.1g of PEG 3350, GoLytely™ also contains 21.5g sodium sulfate, 6.36g sodium
bicarbonate, 5.53g sodium chloride, and 2.82g potassium chloride all mixed with 4L of water.
The additional salts are electrolytes to help prevent osmotic imbalances as one prepares for a
colonoscopy.
To improve our hydrogel system, we must also test the ideal concentration of PEG 3350,
sodium alginate, along with these electrolytes. It appears as if 10 wt% PEG and 15 wt% PEG
have the most ideal drug release time frame. As such, it would be best to test these
concentrations and 5wt% PEG3350 solutions along with their respective electrolytes to ensure
that PEG 3350 is still being released in gastrointestinal simulation fluid with a similar drug
release profile.
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8.2.5 Encapsulation of bacteria and other
materials using stimulus-responsive
polymers for targeted drug delivery
The hydrogel system that we developed in
Chapter 7 to deliver GI preparation drugs to
the stomach utilizes a pH-responsive system to
deliver drugs to the stomach as a bolus dose.
However, it would be useful to be able to
deliver drugs or other cargo to distinct areas of
the GI tract, such as the small intestine or the
colon. It is known that each of these areas of
the gut commonly function in slightly different
Figure 8.4. Hydrogels for small intestine and
colon delivery. Hydrogels are responsive to
natural digestive enzymes that are produced by
the body, slowly degrading to release the drug
of choice.

pH environments (e.g., the pH of the small
intestine is ~6-8, in the colon it is 5-7).
Therefore, in the future, we envision that the

“Bubblyte™” system could be adapted to create a multi-layered hydrogel that is capable of
delivering other health promotive cargo (e.g., probiotics, vitamins, and healthy gut bacteria)
by creating sequentially digested layers of the gel core.
Multi-layered hydrogels will be fabricated for site-specific drug delivery (Figure 8.4) to the
end of the small intestine and the colon. The outer shell of the hydrogel will consist of sodium
alginate and collagen which will promote stability in the acidic environment of the stomach.
Sodium alginate and collagen are both fibrous materials that are known to be difficult to digest
by the small intestine. Consequently, release of drugs will be delayed until the hydrogel reaches
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the desired location. The inner shell will consist of gelatin and chitosan. Gelatin will be
digested by natural enzymes in the small intestine, leaving chitosan with a specific cell-binding
sequence and the drug.
Hydrogel properties will be characterized by (i) determination of rheological properties using
a rheometer, (ii) visualization using confocal microscopy and scanning electron microscopy,
and (iii) testing its capability to release drugs. Hydrogels can be exposed to gastric simulation
fluid initially followed by small intestine fluid to determine vitamin release of the hydrogel
where NMR is taken to determine if the correct drug is being released at the correct time.
Similar studies using a fluorescently labeled vitamin model could also allow for mathematical
calculations of the amount of drug being released over time.
The test material for this system will be probiotics or vitamins to demonstrate the small
intestine delivery capabilities of this system. In the case of bacteria-based systems, release of
the bacteria will be tracked in situ by placing hydrogels into GSF for 3 hours followed by
exposure to small intestine simulation fluid (SISF) for 5 hours. Hydrogels will be monitored
and weighed every 30 minutes to determine degradation. Live/dead and other viability assays
can be performed with both fluid types using a flow cytometer to evaluate bacterial viability
and release from the hydrogel.
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